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ABSTRACT  
The hepatitis B virus (HBV) vaccine has contributed greatly to decreasing the HBV 
epidemic. However, it remains unclear why 5-10% of individuals do not mount an 
adequate antibody response. Previous studies have shown that genetic variation 
influences HBV vaccine response. Since such studies are lacking in South African 
individuals, we examined the associations between HBV vaccine response and genetic 
variation in HLA-DPB1, additional candidate genes and HLA-DPB1 expression levels in 
a South African cohort. HLA-DPA1 and -DPB1 allele typing was performed using 
Luminex technology, twenty-four candidate SNPs were typed by MassArray Analysis 
and HLA-DPB1 mRNA expression levels were measured by qPCR. HLA-DPB1*01:01, 
*04:01:01G and *09:01 and SNPs and haplotypes in IL1B, IL4, IL12B, IFNG and the 
HLA region were significantly associated with HBV vaccine response. A trend of lower 
HLA-DPB1 expression associating with better anti-HBs response was observed, although 
this was not significant. Response to the HBV vaccine is multi-genic but HLA-DP plays 
an important role.
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1.1 Hepatitis B Virus  
The hepatitis B virus (HBV) is an enveloped DNA virus of the Hepadnaviridae family 
(Shepard et al., 2006), identified in 1970 (Dane et al., 1970). The virus is 42 nm in diameter, 
and is comprised of an envelope that surrounds an inner capsid, or core, which contains the 
viral genome and a polymerase with reverse transcriptase activity (Nassal and Schaller, 1993; 
Seeger and Mason, 2000; Shepard et al., 2006). 
The HBV genome is a partially double-stranded DNA molecule (Locarnini, 2004; Nassal and 
Schaller, 1993; Seeger and Mason, 2000; Shepard et al., 2006). It is only 3 200 base pairs (bp) 
in size (varying slightly with genotype) but has a compact organisation: the open-reading 
frames (ORF) overlap, as do all regulatory and coding regions (Kramvis et al., 2005; Nassal 
and Schaller, 1993; Shepard et al., 2006). There are four ORFs: one ORF (C) encodes the 
hepatitis B core antigen (HBcAg) and the hepatitis B e antigen (HBeAg), another ORF (P) 
encodes the polymerase, a third ORF (S) encodes the envelope proteins and the last ORF (X) 
encodes a transcriptions trans-activator protein (Kramvis et al., 2005; Locarnini, 2004). 
HBcAg assembles into the icosahedral capsid particles which is surrounded by the envelope 
(Seeger and Mason, 2000). The envelope is made up of small (S), middle (M) and large (L) 
surface proteins (Nassal and Schaller, 1993; Seeger and Mason, 2000). The S surface protein 
is known as hepatitis B surface antigen (HBsAg) and can also be found as self-assembling, 
non-infectious envelope particles (Seeger and Mason, 2000; Shepard et al., 2006), which may 
serve to trap antibodies against the virus, thereby weakening the immune response against HBV 
(Nassal and Schaller, 1993). The viral polymerase is important for viral replication (Seeger and 
Mason, 2000). The functions of the X protein and HBeAg are unknown; however, the X protein 
is thought to function in the establishment of infection in vivo and HBeAg possibly influences 
the level of viral replication and immune responses (Nassal and Schaller, 1993; Seeger and 
Mason, 2000).  
There are ten genotypes of HBV (A-J), whose genomes differ from each other by more than 
8% (Kramvis et al., 2005; Lin and Kao, 2013; Locarnini, 2004; Sunbul, 2014). Additionally, 
some of the genotypes can be further classified into sub-genotypes (Custer et al., 2004; 
Locarnini, 2004), and based on the variation of HBsAg, serological subtypes can be identified 
(Kramvis et al., 2005). The major subtypes include adw, adr, ayw and ayr, but the identification 
of additional sub-determinants has increased the number of serological subtypes (Kramvis et 
al., 2005). 
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1.2 Hepatitis B Virus Epidemiology 
According to the World Health Organisation (WHO), more than two billion people worldwide 
are, or have been, infected with HBV (WHO, 2009). Geographic regions are classified into 
three categories of HBV endemicity according to the prevalence of chronic HBV: high (≥8%), 
intermediate (2-8%), and low (<2%) (Romano et al., 2011). The life risk of exposure to HBV 
(prior to vaccine introduction) is 60% or greater in high endemic areas, 20-60% in intermediate 
endemic regions and below 20% in low endemic areas (Romano et al., 2011). HBV is highly 
endemic to Asia and Africa, especially sub-Saharan Africa (Kew, 1996; Kiire, 1996; Romano 
et al., 2011).  
The HBV genotypes have distinct geographical distributions, and are associated with 
differences in disease progression, which may contribute to regional differences in endemicity 
(Lin and Kao, 2013; Sunbul, 2014). Genotype A is common in Northern Europe and sub-
Saharan Africa; genotypes B and C are found in Asia and C in Australia; genotype D occurs 
across Africa, Europe, India and the Mediterranean region; E is restricted to West Africa; G is 
observed in the United States, France and Germany and F and H is found in Central and South 
America (Custer et al., 2004; Lin and Kao, 2013; Locarnini, 2004; Sunbul, 2014). Genotypes 
I and J are newly defined and have been observed in Vietnam and in Japan, respectively 
(Sunbul, 2014).  
Transmission of HBV occurs by percutaneous or mucosal exposure to infected bodily fluids, 
which can occur either through horizontal or vertical transmission routes (Shepard et al., 2006). 
The route of transmission may also play a role in the distribution of genotypes, for example 
genotypes B and C are predominant in Asia where vertical transmission is the major route, 
whereas other genotypes are found in locations where horizontal transmission is the dominant 
route (Lin and Kao, 2013). In Africa, HBV is most commonly transferred in early life via child-
to-child transmission and in later life by sexual contact (Burnett et al., 2012; Hennig and Hall, 
2012; Kew, 1996). Health care workers (HCWs) are also at risk from occupation-related blood 
or body fluid exposures, particularly in countries endemic for HBV (Burnett et al., 2012). 
Transmission may also occur indirectly via contaminated items since HBV can remain viable 
on surfaces for more than seven days (Shepard et al., 2006). 
HBV replicates in the liver cells and can result in asymptomatic infection or acute or chronic 
hepatitis (Shepard et al., 2006; WHO, 2009). Acute HBV infection is detected by a combination 
of the presence of the HBsAg as well as antibodies against the HBV core and surface antigens, 
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that is, anti-HBc and anti-HBs, respectively (Shepard et al., 2006). HBsAg is cleared from the 
blood in individuals who recover from HBV infection (and these individuals will have anti-
HBs as well), but HBsAg remains present in chronic carriers as they do not develop anti-HBs 
(Hennig and Hall, 2012; Shepard et al., 2006). Immunity against HBV after natural infection 
is marked by the presence of anti-HBs, at a titre of more than 10 IU/L (Shepard et al., 2006; 
WHO, 2009). Acute HBV infection does not usually require treatment. Chronic HBV infection 
can be treated with antivirals, such as pegylated interferon-alpha (IFNα), or nucleoside reverse 
transcriptase inhibitors (NRTIs) such as, entecavir, lamivudine and tenofovir (de Clercq et al., 
2010; WHO, 2015). Treatment guidelines for chronic HBV infection were issued by WHO in 
2015. HBV infection can, however, be prevented by vaccination (Hennig and Hall, 2012). 
It is estimated that 360 million infected individuals are chronic carriers, at high risk of suffering 
from the sequelae of cirrhosis and hepatocellular carcinoma (WHO, 2009). The rate of chronic 
carriage (uncleared chronic infection) of HBV worldwide is about 10% in individuals older 
than five years of age, with a higher prevalence in younger children (Frodsham, 2005; Shepard 
et al., 2006). In Africa (prior to the introduction of the HBV vaccine), the prevalence of chronic 
carriage was approximately 15%, but differed between gender and regions, even within a 
country (Kiire, 1996). Additionally, the carrier rates in rural areas are higher than those in urban 
areas, and HBV infection is more prevalent in black South Africans than in the Caucasian, 
Indian and Coloured population groups in South Africa (SA) (Kew, 1996, 2008). In black South 
Africans, the carrier rate was 9.6% and 76% had been exposed to HBV (Kiire, 1996), whereas 
in Coloured, Indian and Caucasian South African populations, the prevalence of chronic 
carriage ranges between 0.2-0.4% and only 3-5% had previous exposure, prior to the 
introduction of vaccination (Kew, 1996). HBV genotype may contribute to the higher chronic 
carriage rate observed in Africa compared to the global carriage rate, as genotype A (commonly 
found in sub-Saharan Africa) is associated with increased rates of chronic HBV infection (Kew, 
2008; Sunbul, 2014). The observed differences in carrier rates may also be due to variations in 
host genetics, as described below.  
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1.3 Factors Influencing HBV Infection Outcome 
Several factors have been found to influence the outcome of HBV infection and clearance or 
persistence of the virus (Frodsham, 2005). These factors include age at infection, viral load, 
gender and host genetic factors (Frodsham, 2005). Most published studies on host genetic 
factors and HBV persistence have associated the major histocompatibility complex (MHC) - 
known as human leukocyte antigen (HLA) in humans - particularly class II molecules, with 
HBV infection outcome (Frodsham, 2005) and details of these findings are summarised below.  
A study in a Gambian population found that HLA-DRB1*13:02 was protective against the 
development of chronic hepatitis B in adults and children (Thursz et al., 1995), and this was 
later replicated in a Caucasian (American) and Asian populations (Mbarek et al., 2011; Thio et 
al., 2003). Yan et al. (2012) conducted a meta-analysis of 2609 cases and 606 controls including 
various ethnicities, and showed that HLA-DR*01, *04 and *13 alleles were significantly 
associated with HBV clearance in clearance, while DR*03 and *07 alleles had a significantly 
increased risk of chronic HBV persistence. HLA-DQA1*05:01 and HLA-DQB1*03:01 were 
associated with chronic infection in African-Americans (Thio et al., 1999). A meta-analysis of 
HBV infection outcome with HLA-DQB1 alleles in 815 cases and 731 controls found HLA-
DQB1*03:03 and *06:04 significantly associated with decreased risk of chronic HBV 
infection, whereas HLA-DQB1*02:01, *03:01 and *05:02 associated with increased risk of 
chronic infection (Huang et al., 2016). A genome-wide association study (GWAS) identified 
the HLA class II DP locus as being strongly associated with HBV infection outcome in Asian 
populations (Kamatani et al., 2009). The haplotypes including HLA-DPA1*01:03 and either 
HLA-DPB1*04:01 or *04:02 were associated with protection against the development of 
chronic HBV, while the haplotypes including HLA-DPA1*02:02 and either HLA-DPB1*03:01 
or 05:01 were associated with increased risk of chronic HBV (Kamatani et al., 2009). In an 
African- and European-American cohort, HLA-DPB1*04:01 was also associated with HBV 
clearance and HLA-DPB1*01:01 was associated with HBV persistence (Thomas et al., 2012).  
A role for HLA-DP variants in HBV infection risk, HBV clearance and hepatocellular 
carcinoma was replicated in several subsequent studies in Asian populations (Guo et al., 2011; 
Hu et al., 2012; Mbarek et al., 2011; Nishida et al., 2012; Thomas et al., 2012). A meta-analysis 
of 29 case-control studies involving a total of 62 050 subjects was performed (Yu et al., 2015) 
and found that the A alleles of HLA-DPA1 rs3077 and HLA-DPB1 rs9277535 significantly 
decreased the risk of HBV infection and increased the possibility of HBV clearance. In African- 
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and European-Americans, HLA-DPB1 rs9277534 showed a stronger association with HBV 
infection outcome than the rs9277535 variant (Thomas et al., 2012). Additionally, Thomas et 
al. (2012) showed that variants in the HLA-DP region that were associated with HLA-DP 
expression levels predicted recovery from HBV infection. More specifically, the rs9277534 
GG genotype was associated with HBV persistence and with a higher HLA-DPB1 expression 
level (Thomas et al., 2012). 
HLA class I alleles have also been associated with HBV infection outcome in Caucasian 
Americans: HLA-A*03:01 and -B*08 have been associated with viral clearance and 
persistence, respectively (Thio et al., 2003). Various other non-HLA genes have been 
associated with HBV infection outcome, such as variations in the vitamin D receptor and 
tumour necrosis factor-alpha (TNFα) genes, both of which play a role in immune response 
(reviewed in Frodsham, 2005).  
There are limited studies of host genetic associations with HBV infection outcome in 
populations from the African continent (Hennig and Hall, 2012). Several have been performed 
in Gambian cohorts (Bellamy et al., 1999,1998; Frodsham et al., 2006; Thursz et al., 1996, 
1995) and a few in the west African countries including Senegal (Dieye et al., 1999; Obami-
Itou et al., 2000) and Togo and Benin (Bronowicki et al., 2008). However, no such studies have 
been performed in South Africans. 
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1.4 Hepatitis B Vaccine 
The HBV vaccine was first licensed in the United States in 1981 and due to its success, it is 
now part of the routine vaccination schedules for infants in many countries (Shepard et al., 
2006). The introduction of immunization at birth has greatly reduced the occurrence of HBV 
transmission in many countries (WHO, 2009). The HBV vaccine has been included in the 
South African Expanded Program of Immunisation (EPI) schedule since 1995 (Kew, 2008; 
Young et al., 2013). Since the introduction of the HBV vaccine in SA, less than 0.5% of 
vaccinated children from both rural and urban environments, were found to be HBsAg-positive 
and HBV DNA-positive due to natural infection (Hino et al., 2001; Schoub et al., 2002; Tsebe 
et al., 2001). Additionally, protective levels of anti-HBs were found in 84 to 87% of the 
vaccinated cohorts (Hino et al., 2001; Schoub et al., 2002; Tsebe et al., 2001).  
The vaccine contains the HBsAg which is the viral protein that elicits an immune response in 
natural infections (Burnett et al., 2012; Young et al., 2013). The first HBV vaccine consisted 
of purified HBsAg derived from plasma of chronic carriers of HBV (Szmuness et al., 1981). 
This vaccine was soon replaced by HBsAg produced in yeast using recombinant technologies 
(McAleer et al., 1984; Zuckerman, 1996). The HBV vaccine is usually given in a three-dose 
series (Shepard et al., 2006; WHO, 2009), although as of 2016, in addition to the HBV vaccine 
doses given at 6, 10 and 14 weeks of age, a booster dose at 18 months was introduced into the 
South African EPI (Motaze and Suchard, 2016).  
 
1.4.1 Serological markers of HBV immune response 
An anti-HBs response of more than 10 IU/L after three vaccine doses is the accepted correlate 
of protection against HBV infection (Young et al., 2013), with some individuals mounting 
responses of several thousand IU/L (Tripathy et al., 2011). While an anti-HBs titre > 10 IU/L 
indicates immunity to HBV, this immunity may have arisen either from natural infection or 
from vaccination (Krajden et al., 2005; Shepard et al., 2006). The source of immunity to HBV 
can be determined by the presence or absence of anti-HBc (Krajden et al., 2005) since the core 
protein of the virus is not included in the vaccine preparation (Szmuness et al., 1981). An anti-
HBc negative result indicates no previous infection with HBV and therefore immunity because 
of vaccination, whereas an anti-HBc positive result indicates infection with HBV which may 
be resolved infection (an absence of HBsAg) or ongoing infection (a presence of HBsAg) 
(Krajden et al., 2005).   
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1.4.2 HBV vaccine responses 
A decline in anti-HBs level over time following infection or immunisation occurs in some cases 
(Shepard et al., 2006; Zuckerman, 1996) and is associated with an increasing risk of infection 
(Jack et al., 1999). However, previously vaccinated individuals whose antibody titres decrease 
– even to undetectable levels – years after vaccination are generally still protected from 
infections upon subsequent exposures (Shepard et al., 2006; WHO, 2009) due to 
immunological memory (Zuckerman, 1996). Immune memory to HBsAg is achieved by both 
memory T and B cells, however, their detection is difficult as a result of their low frequency, 
especially in the peripheral blood (Bauer and Jilg, 2006). These cells represent a second 
correlate of protection against HBV. In a small study of successful vaccinees whose antibody 
levels had declined to undetectable levels over 4-8 years, the number of HBsAg-specific 
memory T and B cells was found to be approximately 1-2 and 2-4 cells per one million of 
peripheral blood lymphocytes respectively (Bauer and Jilg, 2006). Despite the low frequencies 
of T and B memory cells, re-vaccination of the subjects resulted in good anti-HBs responses 
with titres ranging between 110 and 13500 IU/L after one month (Bauer and Jilg, 2006). 
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1.5 Vaccine Efficacy 
Vaccines in general have saved millions of lives in the past century and are among the most 
cost-effective health interventions available (Ehreth, 2003). Vaccination has resulted in the 
eradication of smallpox, the near eradication of polio and the control of other diseases such as 
measles and tetanus (Ehreth, 2003). However, the problems encountered in designing 
successful vaccines against certain diseases, such as human immunodeficiency virus (HIV), 
malaria and hepatitis C, as well as the less than 100% efficacy of most vaccines (Grimm and 
Ackerman, 2013) highlight the gaps in our knowledge of how vaccines work. The 
immunological mechanisms underlying vaccine response must be fully elucidated for the 
rational design and development of effective novel and improved vaccines.  
There are several terms, including immunogenicity, efficacy and effectiveness, used to 
differentiate measures of how well a vaccine works. Immunogenicity is defined as the ability 
of the vaccine to induce an immune response in a vaccinated individual (Banaszkiewicz and 
Radzikowski, 2013). Efficacy of a vaccine is the percentage reduction of disease in a 
vaccinated group of people compared to an unvaccinated group, measured in a randomized, 
placebo-controlled study (Banaszkiewicz and Radzikowski, 2013) and since it is measured 
under controlled conditions, it proves the best possible scenario (Weinberg and Szilagyi, 2010). 
Effectiveness is measured from observational studies of protection against disease after vaccine 
use in the general population (Banaszkiewicz and Radzikowski, 2013), thus providing a more 
realistic measure of how well the vaccine reduces the disease in the population (Weinberg and 
Szilagyi, 2010). 
Additionally, protection against infection and/or disease is ideally associated with a ‘correlate 
of immunity’, a quantifiable indication of immunity that can be directly measured (Plotkin, 
2008). For many vaccines, antibody quantity is the predominant correlate of immunity, 
although in some cases correlates of protection may be T cell responses or quantity of memory 
T or B cells (Plotkin, 2010, 2008). Correlates of immunity may be absolute quantities, where 
a particular level of response is highly correlated with protection (Plotkin, 2008). However, the 
case is often more complex as many correlates of immunity are relative, meaning that while 
most infections are prevented at a certain level of response, some will occur above that level 
(Plotkin, 2008). Furthermore, there may be no identifiable or easily measurable correlate of 
immunity in which case a surrogate measure, which is not in itself protective and is only 
indirectly related to the true correlate of protection, must be used as a substitute (Plotkin, 2008). 
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There can also be more than one correlate of immunity since vaccine-induced protection may 
be achieved by multiple mechanisms (Plotkin, 2010). These factors, among others, illustrate 
that certain mechanisms of action of vaccines may be unknown, while other aspects may be 
well described for the same vaccine and can also make it difficult to assess the success of a 
vaccine. 
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1.6 HBV Vaccine Efficacy 
Despite the success of the HBV vaccine, studies have shown that a percentage of healthy 
subjects do not produce a sufficient antibody response (Zuckerman, 1996). HBV vaccine non-
response is characterized by an antibody titre of less than 10 IU/L (Zuckerman, 1996). Non-
responders continue to be susceptible to HBV infection (Zuckerman, 1996). Globally, 
approximately 5 to 10% of healthy individuals fail to mount an antibody response to the HBV 
vaccine (Zuckerman, 1996). In SA, although only a few studies have been performed in this 
population, a somewhat higher percentage of individuals do not respond to the HBV vaccine. 
The percentage of non-responders in SA ranges from 7% (Mphahlele et al., 2002) to 20% 
(Young et al., 2013), with an average of 14% (calculated from data from Hino et al., 2001; 
Mphahlele et al., 2002; Schoub et al., 2002; Simani et al., 2009; Tsebe et al., 2001; Young et 
al., 2013). Most of these studies were performed in children under three years of age, and only 
Tsebe et al. (2001) noted an association of younger age and more recent vaccination with higher 
anti-HBs levels. The relatively high non-response rate of 20% was observed in women between 
the ages of 18 and 49 years (Young et al., 2013), and may be as a result of the older age of the 
subjects, as older age is a clinical factor of non-response to the HBV vaccine (Zuckerman, 
2006); however, the high non-response rate is likely due to the anti-HBs titres being measured 
after only two vaccine doses (Young et al., 2013).  
There is a direct correlation between HBV vaccine efficacy and anti-HBs titre (Jack et al., 
1999) and hence, antibody titre is the standardly used and easily implemented correlate of 
protection for HBV vaccine studies (Plotkin, 2008). T cell correlates of protection for HBV 
vaccine have also been identified (Carollo et al., 2013) but are less easy to implement as a 
standardised test (Suchard, 2012). Due to these well-established correlations of protection, 
responders and non-responders to HBV vaccination can be clearly defined. Therefore, HBV 
vaccination is an excellent model by which to study the mechanisms resulting in vaccine 
response versus non-response. This, in turn, could offer insight into mechanisms of immune 
response which may assist in the rational development of effective vaccines, not only against 
HBV, but also against other infectious diseases for which no vaccines are yet available.  
In order to understand mechanisms of vaccine response, a thorough understanding of the 
immunology behind the vaccine-induced immune response must be obtained. In the case of 
HBV, the immune response towards HBsAg provided in vaccines is thought to be very similar 
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to the immune response to natural HBV infection. The following sections provide a brief 
review of the immune response to HBV vaccine. 
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1.7 Adaptive Immune Response To HBsAg 
HBsAg (whether from natural infection or from vaccine), like many other protein antigens 
induces both a T cell and a B cell response (Cupps et al., 1984; Milich and Leroux-Roels, 
2003).  
 
1.7.1 T cell response 
Antigen presenting cells (APCs), such as macrophages, dendritic cells (DCs), and B 
lymphocytes, internalize pathogens or antigens (such as HBV or HBsAg) and process them 
into peptides that can be attached to HLA molecules and presented on the cell surface (Milich 
and Leroux-Roels, 2003). There are two classes of HLA molecules, class I and II. Class I 
molecules generally present intracellular antigens (such as viral peptides) and activate CD8+ 
cytotoxic T lymphocytes (CTLs) to kill the infected cell, and class II molecules usually present 
extracellular antigens and activate CD4+ helper T (Th) cells which produce cytokines that 
induce cellular and humoral responses (Bonilla and Oettgen, 2010).  
The class I and class II HLA molecules are the most polymorphic human proteins (Janeway et 
al., 2001; The MHC sequencing consortium, 1999). This highly polymorphic nature of the 
HLA molecules is thought to be driven by evolutionary pressure for the immune system to 
identify constantly evolving pathogens (The MHC sequencing consortium, 1999). The HLA 
genes are located on chromosome 6 in one of the most gene-dense regions of the human 
genome (Janeway et al., 2001; The MHC sequencing consortium, 1999).  The HLA class I and 
class II genes are also polygenic with three class I HLA genes (HLA-A, HLA-B and HLA-C) 
encoding the α chain of HLA class I molecules and three pairs of HLA class II genes (HLA-
DR, HLA-DQ and HLA-DP) encoding the α and β chains of class II molecules (Janeway et al., 
2001). The presence of several genes encoding HLA molecules allows an individual to present 
a broad variety of antigenic peptides (Janeway et al., 2001). 
There are several subsets of T cells, the largest subsets include CD4+ Th cells, CD8+ CTLs 
which are activated via the classical HLA class I and II molecules (Bonilla and Oettgen, 2010). 
A small T cell subset known as gamma delta T cells, as well as the natural killer T (NKT) cell 
subset do not recognise the the HLA class I and II molecules but rather recognise the 
nonclassical CD1 family of molecules (Bonilla and Oettgen, 2010). T cells can be furhter 
defined by a variety of cell surface markers indicative of exposure to antigen, state of mutation, 
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state of activation, memory, homing preference or other functional properties (Broere et al., 
2011). 
CD4+ and CD8+ naïve T cells are activated by two major signals which are received via their 
interactions with peptides presented via HLA on the surface of APCs. The first signal is 
achieved through the binding of the T cell receptor (TCR) to the HLA-peptide complex present 
on the APC cell surface (Bromley et al., 2001). In CD8+ T cells, this signal involves HLA class 
I molecules which are expressed on the surface of any nucleated cell, and the interaction is 
stabilized by CD8 (Bonilla and Oettgen, 2010; Broere et al., 2011; Bromley et al., 2001). In 
the case of CD4+ T cells, the interaction involves HLA class II molecules, expressed 
exclusively on APCs, and is stabilized by CD4 (Bonilla and Oettgen, 2010; Broere et al., 2011; 
Bromley et al., 2001). 
The second signal for T cell activation is a costimulatory signal (Bromley et al., 2001). There 
are many costimulatory signalling/receptor pairs involved at the T cell/APC immune synapse 
as seen in Figure 1.1. An example of costimulatory molecules involved in CTL activation is 
Fas ligand on the CD8+ T cell binding to Fas on the surface of the target cell (Bonilla and 
Oettgen, 2010; Broere et al., 2011). The classical example involved in Th cell activation is 
CD28 on the CD4+ T cell interacting with B7 (CD80/CD86) on the APC (Bromley et al., 2001).  
Upon activation, T cells proliferate rapidly in a clonal fashion with each clone having the same 
TCR and antigen specificity (Milich and Leroux-Roels, 2003). Some of these develop into 
memory T cells . Clonal CTLs kill infected cells either by the cytolytic granules granzymes 
and perforin, or through triggering Fas/Fas ligand-mediated apoptosis and also produce various 
cytolines (Bonilla and Oettgen, 2010; Broere et al., 2011). Th cells produce cytokines that assist 
in enhancing humoral and cellular immune responses (Bonilla and Oettgen, 2010). 
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Figure 1.1. Interactions made at the immunological synapse between the T cell and the interacting 
APC. CD, cluster of differentiation; CTLA, cytotoxic T lymphocyte associated protein; ICAM, 
intercellular adhesion molecule; LFA, lymphocyte function-associated antigen; MHC, major 
histocompatibility complex; PD(-L), programmed death (-ligand); TCR, T cell receptor. Adapted from 
den Haan et al., 2014. 
 
Activated CD4+ T cells can be further differentiated into Th1, Th2, Th17, follicular helper  T 
(TFh) and regulatory T (Treg) cell subsets according to the cytokines they produce (Broere et 
al., 2011). Th1 cell subset characteristically produces interleukin (IL)2, interferon gamma 
(IFNɣ) and TNFα, while Th2 cells produce IL4, IL5 and IL13 (Abbas et al., 1996; Bonilla and 
Oettgen, 2010; Broere et al., 2011). Cytokines which assist development of Th1 cells include 
IFNɣ and IL12 and those that support Th2 development include IL4 (Abbas et al., 1996; Broere 
et al., 2011). Th1 cells are predominantly involved in enhancing cellular immune responses 
whereas Th2 cells are necessary for antibody production by B cells (Broere et al., 2011), 
although this is an oversimplified categorisation since Th-type cytokines can be involved in 
humoral immune responses and vice versa (Abbas et al., 1996). For example, IFNɣ is involved 
in macrophage activation but also in the production of antibodies involved in opsonization and 
phagocytosis (Abbas et al., 1996). The differentiation of Th cells into these subsets are 
influenced by the antigen and by exposure to particular cytokines (Broere et al., 2011) and may 
also be influenced by HLA allele (Jafarzadeh and Shokri, 2012; Mangalam et al., 2013) and/or 
its expression levels (Thomas et al., 2012). 
The Th17 cell subset is a more recently described group of Th cells that produce IL17 and IL22 
(Bonilla and Oettgen, 2010; Broere et al., 2011). It is the first subset produced upon infection 
 
 
16 
 
and plays a role in pro-inflammatory actions (Broere et al., 2011). TFh cells are important in B 
cell differentiation and the in the generation of memory B cells (Crotty, 2011). Conversely, 
Treg cells are involved in down-regulation of immune responses (Broere et al., 2011). Treg 
cells produce anti-inflammatory cytokines such as IL10 and Transforming growth factor beta 
(TGFβ) (Bonilla and Oettgen, 2010; Broere et al., 2011). Treg also form a small set of CD8+ T 
cells (Broere et al., 2011). 
 
1.7.2 B cell response (T-dependent) 
In a manner analogous to T cell activation, B cells are activated after receiving two major 
signals (Bonilla and Oettgen, 2010). The first signal involves the cross-linking of B cell 
receptors (BCRs). BCR cross-linking is caused by the interaction of BCRs with whole native 
antigen in its 3-dimensional conformation (Bonilla and Oettgen, 2010). Cross-linking of BCRs 
results in the activation of intracellular signalling pathways (Bonilla and Oettgen, 2010). The 
first signal results in B cells being able to interact with activated T cells which will provide the 
second signal (Bonilla and Oettgen, 2010).  
B cells themselves are APCs which present peptides on HLA class II molecules after 
internalizing and processing antigen recognised by the BCR (Bonilla and Oettgen, 2010). The 
antigen presenting B cell can then interact with a Th cell specific for the HLA class II-peptide 
complex (Bonilla and Oettgen, 2010). The HLA class II-peptide complex expressed on the 
surface of the B cell is recognized by the TCR of the interacting T cell, which was previously 
activated by interaction with an APC (Milich and Leroux-Roels, 2003). This interaction 
between TCR and HLA-peptide complex is stabilized by the CD4 molecule on the T cell 
surface (Broere et al., 2011). Additionally, costimulatory signals are generated through the 
interaction of signal/receptor pairs on the B and T cell, such as the CD40-CD40 ligand 
interaction (Figure 1.2) (Milich and Leroux-Roels, 2003). Both cells involved in this B cell/Th 
cell immunological synapse are activated: the Th cell secretes Th2-type cytokines (such as IL4, 
IL5 and IL13) and these cytokines, together with the signals described above, result in the 
differentiation of the B cell into antibody-secreting plasma cells or memory cells (Bonilla and 
Oettgen, 2010; Broere et al., 2011). 
 
 
 
17 
 
Figure 1.2. Costimulatory pairs in B cell/T cell interactions. A follicular T helper (TFH) cell 
interacting with a B cell to induce the production of memory B cells or antibody-producing plasma 
cells. CD, cluster of differentiation; CD40L, CD40 ligand; CXCR5, chemokine C-X-C motif receptor 
5; ICOS(L), inducible costimulatory (ligand); IL-21(R), interleukin-21 (receptor); MHC, major 
histocompatibility complex; PD(L)-1, programmed death (ligand)-1; TCR, T cell receptor. Adapted 
from Shekhar and Yang, 2012. 
 
Additionally, the humoral response is assisted by certain proteins of the complement system 
(Milich and Leroux-Roels, 2003). The generation of memory B cells which occurs in germinal 
centres is reliant on contact with antigens held by follicular dendritic cells (FDCs) (Milich and 
Leroux-Roels, 2003). FDCs retain antigens that are coated with the complement components 
C3d and C4d (Milich and Leroux-Roels, 2003). However, FDCs do not process and present 
antigens via MHC; they present intact antigen-antibody complexes on their cell surface using 
Fc receptors (FcR) or complement receptors CD21 or CD35 (Milich, 2002). 
In responders to HBV vaccine, both memory T and B cells are produced which provide 
protection against HBV infection upon subsequent exposure to the virus (Hennig et al., 2008). 
While immune response is vital in protection against disease, its regulation is equally 
important. B and T lymphocytes can be kept in check by the inhibition of costimulatory signals, 
in which case the cells become anergic (unable to respond to antigen) (Wang and Zheng, 2013). 
However, more commonly described is the mechanism of regulation through the production of 
regulatory cytokines by Treg cells, including both CD4+ and CD8+ Treg cells (Broere et al., 
2011; Wang and Zheng, 2013). Treg cells are mainly involved in the regulation of T cells, but 
they have been found to regulate other cell types as well, including B cells (Wang and Zheng, 
2013). For example, the regulatory cytokine IL10 is capable of suppressing both cellular (via 
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Th1 cells) and humoral (via Th2 cells) immune responses by reducing production of IL2, TNFα 
and IL5 (Broere et al., 2011). IL10 is also able to reduce T cell activation indirectly by down-
regulating APC expression of HLA and costimulatory molecules (Broere et al., 2011). In 
addition to suppressing B cells by cytokine production, Treg cells can release granzyme B and 
perforin to kill B cells (Wang and Zheng, 2013). Moreover, activated B cells can also produce 
cytokines, including IL4, IL 6, IL 10, IL23 and TNFα, which add to the regulation of immune 
responses (Wang and Zheng, 2013). 
As can be seen from the above simplified explanation of the immune responses to an antigen 
(such as HBsAg), there are many interacting pathways involving numerous molecules. Natural 
genetic variation in the genes encoding these molecules can cause changes in the immune 
pathways described. This, in turn, may result in non-responsiveness to HBV vaccination. From 
this we can understand the hypotheses put forward to explain the mechanisms underlying non-
response. 
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1.8 Factors Causing Non-Response To HBV Vaccine 
1.8.1 Clinical factors 
Several clinical factors have been associated with poor antibody response to HBV vaccination. 
These factors include the site and route of injection, gender, age, body mass, cigarette smoking 
and immunosuppression or immunodeficiency (Averhoff et al., 1998; Chathuranga et al., 2013; 
Cleveland et al., 1994; Fisman et al., 2002; Ingardia et al., 1999; Milner and Beck, 2012; 
Roome et al., 1993; Shaw et al., 1989; Tohme et al., 2011; Young et al., 2013; Zuckerman, 
1996). In a Gambian twin study, a relatively high heritability was observed for anti-HBs 
response (Newport et al., 2004), suggesting a genetic mechanism for non-response to HBV 
vaccine. However, genetic and/or cellular mechanisms underlying these associations with lack 
of response to vaccination remain unclear, as discussed below. 
 
1.8.2 Immunogenetic hypotheses investigated to explain non-response  
While numerous studies have investigated immunogenetic causes of non-response to the HBV 
vaccine in Caucasian and Asian populations (such as Höhler et al., 2002; Kardar et al., 2002; 
Li et al., 2013), few have been performed in African populations (Hennig et al., 2008; Newport 
et al., 2005; Ryckman et al., 2010), and none in South African individuals. 
Defects in the genes encoding any molecule involved in any step along the immune pathways 
described above could potentially cause a lack of antibody production in response to HBV 
vaccination. Appropriate genes can be studied using a candidate-specific approach or using a 
genome-wide approach. The candidate gene approach involves analysing a gene/mutation that 
may play a role in the phenotype of interest, either due to its function or due to other evidence 
that may implicate it (Hirschhorn and Daly, 2005). Genome-wide association studies (GWAS) 
involve surveying the whole genome without any prior hypothesis as to the causal candidates 
in order to identify genetic variants commonly associated with a phenotype (Hirschhorn and 
Daly, 2005). To date the candidate gene approach has been used more often than GWAS for 
identifying gene variants associated with non-responsiveness to the HBV vaccine, possible due 
to the expense and large sample sizes required by GWAS. 
The literature review below summarises findings from GWAS, as well as from candidate 
approaches which studied associations with, and mechanisms for, non-response to HBV 
vaccination.  
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1.8.2.1 Identifying genetic associations with HBV vaccine response 
There is value in examining genetic associations in multiple populations or ethnic groups. Rates 
of disease and of other phenotypes, such as adverse response to treatment, vary between 
populations due to variation in both genetic and non-genetic risk factors (Risch et al., 2002; 
Rosenberg et al., 2002). Specific alleles or allele frequencies can differ across populations and 
a variant might only occur, or be common, in certain populations (Adeyemo and Rotimi, 2010; 
Keita et al., 2004; Myles et al., 2008; Rosenberg et al., 2010). Furthermore, the effect sizes of 
risk variants may differ across populations, so that the underlying determinants of the same 
disease may vary between populations (Rosenberg et al., 2010; Tang, 2006).  Additionally, 
differences in linkage disequilibrium (LD) patterns across populations means that finely 
localizing the risk variant(s) will be more probable in populations with lower LD (Rosenberg 
et al., 2010; Teo et al., 2010). As considerable genetic variation may be specific to regions or 
populations, there is an interest in the potential role of the geographic distribution of genetic 
variation in contributing to phenotypic differences between groups (Keita et al., 2004; 
Mountain and Risch, 2004).  
As mentioned, genome-wide approaches aim to identify genetic variants associated with the 
phenotype of interest without any a priori assumptions or candidate genes in mind. While 
several GWAS have been performed looking for genetic associations with HBV infection 
outcomes (Al-Qahtani et al., 2013; Hu et al., 2013; Kim et al., 2013b; Mbarek et al., 2011; 
Nishida et al., 2012), relatively few GWAS have been performed looking for genetic 
associations with HBV vaccine response. One GWAS performed in an Indonesian population, 
with an initial scan of over 400 000 single nucleotide polymorphisms (SNPs), found multiple 
significant genetic determinants within the HLA region (Png et al., 2011), including rs3135363 
in HLA-DR, rs9277535 in HLA-DP and rs9267665 in the HLA class III region. Pan et al. (2013) 
performed a GWAS in a Han Chinese cohort and found that the strongest associations HBV 
vaccine non-response were 21 variants in the HLA region on chromosome 6. These 21 SNPs 
could be tagged by rs477515, rs28366298, rs3763316 and rs13204672, but the strongest 
association was rs477515 (upstream of HLA-DRB1) which reached genome wide significance 
even after Bonferroni correction (Pan et al., 2013). A recent GWAS performed in Taiwan found 
many significant associations in the HLA-DP locus, with rs7770370, an HLA-DPB1 intronic 
variant, reaching genome-wide significance (Wu et al., 2015). 
Another study investigated 715 SNPs in 133 candidate genes that specifically excluded the 
MHC region and found that variations in mitogen-activated protein kinase 8 (MAPK8), as well 
 
 
21 
 
as in the cytokine genes interferon gamma (IFNG) and IL10RA, affected peak anti-HBs levels 
in the studied Gambian population (Hennig et al., 2008). While MAPK, a kinase, is not an 
obvious player in immune response pathways, it is a key player in the signal transduction 
pathways that result in the consequent response after receiving a signal (Hennig et al., 2008). 
This highlights that molecules involved in these transduction pathways cannot be ignored when 
attempting to identify causative molecules of HBsAg non-responsiveness. 
 
1.8.2.2 Defects related to antigen presentation in association with HBV vaccine response 
One major hypothesis suggested to explain non-responsiveness to the HBV vaccine is defective 
antigen presentation which results in either an inefficient T cell response or an inefficient B 
cell response. Defective antigen presentation could involve HLA-mediated antigen 
presentation (during APC/T or T/B cell interactions), or HLA independent antigen presentation 
(during B/FDC interaction) as discussed in section 1.7.2 above. Several aspects of antigen 
presentation have been examined in the literature in association with HBV vaccine response, 
including HLA variation, binding of HBV antigen to HLA alleles, variation in secondary 
signalling molecules, variation in complement influencing antigen presentation and TCR 
variation. Results of these studies are reviewed below. 
HLA genes are the most polymorphic genes involved in T cell/APC interactions and influence 
the outcomes of many viral and bacterial infections and vaccines (reviewed in Blackwell et al., 
2009; Yucesoy et al., 2013) therefore, they are obvious candidate genes to be examined. Many 
significant associations between particular HLA alleles and non-response to HBV vaccination 
have been detected (Hennig and Hall, 2012). HLA class II alleles and their association with 
antibody response to the HBV vaccine have been studied extensively in Caucasian and Asian 
subjects (Amirzargar et al., 2008; Caillat-Zucman et al., 1998; Craven et al., 1986; Desombere 
et al., 1998; Höhler et al., 2002b; Kimman et al., 2007; Langö-Warensjö et al., 1998; Martinetti 
et al., 2000; Milich and Leroux-Roels, 2003; Wang et al., 2004; Wu et al., 2014, 2013).  
In order to improve the statistical power of these studies and to summarise published data, Li 
et al. (2013) performed a meta-analysis involving fifteen studies and a total of 2 308 Caucasian 
and Asian subjects. The meta-analysis showed the following significant associations between 
HLA variants and HBV vaccine response: HLA-DRB1*01, -DRB1*13:01, -DRB1*15, HLA-
DQB1*05 (*05:01) and -DQB1*06 (*06:02) were associated with a good (>10 IU/L) antibody 
response. HLA class II alleles associated with non-response (<10 IU/L) to the HBV vaccine 
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were HLA-DRB1*03 (*03:01), -DRB1*04, -DRB1*07 and -DRB1*13:02 and -DQB1*02 (Li 
et al., 2013). Relatively few studies have studied HLA-DP variation, but HLA-DPA1*01:03 
and HLA-DPB1*02:02, *04:01 and *13:01 have been associated with good response, although 
*04:01 is the most consistent association  (Desombere et al., 1998; Martinetti et al., 1995; 
Mineta et al., 1996; Wu et al., 2015, 2014, 2013) and HLA-DPB1*05:01, *09:01 and *11:01 
have been associated with non-responsiveness in Asian and Caucasian populations (Desombere 
et al., 1998; Wataya et al., 2001). 
Most of these risk and protective alleles associated with HBV vaccine response are similar to 
those identified in association with HBV infection outcome. Only HLA-DRB1*13:02 showed 
contrary effects – a risk allele for HBV vaccine non-response, but protective against chronic 
HBV infection. Additionally, there were several alleles associated with HBV vaccine response 
that were not reported as being associated with HBV infection outcome and vice versa. 
HLA class I associations have not been studied as extensively as class II in the context of HBV 
vaccine response because exogenous protein antigen, such as the HBsAg, is expected to be 
presented by HLA class II and not by HLA class I. HLA-A*26:02 (Mineta et al., 1996) and 
HLA-Cw*03 (Wang et al., 2004) are associated with low antibody production. Barnaba et al. 
(1990) found that if antigen cross presentation occurs in B cells (that is, antigen is displayed 
via B cell HLA class I instead of on HLA class II as usually expected), then the B cell may be 
targeted for antigen-specific CTL-mediated lysis and lower antibody production may occur. 
Factors driving HLA cross presentation are unclear.   
The above describes associations found between single HLA alleles and responsiveness, 
however, studies involving associations with the genes of the MHC region are confounded by 
the high levels of linkage disequilibrium (LD) between the HLA loci (Paximadis et al., 2012). 
As a result of this LD, it is often difficult to identify the precise causative variation involved, 
and therefore, haplotypes are described in association with responsiveness to HBsAg. For 
example, of the HLA class II alleles associated with non-response described above, HLA allele 
HLA-DQB1*06:02 is in LD with HLA-DRB1*15:01 and HLA-DQB1*02:01, -DRB1*07:01 
and -DRB1*03:01 are in strong LD with each other (Wang et al., 2004; Zuckerman, 1996). 
Other haplotypes associated with non-response to the HBV vaccine are haplotypes HLA-
DRB1*07-DQB1*02, HLA-DRB1*07-DQB1*03 (Wang et al., 2004) and HLA-B18-
DRB1*03:01-DQB1*02:01 (Milich and Leroux-Roels, 2003). Haplotypes associated with 
good response to HBV vaccination include HLA-B*15-Cw*03, HLA-DRB1*15-DQB1*06 
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(Wang et al., 2004), HLA-DQB1*06:02-DQA1*01:02-DR15 and HLA-DQB1*06:03-
DQA1*01:03-DR13:01 (Milich and Leroux-Roels, 2003). Haplotypes including the HLA-
DPB1 locus have not been examined. 
HLA allele frequency distributions differ between different ethnicities (Paximadis et al., 2012; 
Sidney et al., 2010) and different HLA alleles could potentially mediate different immune 
responses in different populations. Few studies have been conducted in African populations, 
however, the association observed between HLA-DRB1*07:01 and HLA-DQB1*02 and non-
responsiveness and between HLA-DRB1*15 and HLA-DQB1*06 and good response to the 
HBV vaccine were confirmed in one study in African-American subjects (Wang et al., 2004). 
Most of the class I and class II HLA-DR and -DQ alleles associated with response to HBV 
vaccination are present at reasonable frequencies in South African black populations (Lombard 
et al., 2006; Paximadis et al., 2012; Pirie et al., 2001), as shown in Table 1.1. Only HLA-
A*26:02 and -B*18 are not common in a black South African population as they are found at 
a frequency of less than 5%. However, of the HLA-DP alleles associated with vaccine response, 
only HLA-DPB1*04:01 is found at a frequency greater than 5% in black South African 
populations (Lombard et al., 2006). 
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Table 1.1. HLA alleles associated with HBV vaccine response and their frequency in black South 
African populations 
HLA allele 
Association with HBV 
vaccine response* 
Reference for association with 
HBV vaccine response 
Frequency 
(%) 
Reference for 
frequency 
A*26:02 Low Mineta et al., 1996 0 Paximadis et al., 2012 
B*15 High Wang et al., 2004 12.9 Paximadis et al., 2012 
B*18 Low Milich and Leroux-Roels, 2003 5.1 Paximadis et al., 2012 
Cw*03 Low Wang et al., 2004 6.8 Paximadis et al., 2012 
DRB1*01 High Caillat-Zucman et al., 1998; 
Desombere et al., 1998;  
Höhler et al., 2002b  
7.2 Pirie et al., 2001; 
Lombard et al., 2006; 
Paximadis et al., 2012 
DRB1*03 
(03:01) 
Low Amirzargar et al., 2008;  
Caillat-Zucman et al., 1998;  
Craven et al., 1986;  
Martinetti et al., 2000 
32.4  
(13.7) 
Pirie et al., 2001; 
Lombard et al., 2006; 
Paximadis et al., 2012 
DRB1*04 Low Amirzargar et al., 2008 10.5 Pirie et al., 2001; 
Lombard et al., 2006; 
Paximadis et al., 2012 
DRB1*07 Low Amirzargar et al., 2008;  
Craven et al., 1986;  
Desombere et al., 1998;  
Martinetti et al., 2000;  
Wang et al., 2004 
12.6 Pirie et al., 2001; 
Lombard et al., 2006; 
Paximadis et al., 2012 
DRB1*13:01 High Langö-Warensjö et al., 1998 10.4 Lombard et al., 2006; 
Paximadis et al., 2012 
DRB1*13:02 Low Langö-Warensjö et al., 1998 9.2 Lombard et al., 2006; 
Paximadis et al., 2012 
DRB1*15 High Caillat-Zucman et al., 1998;  
Höhler et al., 2002b;  
Langö-Warensjö et al., 1998;  
Wang et al., 2004 
16.2 Pirie et al., 2001; 
Lombard et al., 2006; 
Paximadis et al., 2012 
DQA1*01:02 High Langö-Warensjö et al., 1998 41.1 Pirie et al., 2001; 
Lombard et al., 2006 
DQA1*01:03 High Langö-Warensjö et al., 1998 12.45 Pirie et al., 2001; 
Lombard et al., 2006 
DQB1*02 
(02:01) 
Low Amirzargar et al., 2008;  
Desombere et al., 1998;  
Martinetti et al., 2000;  
Wang et al., 2004 
31.3 
 (16.1) 
Pirie et al., 2001; 
Lombard et al., 2006 
DQB1*03 Low Martinetti et al., 2000 30.3 Pirie et al., 2001; 
Lombard et al., 2006 
DQB1*05 
(05:01) 
High Desombere et al., 1998 24.3  
(20.5) 
Pirie et al., 2001; 
Lombard et al., 2006 
DQB1*06 
(06:02) 
High Langö-Warensjö et al., 1998;  
Wang et al., 2004 
58.5  
(28.9) 
Pirie et al., 2001; 
Lombard et al., 2006 
DQB1*06:03 High Langö-Warensjö et al., 1998;  
Wang et al., 2004 
8.5 Pirie et al., 2001; 
Lombard et al., 2006 
DPB1*02:02 High Mineta et al., 1996; Wu et al., 2013 1.3 Lombard et al., 2006 
DPB1*04:01 High Desombere et al., 1998;  
Mineta et al., 1996;  
Wu et al., 2015, 2013 
15.5 Lombard et al., 2006 
DPB1*05:01 Low Wu et al., 2015, 2014, 2013 0.6 Lombard et al., 2006 
DPB1*09:01 Low Wu et al., 2013 0.0 Lombard et al., 2006 
DPB1*11:01 Low Desombere et al., 1998 2.8 Lombard et al., 2006 
DPB1*13:01 High Martinetti et al., 1995;  
Mineta et al., 1996 
2.3 Lombard et al., 2006 
*High antibody response characterised by antibody titre > 10 IU/L 
  Low antibody response characterised by antibody titre < 10 IU/L 
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The common association observed between HLA alleles and responsiveness to vaccines would 
seem to imply that lack of response is due to defective antigen presentation, that is, that certain 
HLA alleles do not bind HBsAg peptides for T cell recognition. However, Godkin et al. (2005) 
studied the affinity of HBsAg-derived peptide binding to selected HLA alleles and found that 
HLA alleles previously associated with non-responsiveness often show normal binding 
capabilities. In addition, it has been shown that APCs with HLA class II molecules associated 
with poor/non-response used in in vitro studies, were able to bind and present HBsAg peptides 
to T cells and stimulate appropriate T cell responses such as proliferation (Desombere et al., 
1995). 
Activation of the T and B cells may be affected by variation in secondary signalling molecules 
such as those shown in Figures 1.1 and 1.2. Therefore, response to HBV vaccination may also 
be influenced by variation in secondary signalling molecules, such as genetic mutations found 
in the candidate genes CD58 (Ryckman et al., 2010) and Integrin alpha-L (ITGAL) which were 
identified in a GWAS (Hennig et al., 2008). CD58, or Lymphocyte function-associated antigen 
(LFA)-3, is a molecule present on APCs that has previously been associated with T cell 
proliferation and/or differentiation in response to a poxvirus vaccine in mice, and it may be 
responsible for such a response after stimulation by other vaccines including the HBV vaccine 
(Ryckman et al., 2010). As a result, variations in the CD58 gene may result in a defective T 
cell response; this would explain the association observed between variant alleles of CD58 and 
lower antibody production (Ryckman et al., 2010). ITGAL, or LFA-1, is a protein with a central 
role in immune cell-cell interaction; thus, variation in the gene encoding ITGAL may 
detrimentally affect the T and B cell interaction, thereby leading to a decreased production of 
antibodies (Hennig et al., 2008). A study of genetic variation in some other secondary 
signalling molecules, specifically B7, suggested no role for variation at this locus in HBV 
vaccine response (Desombere et al., 2005). Reduced expression of the CD40 ligand was 
observed on Th cells in non-responders to the HBV vaccine (Goncalves et al., 2004). The CD40 
ligand-CD40 interaction is important in the activation of B cells and the switching of 
immunoglobulin (Ig) classes (Goncalves et al., 2004).  Molecules present on T cells such as 
CD25 and CD69 that are involved in T cell activation, have also been found to be expressed at 
lower levels in HBV vaccine non-responders compared to responders (Goncalves et al., 2004). 
However, there has not been a focused study of genetic variation in secondary signal 
interactions between APC and T cells, or between T and B cells. 
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Genetic variation along the B cell/FDC antigen presentation pathway (which is not HLA-
dependent) may also influence response to HBV vaccination. For example, C4 and C3 
molecules of the complement system play a role in FDC antigen presentation to B cells in 
germinal centres, as explained previously (Höhler et al., 2002a; Milich and Leroux-Roels, 
2003). Deficiencies in the complement components C4 are common in the Caucasian 
population where C4A gene deletions and the non-expressed C4AQ0 allele have been 
associated with non-response to the HBsAg (Höhler et al., 2002a; Milich and Leroux-Roels, 
2003). While this association has not been studied in Africans, C4A deficiencies are present in 
South African black populations, with differences between ethnic groups (Creemers and du 
Toit, 1996; Steuer et al., 1994), and therefore, may play a role in non-responsiveness in African 
populations. The influence of genetic variation in other molecules along this pathway, such as 
FcɣR, CD21 or CD35, has not been examined. 
 
Lastly, the possibility of a ‘hole’ in the TCR repertoire has been considered as a possible cause 
of poor response to the HBV vaccine, where the T cells are unable to recognise particular HLA-
peptide complexes due to changes in their TCR (Desombere et al., 2000; Roukens and Visser, 
2011). However, findings regarding the TCR repertoire in HBV vaccine responders and non-
responders do not support this theory (Soroosh et al., 2003).  
 
1.8.2.3 T cell response/cytokine production pathway in association with HBV vaccine response 
If defective antigen presentation is not the immunological cause of non-response to HBV 
vaccination, then defects in immune events that occur after antigen presentation should be 
considered, such as defects in T cell proliferation, cytokine production or memory cell 
formation. 
A poor T cell proliferative response has been demonstrated in non-responders to the HBV 
vaccine (Goncalves et al., 2004). Cytokine studies have shown that non-responders do indeed 
exhibit different cytokine levels compared to those observed in responders (Garner-Spitzer et 
al., 2013; Goncalves et al., 2004; Jafarzadeh and Shokri, 2003; Jafarzadeh et al., 2004; 
Jarrosson et al., 2004; Kardar et al., 2002; Larsen et al., 2000; Velu et al., 2008; Wataya et al., 
2001). Cytokine profiles of responders were found to differ from those of non-reponders, 
indicating a T cell dysfunction involved in non-responsiveness to the HBV vaccine (Jafarzadeh 
and Shokri, 2003; Kardar et al., 2002; Velu et al., 2008). In particular, decreased production of 
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various Th1 and Th2 cytokines including IL2, IL4, IL10, IL13 TNFα, TNFβ and IFNɣ, was 
found in non-responders compared to responders to the HBV vaccine (Goncalves et al., 2004; 
Jafarzadeh and Shokri, 2003; Kardar et al., 2002; Larsen et al., 2000; Velu et al., 2008). This 
is in contrast to the control of phytohaemagluttinin (PHA) induced cytokine production, which 
induces similar quantities of cytokines in responders and non-responders (Jafarzadeh and 
Shokri, 2003; Kardar et al., 2002; Velu et al., 2008). 
Other cytokines may also be of interest in vaccine-induced immune response. For example, 
IL28B has been associated with decreased Th2 cytokine production, decreased B lymphocyte 
proliferation and antibody production, and with lower seroconversion rates to the Influenza 
virus vaccine (Egli et al., 2014). The effect of IL28B variation on HBV infection is still a matter 
of debate. For example, Kim et al. (2013a) and Shi et al. (2015) found that genetic variants of 
IL28B were associated with outcomes of HBV infection and Lampertico et al. (2013) found 
that genetic variants of IL28B were associated with treatment outcomes of chronic HBV 
infection, while Martin et al. (2010) found that genetic variants of IL28B were not associated 
with outcomes of chronic HBV infection. Thus, whether IL28B associates with HBV vaccine 
non-response would be an interesting aspect to explore. Such an association, or lack thereof, 
may provide insight into whether non-responsiveness is a general or antigen-specific defect.  
Garner-Spitzer et al., (2013) examined if non-responders to HBV vaccination were also non-
responders to other antigens, that is, whether the cytokine defects were antigen specific or not. 
In response to a non-HBV antigen, HBV vaccine non-responders produced lower levels of IL2 
and IFNɣ and showed an increased production of IL10 and TNFβ (Garner-Spitzer et al., 2013) 
which may suggest a non-antigen specific mechanism for non-response. The high level of IL10 
production may be responsible for the reduced T cell proliferation to antigens observed in these 
individuals (Garner-Spitzer et al., 2013). Additionally, non-responders were found to have a 
somewhat lower mean percentage of naïve T cells and higher percentages of T effector memory 
cells, which may possibly be a compensation for lack of antibody (Garner-Spitzer et al., 2013).  
However, another study that identified differences in the cytokine profiles of non-responders 
and responders after HBsAg stimulations, noted that these differences were absent after 
stimulation with tetanus toxoid (Larsen et al., 2000), which suggests an antigen-specific non-
response. 
Consistent with the idea that defects in cytokine response in some non-responders may be due 
to a non-antigen specific mechanism, genetic polymorphisms in the genes encoding cytokines 
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and/or their receptors may contribute to poor antibody response. For instance, allele 2 of the 
IL12B promoter (which contains a 4-bp deletion) has been associated with HBsAg non-
responsiveness, while the IL4 TTC haplotype has been associated with response to the HBV 
vaccine in both European- and African-Americans (Wang et al., 2004).  
In summary, there is evidence supporting several mechanisms explaining defective T cell 
proliferation, abnormal cytokine production or defective T cell differentiation in HBV vaccine 
non-responders. In addition, cytokine production profiles have been associated with the HLA 
alleles (Jafarzadeh and Shokri, 2012), which still supports the hypothesis of a specific antigen-
presentation defect driving aberrant cytokine production. However, how this may occur has 
not yet been deciphered. 
 
1.8.2.4 B cell response/antibody production pathway in association with HBV vaccine response 
While the average percentages of naïve and specific CD19+ B cells were comparable between 
responders and non-responders prior to vaccination, HBsAg-specific B cells have been found 
to be significantly lower in non-responders than in responders following vaccination 
(Shokrgozar et al., 2001). Additionally, anti-HBs titres and activated B cells were found to be 
positively correlated (Shokrgozar et al., 2001). This would indicate that the decreased antibody 
production characteristic of non-response may be due to defects in the B cell response rather 
than in the antibody production pathway (Shokrgozar et al., 2001). This may be due to defects 
in the pathways generating the primary B cell repertoire or a defect in the B cell proliferation 
phase (Shokrgozar et al., 2001). This, in turn, can partially be caused by defects in the Th cell 
pathways as described above.  
Moreover, a higher percentage of transitional (immature) B cells has been observed in non-
responders compared to responders (Garner-Spitzer et al., 2013). These B cells possibly have 
regulatory function through the production of IL10 (Garner-Spitzer et al., 2013). This 
regulation may affect Th cells as well, which would then contribute to defects in B cell 
proliferation and differentiation, as described previously. 
A defect in the generation of memory B cells could contribute to the low antibody levels 
observed in non-responders. Variation in the C4 and C3 genes of the complement system as 
explained previously may affect B cell activation and B cell memory development (Höhler et 
al., 2002a; Milich and Leroux-Roels, 2003). However, the frequency of B memory cells in non-
responders has not been compared to that in responders. 
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To conclude, there are numerous genetic and functional immune characteristics which 
associate with antibody response to HBV vaccine. Variation in the HLA class II alleles and 
changes in T cell cytokine production seem to be the most common characteristics associated 
with HBsAg responsiveness. However, it is unclear why such strong associations with HLA 
exist since antigen presentation seems to be functional in non-responders (Desombere et al., 
1995). Few studies have examined both HLA variation and cytokine production in the same 
individual (except for Jafarzadeh and Shokri, 2012). It is still unclear whether variation in the 
HLA class II alleles and defective T cell function (the most common associations) are 
independent or relate to each other in some way. Thus, despite the findings described above, 
the mechanism underlying non-responsiveness to HBV vaccination is yet to be explained.  
 
1.8.3 HLA expression and HBV vaccine response 
There are still many immunogenetic mechanisms contributing to vaccine response that have 
not yet been examined in the context of the HBV vaccine. Furthermore, although defective 
antigen presentation, so far, is not thought to be a likely cause of non-response, it cannot be 
ruled out as several aspects of antigen presentation have not been fully examined. For example, 
the role of variation in HLA class II expression levels in vaccine response has not yet been 
studied, and this aspect is discussed further below. 
HLA class I molecules are expressed on all nucleated cells, with HLA-C being expressed at a 
level much lower than (approximately 10% of) that of HLA-A and -B (Zemmour and Parham, 
1992). Expression of HLA class II molecules (on B cells, macrophages and DCs) is tissue-
specific, varies with the developmental/maturation stage of the cell as well as in response to 
antigen and cytokine exposure (Glimcher and Kara, 1992). The frequency of cells expressing 
HLA-DP is generally lower than the frequency of cells expressing HLA-DR, but higher than 
that expressing HLA-DQ  (Edwards et al., 1986, 1985; Gansbacher and Zier, 1988). 
Allele-specific HLA-C expression levels have been shown to affect the progression of certain 
diseases, including HIV and Crohn’s disease (Apps et al., 2013; Kulkarni et al., 2011). 
Expression levels of HLA-DP alleles have been associated with recovery from HBV infection 
(Thomas et al., 2012) and with graft-versus-host disease during tissue transplants (Petersdorf 
et al., 2015). In particular, Thomas et al. (2012) showed that HLA-DPB1*01:01 had a higher 
expression level compared to the *04:01 allele, and HLA-DPB1*01:01 was associated with 
chronic HBV infection, while *04:01 was associated with HBV clearance. 
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Additionally, it has been suggested that the concentration of HLA-peptide complexes available 
on the surface of APCs may affect Th cell differentiation into Th1 and Th2 cells; such an 
association could provide a link between HLA allele and T cell function (Jafarzadeh and 
Shokri, 2012). In particular, increased HLA class II expression is predicted to sway Th response 
towards Th1 differentiation (Baumgart et al., 1998; Cavalli et al., 2016). However, the effect 
of HLA expression on response to the HBV vaccine is yet to be investigated.  
This research project therefore aims to examine the role of HLA-DP genetic variation and 
expression levels in response to HBV vaccination in a vaccinated South African cohort. 
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1.9 Aims and Objectives 
This research study aimed to firstly establish a South African cohort in which response to HBV 
vaccination, and immunogenetic mechanisms for this response, could be explored. This was 
the focus of chapter 2. 
Our second aim was to explore HLA-DP and other HLA class II and cytokine SNP variation in 
South African individuals, and to investigate the association between these genetic variants and 
anti-HBs titres. This work is discussed in chapter 3. 
Thirdly, we aimed to explore the relationship between HLA-DPB1 expression levels and HBV 
vaccine response in South Africans. We hypothesized that high expressed HLA-DP alleles may 
associate with poor anti-HBs responses, whereas low expressed HLA-DP alleles may associate 
more with good HBV vaccine response. We also examined whether HLA SNPs from chapter 3 
were associated with HLA-DPB1 expression levels. This work is discussed in chapter 4. 
A final summary is given in chapter 5. 
Study objectives included: 
1. Recruit 150 South African laboratory workers previously vaccinated against HBV, 
collect blood samples, test HBV antibody titres and classify participants as responders, 
poor-responders or non-responders to the HBV vaccine. 
 
2. Extract DNA from blood samples and genotype DNA for HLA-DP alleles, selected 
SNPs in the HLA class II region and selected SNPs in cytokine genes. 
 
3. Analyse the genetic variation data by comparing the variation observed in different 
ethnic groups in the South African cohort, and by comparing the genetic variation to 
reference populations; and finally determine whether genetic variation associates with 
response to the HBV vaccine. 
 
4. Extract RNA from blood samples and use this in qPCR to measure HLA-DPB1 
expression levels. 
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5. Analyse whether HLA-DPB1 allele-specific mRNA expression levels occur, and if 
expression levels associate with response to vaccine. More specifically: 
a) Test if HLA-DPB1*04:01 homozygosity or heterozygosity associates with low 
expression and HLA-DPB1*01:01 homozygosity associates with high expression. 
b) Test if other SNPs in the HLA-DPB1 region (rs9277534, rs7770370 and rs931) 
associated with expression level. 
c) And compare HLA-DPB1 expression levels with anti-HBs titres to test if low-
responders had high or low HLA-DPB1 expression levels. 
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2.1 Introduction 
As described in Chapter 1, HBV has affected more than two billion people worldwide and 
approximately 360 million infected individuals are chronic carriers, at high risk of suffering 
from the sequelae of cirrhosis and hepatocellular carcinoma (WHO, 2009). HBV is highly 
endemic to Asia and Africa, especially sub-Saharan Africa (Kew, 1996; Kiire, 1996; Romano 
et al., 2011). In Africa, the carrier rate is approximately 15%, but differs between gender and 
regions, even within a country (Kiire, 1996), compared to the global carrier rate of 10% 
(Frodsham, 2005; Shepard et al., 2006). 
However, HBV infection can be prevented by vaccination. Since its inclusion in the South 
African EPI since 1995 (Kew, 2008; Young et al., 2013), it has greatly reduced the HBV 
infection rates (Hino et al., 2001; Tsebe et al., 2001; Schoub et al., 2002). Despite the success 
of the HBV vaccine, studies have shown that 5-10% of healthy individuals, globally, do not 
produce sufficient antibody titres (<10 IU/L) following vaccination (Averhoff et al., 1998; 
Cleveland et al., 1994; Coates et al., 2001; Dienstag et al., 1984; Roome et al., 1993; Szmuness 
et al., 1982, 1981, 1980). The few studies that have been performed in South Africans, observed 
a higher rate of non-response, with an average of 14% (calculated from  data from Hino et al., 
2001; Tsebe et al., 2001; Mphahlele et al., 2002; Schoub et al., 2002; Simani et al., 2009; 
Young et al., 2013). Many European and Asian studies have investigated the factors 
contributing to HBV vaccine non-response and several demographic and genetic factors have 
been associated, yet the immunogenetic mechanisms of non-response are yet to be explained. 
There is a lack of South African data on the genetics of HBV vaccination, so in order to explore 
immunogenetic mechanisms of HBV vaccine response in South Africans, a cohort was needed 
for this study.  
The aim of this chapter was to describe the establishment of a South African cohort in which 
response to HBV vaccination and the immunogenetic mechanisms for response, could be 
investigated. The objectives were to recruit 150 South African laboratory workers, collect 
blood samples and test for HBV antibody titres in order to classify particpants as responders, 
poor responders or non-responders to the HBV vaccine. 
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2.2 Materials and Methods 
2.2.1 Recruitment and enrolment 
South African health care and laboratory workers from the National Health Laboratory Service 
(NHLS) at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH), the NHLS in 
Braamfontein, the National Institute for Communicable Diseases (NICD) and the School of 
Pathology at Wits University were recruited to participate in this study. Many adults in SA 
remain unvaccinated against HBV since the vaccine was only introduced into the South African 
EPI in 1995, given at 6, 10 and 14 weeks (and recently 18 months) of age. Adults from these 
workplaces were targeted since immunity to HBV is a routine requirement of employment. 
Inclusion criteria were:   
• NHLS / School of Pathology health care and laboratory workers with the exception of 
staff at NICD Centre for Vaccines and Immunology (CVI) (due to study collaboration 
with CVI) 
• previously vaccinated against HBV 
• HIV-negative.  
• South African, any ethnicity 
• over 18 years old 
The study was approved by the Human Research Ethics Committee (Medical) of the University 
of the Witwatersrand, South Africa (clearance certificate no. M140954; see Appendix A) and 
written, informed consent was obtained from the participants. One hundred and seventy South 
African, HIV-negative health care and laboratory workers were recruited into this study over 
three months August-October 2015. 
HIV testing, using a rapid HIV test (Alere DetermineTM HIV – 1/2), was performed by an 
independent phlebotomist after counselling. Researchers were not made aware of the identities 
of any participant excluded due to positive HIV results. Following confirmation of negative 
HIV status, a venous blood sample of 33 ml was taken. Serum, plasma and cells were isolated 
and stored on the same day as collection as described below.  
Information regarding demographics (age, sex, weight, ethnicity), hepatitis infection history, 
HBV vaccination history and other factors that may affect response to the HBV vaccine 
(smoker-status, history of cancer, auto-immune disease) was requested through participant self-
recall in the form of a brief questionnaire (Appendix B).  Where possible, additional data with 
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regards to HBV vaccination history and antibody titres were obtained from NHLS records, 
with permission granted from the Head of Occupational Health, NHLS, and from the 
participants. 
 
2.2.2 Preparation of blood samples for storage  
The 33 ml of blood taken per participant were collected into seven blood collection tubes, as 
described in Table 2.1. In the case that the total blood volume required was not obtained, 
whatever blood was taken was used as resourcefully as possible. 
 
Table 2.1. Blood collected and purpose thereof 
Tube type Number of tubes Volume per tube* (ml) Purpose of storage  
CAT 1 2 Serum for antibody tests 
EDTA 1 2 Full blood count** 
EDTA 2 4 
Future DNA and RNA 
extraction 
ACD 3 7 
Plasma and PBMCs for 
functional assays 
Total 7 33  
*Volumes are approximate 
**Full blood count was performed by Ampath Laboratories 
Abbreviations: CAT, Clot Activator Tube; EDTA, Ethylenediaminetetraacetic Acid; ACD, Acid Citrate 
Dextrose; PBMC, Peripheral Blood Mononuclear Cells 
 
Serum was obtained by centrifugation of whole blood in Clot Activator (CAT) tubes at 1 250 
g for 10 minutes and stored at -75°C. Plasma was removed from three Acid Citrate Dextrose 
(ACD) tubes after centrifugation at 750 g for 10 minutes. The plasma was then centrifuged at 
750 g for 15 minutes and the purified plasma was stored at -75°C.  
Peripheral Blood Mononuclear Cells (PBMC) were isolated from Ethylenediaminetetraacetic 
Acid (EDTA) and ACD blood tubes. PBMCs were isolated by density gradient centrifugation 
over Ficoll-Paque PLUS (GE Healthcare Bio-Sciences AB, Sweden). After removal of the 
plasma, the blood was diluted approximately 1:1 with Phosphate buffered saline (PBS) (Lonza, 
BioWhittaker, USA). Fifteen millilitres of blood/PBS mixture were gently layered onto 15 ml 
of Ficoll and centrifuged at 500 g (Hermle Z400-K) for 30 minutes at 23°C, brake off. This 
resulted in the formation of four distinct layers based on density: plasma/PBS, PBMCs, Ficoll 
and erythrocytes/granulocytes. The plasma/PBS layer was first discarded before gently 
transferring the PBMC layer to a new tube. The PBMCs were washed twice with 30 ml PBS 
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and pelleted by centrifugation at 250 g for 15 minutes. After discarding the supernatants, the 
pellets derived from the ACD and EDTA tubes were resuspended in 10 ml and 5 ml RPMI-
1640 medium (Lonza, BioWhittaker, USA) respectively. 
The PBMCs were counted either manually or using an automated cell counter. For manual cells 
counts, 10 µl of the cell suspension was mixed with an equal volume of 0.1% Trypan Blue 
solution (Sigma, UK) and applied to a disposable Neubauer improved haemocytometer 
(DigitalBio, Korea). Live and dead cells were counted at 400 × magnification using a light 
microscope. Similarly, for automated cell counts (using the Countess™ Automated Cell 
Counter, Invitrogen), 10 µl of the cell suspension were mixed with an equal volume of 0.4% 
Trypan Blue (Life Technologies, USA) and applied to a Countess™ cell counting chamber 
slide. In both cases, cell viability ( 
𝑙𝑖𝑣𝑒 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡
𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡
 ×100), total number of live cells obtained and 
number of live cells per ml of whole blood were calculated. Following the cell counts, 
approximately 4-5 × 106 cells (where possible) were removed from the cells derived from blood 
from the EDTA tubes and stored directly at -20°C for the purpose of subsequent DNA 
extractions. The erythrocyte/granulocyte layer under the Ficoll layer originating from the blood 
of the EDTA tubes was also saved and stored for DNA extraction.  The remaining cells derived 
from blood from the EDTA tubes were mixed with Buffer RLT Plus/β-mercaptoethanol 
solution (Qiagen, USA) and stored at -75°C for subsequent RNA extractions.  
The cells derived from blood from the ACD tubes were stored for functional assays. Cells were 
diluted to 2 million cells/ml (unless >60 million cells were obtained, then the concentration 
was increased to 4 or 6 million cells/ml) with freeze media consisting of inactivated FBS 
(HyClone, USA) with 10% Dimethyl Sulfoxide (DMSO) (Sigma Life Science, USA). Aliquots 
of 1 ml were placed in a CoolCell/Mr Frosty at -80°C for approximately 24 hours for rate-
controlled freezing (-1°C/minute), after which the cells were removed for long term storage at 
<-80°C. 
 
2.2.3 Serology tests and classification of participants 
Serum samples stored at -75°C were batched and used for antibody/antigen testing. If serum 
was not available, plasma was used instead.  Three different antibody/antigen tests were used 
in order to classify study participants as having experienced current or prior infection, or as 
being immune due to vaccination or potential non-responders to vaccination. These tests 
 
 
38 
 
included tests of hepatitis B surface and core antibody (anti-HBs and anti-HBc) and test for 
hepatitis B surface antigen (HBsAg).  
Hepatitis B surface and core antibody (anti-HBs and anti-HBc respectively) testing was 
performed by staff of CVI, NICD using the ARCHITECT i 1000SR Immunoassay Analyzer 
using standard operating procedures. The ARCHITECT Anti-HBs assay (Abbott Ireland, 
Ireland) was used to measure anti-HBs, while the ARCHITECT Anti-HBc II assay (Abbott, 
Germany) was used detect anti-HBc. These assays are two-step chemiluminescent 
immunoassays described below.  
For anti-HBs detection, the sample was combined with recombinant HBsAg (rHBsAg) coated 
microparticles. Anti-HBs present in the sample bound to the antigen coating the microparticles. 
Following a wash step, acridinium-labelled rHBsAg conjugate was added. After washing, 
Trigger solutions were added to the mixture resulting in a chemiluminescent reaction, which 
was measured in relative light units (RLU). There was a direct relationship between RLUs and 
the amount of anti-HBs in the sample. The analyser determines the concentration of anti-HBs 
in the specimen using a calibration curve. A concentration greater or equal to 10 IU/L indicated 
the presence of protective levels of anti-HBs due to either vaccination or infection.  
The detection of anti-HBc used a similar principle, but using rHBcAg coated microparticles, 
and an acridinium-labelled anti-human conjugate. The presence or absence of anti-HBc in the 
specimen was determined by comparing its chemiluminescent signal to the cut-off signal 
determined from the calibration. A value greater than or equal to the cut-off signal (1.0) was 
indicative of the presence of anti-HBc in the sample, suggesting previous or current infection. 
HBsAg was tested in any samples positive for anti-HBc in order to differentiate between 
current and resolved HBV infections, and in samples with anti-HBs titre <10 IU/L in order to 
rule out a current HBV infection. Any positive HBsAg results were confirmed by repeating the 
assay. The ARCHITECT HBsAg Qualitative assay is a one-step chemiluminescent 
immunoassay, where the sample is combined with anti-HBs coated microparticles and 
acridinium-labelled anti-HBs conjugate. After washing, the Trigger solutions are added and the 
resulting chemiluminescent reaction is measured as RLUs. A value greater than or equal to the 
cut-off value of 1.0 indicates the presence of HBsAg in the sample. 
Together, the results of the antibody and antigen testing were interpreted as follows in Table 
2.2. 
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Table 2.2. Classification of participants according to serology results 
Anti-HBs 
(IU/L) 
Anti-HBc 
(S/CO) 
HBsAg 
(S/CO) 
Classification 
<10 <1 <1 Potential non-responder to vaccine 
<10 >1 >1 Current infection 
>10 <1 Not tested Responder to vaccine 
>10 >1 <1 Previous infection 
Abbreviations: Anti-HBs, Antibodies against hepatitis B surface antigen; Anti-HBc, Antibodies against 
hepatitis B core antigen; HBsAg, Hepatitis B surface antigen; IU/L, International Units per Litre; S/CO, 
Signal to cut-off ratio 
 
In addition, for responders where complete vaccine history and previous antibody testing 
records were available, study participants were classified as follows in Table 2.3. 
 
Table 2.3. Classification of participants based on vaccine history and anti-HBs titre records 
Anti-HBs (IU/L) 
(measured within 6 months 
after 3 doses of vaccine) 
Classification 
<10 Non-responder 
<200 Low-responder 
>200 Normal-responder 
                              Abbreviations: Anti-HBs, Antibodies against hepatitis B surface antigen;  
                              IU/L, International Units per Litre 
 
However, due to many instances of incomplete vaccination records, and because our HBV 
serology testing was not performed within six months of vaccination in most participants, it 
could not be ascertained if individuals with anti-HBs <10 IU/L and anti-HBc <1 (“Potential 
non-responder to vaccine”) were true non-responders to the HBV vaccine, or if their antibodies 
had just waned over time, or if they had never been vaccinated nor exposed to HBV. Therefore, 
a single dose HBV vaccine booster (Heberbio HBV, The Biovac Institute, SA) was offered to 
participants with Anti-HBs titre <20 IU/L, and negative anti-HBc and HBsAg results. Anti-
HBs titres were retested 4-8 weeks after booster. After this round of testing, study participants 
were classified as follows in Table 2.4. 
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Table 2.4. Final classification of participants based on pre- and post-booster serology results  
Anti-HBs pre-
boost in 2015 
(IU/L) 
Anti-HBs post-
boost in 2015 
(IU/L) 
Anti-HBc 
(S/CO) 
HBsAg 
(S/CO) 
Classification 
<10 <10 <1 <1 Non-responder  
<10 <200 <1 <1 Low-responder  
<10 >200 <1 <1 Normal-responder  
Abbreviations: Anti-HBs, Antibodies against hepatitis B surface antigen; Anti-HBc, Antibodies against 
hepatitis B core antigen; HBsAg, Hepatitis B surface antigen; IU/L; International Units per Litre; S/CO; 
Signal to cut-off ratio 
 
Thus, the low-responders included participants with historical records of anti-HBs titres <200 
IU/L within six months of receiving the third dose of HBV vaccine, as well as participants who 
remained with anti-HBs titres <200 IU/L post-boost in 2015. 
Analysis of associations between demographic data and responses to HBV vaccine (normal-
responders (>200 IU/L) versus low-responders (<200 IU/l)) were assessed using SPSS v24.0. 
Fisher’s exact test or chi-squared tests were used to assess associations between response and 
discrete variables (for example, gender, ethnicity), whereas Mann-Whitney U test was used to 
assess associations between response and continuous variables (age and weight).  
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2.3 Results 
2.3.1 HBV infection and other exclusion criteria  
One hundred and seventy South African, HIV-negative laboratory workers were recruited into 
this study over the period August-October 2015.  
Four participants were excluded from this study due to discrepant self-reports of HBV 
vaccination (signed consent form which stated they had been vaccinated but on questionnaire 
stated as not vaccinated). Serum samples from the remaining 166 participants were tested for 
levels of anti-HBs and anti-HBc. We found that fourteen individuals tested positive for anti-
HBc, suggesting prior or current infection (14/166 = 8%) (Table 2.5). Samples from these 
individuals were therefore tested for HBsAg. Of these fourteen anti-HBc positive individuals, 
four tested negative for anti-HBs but positive for HBsAg (indicating current infection), while 
ten tested positive for anti-HBs and negative for HBsAg (indicating a resolved previous 
infection). These participants were immune to HBV infection due to natural infection and not 
due to vaccination, and were thus excluded from this study (Table 2.5). Participants with 
current or prior infection were advised of their status and advised to consult a medical doctor. 
Additionally, three participants lacked any records of HBV vaccination and tested negative for 
anti-HBs, anti-HBc and HBsAg. These test results could arise in true non-responders to the 
vaccine or in unvaccinated individuals. Without proof of prior vaccination, these individuals 
were also excluded from the study. In total, 21 individuals were excluded from the study, 
leaving a final sample size of 149 for further investigation. 
One of the questions on the questionnaire asked if participants were aware of ever being 
infected with Hepatitis B.  Responses to this question indicated that 156 (94%) of the cohort 
identified as never having been infected with HBV, while the remaining 6% did not know if 
they had previously had an HBV infection or not. No participant reported knowledge of 
previous or current HBV infection. However, from our testing, 8% of the cohort had either had 
a previous infection or were currently infected; thirteen of these fourteen had self-reported that 
they had never been infected with HBV while only one was not sure. 
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Table 2.5 Cohort classified according to serology results before vaccine booster 
Anti-HBs in 2015 
(IU/L) 
Anti-HBc in 2015 
(S/CO) 
HBsAg 
(S/CO) 
Classification N (%) 
<10 <1 <1 
Potential non-
responder to 
vaccine 
13 (8%)* 
<10 >1 >1 Current infection 4 (2%) 
>10 <1 Not tested 
Responder to 
vaccine 
139 (84%) 
>10 >1 <1 Previous infection 10 (6%) 
    Total = 166 
*Three of these ‘potential non-responders’ were ultimately excluded from the study due to lack of 
vaccination records together with the lack of detectable anti-HBs titres 
Abbreviations: Anti-HBs – Antibodies against hepatitis B surface antigen; Anti-HBc – Antibodies 
against hepatitis B core antigen; HBsAg – Hepatitis B surface antigen; IU/L – International Units per 
Litre; S/CO – Signal to cut-off ratio 
 
2.3.2 Characterisation of cohort regarding response to HBV vaccine 
Thirteen of the 166 participants tested negative for anti-HBs (<10 IU/L), anti-HBc and HBsAg 
(< 1 (S/CO)) in this first round of antibody testing, and were therefore classified preliminarily 
as ‘potential non-responders to HBV vaccine’.  It was unclear if these thirteen were true non-
responders or if their antibody levels had just waned over time since vaccination. Three of these 
‘potential non-responders’ were ultimately excluded from the study due to lack of vaccination 
records together with the lack of detectable anti-HBs titres since they were likely to have never 
been vaccinated. A booster vaccination was offered to all participants with anti-HBs titres <20 
IU/L.  Anti-HBs measurement 4 to 8 weeks after booster vaccination showed that all 
individuals responded to the booster with anti-HBs titres at least >80 IU/L, suggesting that 
there were no true non-responders to the HBV vaccine in this cohort with titres <10 IU/L.   
As seen in Table 2.6, participants were classified as ‘low-responders’ if they had an anti-HBs 
titre <200 IU/L post three-dose vaccine (based on records) or post booster vaccination. Eight 
participants (5%) were identified as low responders, while the remaining participants (n=141; 
95%) were classified as normal-responders. All participants were advised of their antibody 
titres pre- and post-booster vaccination. 
Participants’ self-reported HBV vaccine response status differed somewhat to our test results. 
Of the 149 participants immune to HBV due to vaccination, four participants (2.7%) self-
reported as being non-responders and three participants (2%) self-reported as being low-
responders, however none of these participants had records of anti-HBs titre within six months 
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of vaccination and none were classified as ‘low-responders’ according to our classification 
method. Eighty-six participants (57.7%) self-reported as being responders and 56 participants 
(37.6%) were unsure of their response status. Of the eight participants classified as low-
responders in this study, three self-reported as being responders to the HBV vaccine, while the 
remaining five did not know their response status. 
 
Table 2.6.  Classification of participants as low-responders or normal-responders to the HBV 
vaccine 
Anti-HBs 
in 2015 
(IU/L) 
Anti-HBs post 
boost in 2016 
(IU/L) 
Anti-HBc in 
2015 
(S/CO) 
HBsAg 
(S/CO) 
Classification N (%) 
<10 <10 <1 <1 Non-responder  0 (0%) 
<10 <200 <1 <1 Low-responder  8 (5.4%)* 
>10 >200 <1 <1 Normal-responder 141 (94.6%)** 
     Total=149 
*Includes those with post-booster anti-HBs titres >200 IU/L but with records of anti-HBs <200 IU/L 4-
8 weeks after three-dose vaccination series 
**Includes those with pre-booster anti-HBs titres <10 IU/L but who responded to the boost and had no 
records of low-response following HBV vaccination 
Abbreviations: Anti-HBs, Antibodies against hepatitis B surface antigen; Anti-HBc, Antibodies against 
hepatitis B core antigen; HBsAg, Hepatitis B surface antigen; IU/L, International Units per Litre; S/CO, 
Signal to cut-off ratio 
 
2.3.3 Cohort demographics and association with anti-HBs titre 
The total cohort (n=149) was largely female (79%) with a mean age of 39 years (ranging from 
21 to 74 years) and consisted of Caucasian (50%), black African (33%), Asian (15%) and 
Coloured (2%) South African individuals (Table 2.7). In the Asian category, four participants 
self-identified as Asian or Chinese, while eighteen self-identified as Indian.  
The responder group and low-responder group did not differ significantly with regards to sex, 
age (at recruitment (n=149) or vaccination (n=114)) or ethnicity. However, the two groups did 
differ significantly with regards to weight (n=141, p=0.012), with the mean weight of 
responders being 72 kg (range 40-130 kg) and that of the low-responders being 86 kg (range 
70-106 kg).  
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Table 2.7. Demographics of the responder versus low-responder groups 
 Responders Low-responders p-value Total, N (%) 
Mean age, years (SD)* 39.1 (11.7) 37.9 (9.0) 0.853  
Mean age at vaccination, 
years (SD)* 
28.1 (10.4) 31.3 (7.9) 0.121 
 
Mean weight, kg (SD)* 71.9 (18.0) 86.1 (13.5) 0.012  
African, N (%)** 47 (33.3) 2 (25.0) 1.000 49 (32.9) 
Caucasian, N (%)** 71 (50.4) 4 (50.0) 1.000 75 (50.3) 
Asian, N (%)** 21 (14.9) 1 (12.5) 1.000 22 (14.8) 
Coloured, N (%)** 2 (1.4) 1 (12.5) 0.154 3 (2.0) 
Female, N (%)** 114 (80.9) 4 (50.0) 0.059 118 (79.2) 
*Mann-Whitney U test used to obtain p-value 
**Fisher’s exact test used to obtain p-value 
Abbreviation: SD, Standard deviation 
 
Additional factors that may affect immune response were investigated. These factors 
investigated were: smoker at the time of recruitment, smoker during the vaccination period, 
presence of a malignancy (previous or current), immunodeficiency, auto-immune disease and 
liver disease. The only factor that significantly differed between the responders and low-
responders was smoking during the vaccination period, where this was more frequent than 
expected in the low-responders (Table 2.8). 
 
Table 2.8. Comparison of factors that may affect immune response between responders and 
low-responders 
 Responders, 
N (%) 
Low-responders, 
N (%) 
p-value* 
Total, 
N (%) 
Smoker in 2015 10 (7.1) 2 (25) 0.128 12 (8.1) 
Smoker during vaccination 
period 
6 (4.3) 3 (37.5) 0.008 9 (6.1) 
Have had a malignancy 4 (2.9) 0 1.000 4 (2.7) 
Immunodeficient 0 0 - 0 
Have an auto-immune 
disease 
22 (15.7) 3 (37.5) 0.134 
25 
(16.9) 
Have a liver disease 1 (0.7) 0 1.000 1 (0.7) 
*assessed by Fisher’s exact test 
 
Thus, in this cohort, weight and smoker status at the time of vaccination were significantly 
different between normal-responders and low-responders. 
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2.4 Discussion 
2.4.1 Knowledge of HBV infection and vaccination status 
We noted that none of the currently or previously infected individuals were aware of their 
infection status. Such lack of knowledge of HBV infection status has been seen previously, 
where 56% of South African health care workers (HCW) who had experienced occupational 
exposure to HBV, did not know their HBV infection status (Khan and Ross, 2013). This lack 
of knowledge may arise due to the fact that HBV, which is endemic to sub-Saharan Africa, 
may be acquired in early childhood in rural areas or later in life in urban areas and is often 
asymptomatic or only mildly symptomatic (Kew, 2008). Furthermore, although easily 
identifiable, most cases in SA are not notified (Kew, 2008). Lack of knowledge of HBV 
infection status among laboratory workers may lead to unnecessary prophylactic treatment 
upon accidental exposure and/or to unnecessary HBV vaccination; however, this is a cost-
effectiveness concern, rather than a health issue (Immunization Action Coalition, 2005). It may 
also lead to transmission of the virus to unvaccinated contacts, who could be vaccinated if they 
were aware of the infection risk. 
There were some differences seen in the self-reports of response status and our serology results, 
however, it is difficult to comment on the significance thereof due to the lack of vaccination 
and anti-HBs titre records with which to corroborate self-reports. Nevertheless, self-knowledge 
of HBV vaccine response status was low, with 37.6% of our cohort unsure of their status. This 
was unexpected as laboratory workers’ anti-HBs levels are measured after vaccination to assess 
response. This may suggest lack of communication between the laboratory workers and the 
health care professionals performing these tests. Due to the risk of occupational exposure to 
HBV, it is important for laboratory workers to know the risks, to be vaccinated against HBV 
and to know their response status. 
 
2.4.2 HBV vaccine response in the cohort 
From published reports of HCWs, 4-10% do not respond (<10 IU/L) to three doses of the HBV 
vaccine (Averhoff et al., 1998; Cleveland et al., 1994; Coates et al., 2001; Dienstag et al., 1984; 
Roome et al., 1993; Szmuness et al., 1982). These rates are similar in the normal adult 
population (Coates et al., 2001; Rendi-wagner et al., 2001; Szmuness et al., 1981, 1980). 
However, we observed zero non-responders in this cohort.  
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A difference in response rates between these studies and the current one may be the 
demographic characteristics of the cohorts. Factors that increase the risk of non-response 
include male gender and increasing age (Cleveland et al., 1994; Averhoff et al., 1998; Fisman 
et al., 2002; Tohme et al., 2011), as discussed below in section 2.4.3. Our cohort was mostly 
female (80.9%) and 90% of the cohort was younger than 40 years at the time of vaccination. 
This may have contributed to the lack of non-responders in the cohort.  
Additionally, this difference in response rates may be due to the fact that these aforementioned 
studies are reporting seroconversion rates following a three-dose immunization schedule 
whereas individuals who are at a risk of occupational exposure to HBV (including laboratory 
workers) are recommended to receive additional doses if they do not respond to the initial 
vaccination series (Immunization Action Coalition, 2005). Additional HBV doses increase the 
chance of seroconversion (Clemens et al., 1997; Das et al., 2003; Desombere et al., 1998; 
Heininger et al., 2010; Struve et al., 1994). The reason as to why some individuals respond 
only after additional doses is yet to be explained (Heininger et al., 2010). It has been speculated 
that vaccination may result in cell-mediated immune responses and the humoral response only 
develops after booster vaccination (Chiaramonte et al., 1995); indeed, it has been shown that 
some non-responders do develop a cellular immune response in vitro (Jarrosson et al., 2004). 
Furthermore, as individuals respond to different numbers of booster doses (and non-responders 
show variable levels of response in vitro), there seems to be different grades of poor response 
which suggests that there is a qualitative difference between poor responders that is yet to be 
explained (Desombere et al., 1998; Jarrosson et al., 2004; Zuckerman, 1996). 
Furthermore, a factor which hinders the classification of responders/non-responders in a cross-
sectional study, so long after vaccination, is the waning of anti-HBs levels (Shepard et al., 
2006; Zuckerman, 1996). From available records, it is clear that anti-HBs levels do wane over 
time, as expected. Boosting responder individuals whose antibodies wane to even <10 IU/L is 
possibly unnecessary (Banatvala and Van Damme, 2003) as previous responders remain 
protected due to memory B and T cells (Bauer and Jilg, 2006). 
 
2.4.3 Clinical factors affecting HBV vaccine response 
We found that increased weight and smoking during the vaccination period was associated with 
increased risk of low anti-HBs response. Such associations have been seen previously 
(Averhoff et al., 1998; Roome et al., 1993; Yang et al., 2016). We note that BMI (kg/m2) would 
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be a better measure than weight alone, however, height was not included in the questionnaire 
and thus, BMI could not be calculated. 
In attempt to explain the observed association between weight and HBV vaccine response, it 
has been suggested that the vaccine may be inadvertently deposited into fat rather than into 
muscle in overweight individuals (Shaw et al., 1989). This may result in delayed absorption of 
the antigen thereby allowing time for its enzymatic denaturation (Ingardia et al., 1999; Milner 
and Beck, 2012; Shaw et al., 1989). Deposition of the vaccine into fat may also result in reduced 
immune response due to the scarcity of phagocytes and/or APCs in deep fat (Shaw et al., 1989). 
Additionally, overweight individuals have altered levels of hormones and nutrients such as 
leptin, adiponectin and proinflammatory cytokines (Milner and Beck, 2012). Leptin is a growth 
factor that can increase T cell proliferation and survival; this and the increase in 
proinflammatory cytokines may suppress the Th2 or antibody response leading to the increased 
risk of non-response associated with increasing weight. In contrast, leptin deficiency noted in 
obese individuals due to T cells becoming resistant to leptin signalling may explain the reduced 
vaccine-induced immunity observed in obese persons (Milner and Beck, 2012). This lack of 
leptin signalling may also enhance Treg cell proliferation which could result in the suppression 
of the immune response (Milner and Beck, 2012). 
With regards to smoking, higher leukocyte counts have been observed in smokers compared to 
non-smokers (Holt, 1987; Jensen et al., 1998; Noble and Penny, 1975). It has also been 
observed that nicotine suppresses leukocyte chemotaxis, decreases phagocytic capabilities and 
inhibits T cell function (Noble and Penny, 1975). As HBV vaccine response is T cell dependent 
(Cupps et al., 1984), such suppression of T cell function would adversely affect the HBV 
vaccine-induced immune response (Ingardia et al., 1999). 
Together with weight and smoking, increasing age and male sex are often associated with 
increased risk of non-responsiveness to the HBV vaccine (Averhoff et al., 1998; Cleveland et 
al., 1994; Fisman et al., 2002; Tohme et al., 2011). However, we did not find age or sex 
associated with response to the HBV vaccine.  
Although we did not find an association, there is a biologically plausible reason for the 
association with age – the phenomenon of immunosenescence noted in older individuals, where 
both cellular and humoral immunity wane with age (Effros, 2007; Ginaldi et al., 1999; Hodes, 
1997). Moreover, a meta-analysis performed in 2002 (Fisman et al.) determined that there was 
a significantly increased risk of non-response to the HBV vaccine with increasing age even 
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though they reviewed a similar number of studies that found such an association and those that 
did not. They suggested that insufficient statistical power is the reason behind studies not 
observing an association with age and HBV vaccine response (Fisman et al., 2002). This may 
well apply to this study due to the small sample size of low-responders and the lack of any true 
non-responders. Additionally, as 90% (134/149) of participants were younger than 40 years of 
age at the time of vaccination (which is plausible due to NHLS laboratory workers being 
vaccinated against HBV at the start of their career which would usually translate to vaccination 
at younger age), it is possible that age did not affect the anti-HBs titres significantly in this 
study.  
Although we did not find an association between sex and HBV vaccine response, such an 
association has been observed in previous studies on HBV vaccine response (Averhoff et al., 
1998; Chathuranga et al., 2013; Cleveland et al., 1994). Poorer immune response in males has 
been noted with other vaccines as well (Klein et al., 2015) and also has a biologically plausible 
explanation: oestrogen has the capability of activating signalling pathways and inducing 
transcription of various genes which act on multiple immune pathways, such as B cell 
proliferation and survival, T cell responses and cytokine regulation (Klein et al., 2015; Lang, 
2004). Oestrogen has also been shown to increase immunoglobulin (Ig) production (Kanda and 
Tamaki, 1999), whereas testosterone inhibits the production of IgG and IgM (Kanda et al., 
1996). Furthermore, there are several immune-related genes located on the X chromosome and 
as X inactivation in females may favour the inactivation of mutant genes, females would have 
an advantage over males in the case of deleterious mutations in these genes (Klein et al., 2015). 
Furthermore, the low numbers of males in this study may have affected the findings and the 
lack of true non-responders may have masked any significant differences between the anti-HBs 
responses of the sexes. 
Chronic disease has been associated with HBV vaccine response in older vaccinees (>40 years) 
and not in those <40 years (Averhoff et al., 1998). This may explain why we did not find an 
association between HBV vaccine response and the other factors that may affect immune 
response (presence of malignancy, immunodeficiency, autoimmune disease, liver disease) in 
our cohort that was relatively young (mean age of 29.7 years) at time of vaccination.  
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3.1 Introduction 
HLA-DP is a member of the HLA class II molecules. Each molecule is composed of an alpha 
and beta chain which are encoded by the HLA-DPA1 and –DPB1 genes, respectively. APCs, 
such as macrophages, dendritic cells and B cells, express HLA class II molecules which are 
involved in the presentation of extracellular antigenic peptides to CD4+ T cells. The interaction 
between the HLA-peptide complex and the T cell initiate the immune response. Thus, HLA 
associations with various diseases and vaccine responses have a biological basis. 
In general, studies investigating HLA-DP genes and their impact on human disease are 
somewhat under-represented compared to HLA-DR and –DQ. This may be due to HLA-DPA1 
and –DPB1 being less polymorphic than HLA-DR and –DQ genes and also because HLA-DP 
cell surface expression levels are likely to be lower than that of HLA-DR (Edwards et al., 1986; 
Thomas et al., 2012). Therefore, this study aimed to investigate the role of HLA-DP variation 
in HBV vaccine response. GWAS have consistently associated the HLA region with both HBV 
infection outcome and HBV vaccine response (Hu et al., 2013; Kamatani et al., 2009; Mbarek 
et al., 2011; Nishida et al., 2012; Pan et al., 2013; Png et al., 2011; Wu et al., 2015). Moreover, 
the most significant associations in GWAS of HBV infection outcomes in Asian populations 
are variants located within the HLA-DP region (Guo et al., 2011; Kamatani et al., 2009; Nishida 
et al., 2012). Additionally the HLA-DP locus has also been strongly associated with HBV 
vaccine response in GWAS in Asian populations (Wu et al., 2015). 
Cytokines are key players in the immune response, functioning to promote particular immune 
pathways, such as CTL-mediated cell lysis or antibody production (Broere et al., 2011). 
Furthermore, cytokine profiles differ between HBV vaccine responders and non-responders 
(Larsen et al., 2000; Kardar et al., 2002; Jafarzadeh and Shokri, 2003; Goncalves et al., 2004; 
Velu et al., 2008). Thus, genetic variation in these cytokine genes may affect their functioning 
and is therefore, important to investigate. 
As there is no South African data on the genetics of HBV vaccination, this study aimed to 
investigate the role of HLA-DP and cytokine variation in HBV vaccine response in a South 
African cohort. We aimed to genotype both the HLA-DPA1 and -DPB1 genes, as well as SNPs 
in the HLA class II region (with a focus on the the HLA-DP region) and in cytokine genes 
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3.2 Materials and Methods 
3.2.1 DNA extraction 
Human DNA was extracted from the stored erythrocyte/granulocyte layer using the DNA 
Isolation Kit (Invitrogen, Life Technologies), according to the manufacturers protocol. The 
erythrocyte/granulocyte mixture was thawed at room temperature and 600 µl was combined 
with 900 µl Red Cell Lysis Buffer. After vortexing, the granulocytes were pelleted by 
centrifugation at 12 000 g for 1 minute, and this wash step was repeated a second time. Protease 
in Nuclear Lysis Buffer (125 µl) was added to the pellet after which the tube was incubated at 
65°C in a heat block for 10 minutes with a brief vortex every 2-3 minutes. The 275 µl of Protein 
Clearing Solution was then added to the sample, followed by a 10 minute incubation on ice. 
The cell debris was pelleted by centrifugation for 5 minutes at 13 500 g. The supernatant 
(containing the DNA) was carefully transferred to a clean tube. In order to precipitate the DNA, 
ice cold 90% ethanol was slowly added to the solution and the tube was inverted several times. 
In the case that no DNA was visible, the tube was incubated in a -20°C freezer for 10 minutes 
or overnight. The DNA was pelleted by centrifugation at 13 500 g for 5 minutes. The 
supernatant was discarded while being careful not to disrupt the DNA pellet. Ethanol (70%) 
was added to the pellet before centrifuging at 13 500 g for 2 minutes. The ethanol was discarded 
and the pellet air-dried. The DNA was resuspended in DNA Suspension Buffer by incubation 
at 65°C for 15 minutes.  
The concentration and quality of the DNA was assessed by using the NanoDrop 1000 
spectrophotometer using absorbance at 260 nm (A260) for DNA concentration and the ratio of 
absorbance at 260 nm to that at 280 nm (A280) and to the absorbance at 230 nm (A230) as 
quality assessments. The A260/A280 ratio of pure DNA should be approximately 1.8, while a 
lower ratio indicated the presence of protein or other contaminants that absorb at 280 nm. The 
A260/A230 ratio should ideally be higher than the A260/A280 ratio (usually 2.0 – 2.2); a lower 
ratio indicated the presence of contaminants such as EDTA and phenol. The DNA was then 
diluted to a working concentration of 20 ng/µl with distilled water and stored at -20°C. To 
ensure that the DNA was of appropriate quality for downstream applications, several samples 
were selected to be used in a conventional polymerase chain reaction (PCR) run. As all samples 
were successfully amplified, the DNA was considered of sufficient quality to be used in 
downstream applications. 
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3.2.2 HLA-DPA1 and -DPB1  
3.2.2.1 HLA-DPA1 and -DPB1 genotyping 
HLA-DPA1 and -DPB1 genotyping of the cohort DNA samples was performed using the 
LIFECODES HLA-DPA1/DPB1 SSO Typing Kit (Immucor) on a Luminex instrument at the 
NICD according to the manufacturer’s instructions. The Luminex technology allowed for the 
simultaneous detection of multiple analytes in a single reaction tube or well by the use of 
sequence-specific oligonucleotide (SSO) probes bound to colour-coded microbeads 
(Heinemann, 2009).  
This procedure for typing HLA class II alleles began with the amplification (by PCR) of exon 
2 (and exon 3 for HLA-DPB1), which is the most polymorphic region of the HLA class II gene 
(Heinemann, 2009). Using  biotinylated primers (Heinemann, 2009). The components and 
cycling conditions of the PCR amplification procedure are listed in Tables 3.1 and 3.2 
respectively. A no-template control and a positive control were included. The positive control 
was either DNA extracted from MCF7 cell line (kindly provided by Professor R Veale, Wits 
University) whose HLA-DPB1 alleles have previously been determined (Adams et al., 2005) 
or International Histocompatibility Working Group reference DNA sample IHW09021 (kindly 
provided by Dr H Hong, NICD).   
 
Table 3.1. Reaction components for HLA-DP amplification 
Component Amount per PCR reaction 
LIFECODES Master Mix 6 µl 
Lifecodes Taq Polymerase 0.2 µl 
Genomic DNA Total of ~80 ng 
Nuclease-free water To 20 µl final volume 
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Table 3.2. Thermal cycler conditions for amplification  
Step Temperature Incubation Time Number of Cycles 
1 95°C 3 minutes 1 
2 95°C 15 seconds  
12 60°C 30 seconds 
72°C 30 seconds 
3 95°C 10 seconds  
28 63°C 30 seconds 
72°C 30 seconds 
4 72°C 2 minutes 1 
5 4°C ∞ 1 
 
The amplified DNA was denatured and hybridized to complementary allele-specific SSO 
probes attached to the colour-coded microbeads (Heinemann, 2009) which are provided with 
the kit. The subsequent PCR products were then hybridized with the microbeads according to 
the conditions in Table 3.3. 
 
Table 3.3. Thermal cycler conditions for hybridization 
Temperature Incubation Time 
97°C 2 minutes 
47°C 10 minutes 
56°C 8 minutes 
56°C HOLD 
 
Streptavidin-conjugated with phycoerythrin (SAPE), a fluorescent molecule was then added to 
each well. The streptavidin is capable of binding to the biotin on the PCR products. A solution 
of 170 µl SAPE was added to each well at the 56°C hold.  
The plate was then transferred to the Luminex instrument for reading. Lastly, the beads were 
passed in a single stream through two lasers. One laser excited the colour in the microbead (this 
identified which microbead was being read), while the other excited the colour on the bead 
surface, the SAPE (Heinemann, 2009).  
The Luminex analyser detected the signal and the software assigned the HLA alleles 
(Heinemann, 2009). In order to exclude non-specific background signals and to normalize the 
data, each microbead mixture contains positive and negative control probes (Heinemann, 
2009). MatchIT! DNA software from Immucor was used to analyse the data 
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(http://www.immucor.com/) along with the allele assignment protocol recommended by the 
American Society for Histocompatibility and Immunogenetics (ASHI). The assignment of 
HLA alleles was based on the sequences listed in the IMGT/HLA database 
(http://www.ebi.ac.uk/ipd/imgt/hla/) (Heinemann, 2009).  
Luminex HLA genotyping typically produces results with 2-digit, 4-digit nomenclature or G 
group nomenclature, but does not usually produce results with 6 or 8-digit nomenclature. These 
nomenclature types refer to the following (http://hla.alleles.org/nomenclature/naming.html): 
• 6-8-digit nomenclature e.g. HLA-DPA*01:03:01:01. The 5th and 6th digits refer to 
synonymous DNA changes in coding regions, while the 7th and 8th digits refer to 
differences in a non-coding region. 
• 4-digit nomenclature e.g. HLA-DPA*01:03. This is a unique HLA protein. 
• 2-digit nomenclature: e.g. HLA-DPA*01. Each 2-digit group either encodes a particular 
serological antigen, or includes a group of alleles with high sequence homology. 
• G group: group of alleles with the same exon 2 sequence (for class II alleles) or same 
exon 2+3 sequences (for class I alleles) e.g. HLA-DPA1*02:02:02G includes alleles 
02:02:02 and 02:06. 
However often the 4-digit Luminex genotyping results are ambiguous (that is, where different 
allele combinations produce identical sequences). Therefore, Luminex results are often 
reported as either 2-digit genotypes, ambiguous genotypes (that cannot be further defined 
without further laboratory work) or genotypes containing G group alleles.  
 
3.2.2.2 Statistical analysis of HLA-DPA1 and -DPB1 alleles 
HLA-DPA1 and –DPB1 allele frequencies were compared between the different South African 
ethnicities using chi-squared tests or Fisher’s exact test in SPSS v24.0. The South African 
Coloured population were not included in these analyses due to the small sample size (n=3). 
HLA-DPA1 and –DPB1 allele frequencies within each ethnicity were compared to data from 
the Allele Frequency Net Database (AFND, http://www.allelefrequencies.net/) using Fisher’s 
exact tests in SPSS v24.0. Due to the limited HLA-DP data available from South African 
populations, the South African black population in this study was compared to sub-Saharan 
black populations, the South African Caucasian population was compared to European 
Caucasoid populations (in particular to data from France, Norway, Sweden and UK/England) 
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and the South African Asian population was compared to data from India due to majority 
(18/22) of the ‘Asian’ group self-identifying as Indian. Although individuals of East Asian and 
South Asian descent often have different allele frequencies, participants from these population 
groups were combined and collectively classified as Asian in order to increase the sample size 
in this group. The South African Coloured population were not included in these analyses due 
to the small sample size (n=3). 
The HLA-DPA1 and –DPB1 allele frequencies in the total cohort were compared between 
responders and low-responders using Fisher’s exact tests in SPSS v24.0. 
 
3.2.3 SNP genotyping 
3.2.3.1 SNP selection 
To investigate the associations between SNPs in candidate genes (such as HLA-DP regulatory 
regions, cytokine genes or costimulatory signalling genes) and response to HBV vaccination, 
we chose 31 SNPs of interest to be genotyped from such gene regions. SNPs were selected by 
surveying the literature for SNPs associated with HBV vaccine response, HBV infection 
outcome, other vaccine response and/or HLA-DP expression levels. 
SNPs were included if the minor allele frequency (MAF) in the Luhya in Webuye, Kenya 
(LWK) was >5%. The LWK population was used as a proxy reference population as there is 
limited whole genome or HLA-DP data available for South Africans. MAF >5% in LWK was 
confirmed, by using ENGINES (http://spsmart.cesga.es/engines.php) and 1000 Genomes data 
(http://browser.1000genomes.org/index.html). We note that our cohort was of multiple South 
African ethnicities, but we have tried to select SNPs in this study that would be applicable to 
further genetic studies of black South Africans. Linkage disequilibrium (LD) between the 31 
selected SNPs in the LWK population was determined using the LD TAG SNP Selection tool 
at the National Institute of Environmental Health Sciences website 
(https://snpinfo.niehs.nih.gov/snpinfo/snptag.htm). In the case where there was significant LD 
between SNPs, a tagSNP was selected to represent the relevant SNPs. The SNPs (of the 31 
selected SNPs) captured by these tagSNPs are shown in Appendix C. 
While 31 SNPs of interest were identified (Table 3.4), only 24 SNPs were compatible with 
single multiplex genotyping using the Mass Array system.
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Table 3.4. Details of SNPs selected for genotyping 
SNP ID 
Gene/Gene 
Region 
Chromosomal 
location 
Location 
relative to Gene 
Association Allele Association Study Population References 
rs1800872* IL10 1:206773062 Upstream 
HBV vaccine response 
CC ↑ response Taiwanese Lin et al., 2011 
(in haplotype C ↑ 
response) 
Germans Höhler et al., 2005 
Measles vaccine response T ↑ response 
European-
American; 
Dhiman et al., 2007 
rs1800871* IL10 1:206773289 Upstream 
HBV vaccine response 
CC ↑ response Taiwanese Lin et al., 2011 
(in haplotype C ↑ 
response) 
Germans Höhler et al., 2005 
PCV7 vaccine response A ↓ response European-
American 
Yucesoy et al., 2009 
Measles vaccine response A ↑ response Dhiman et al., 2007 
rs1800896 IL10 1:206773552 Upstream 
HBV vaccine response 
(in haplotype A ↑ 
response) 
Taiwanese Lin et al., 2011 
Germans Höhler et al., 2005 
Diphtheria vaccine 
response 
A ↑ response; 
European-
American 
Yucesoy et al., 2009 
rs1143634 IL1beta 2:112832813 
Exon, 
synonymous 
HBV vaccine response A ↑ response 
European-
American 
Yucesoy et al., 2002 
rs1143633 IL1beta 2:112832890 Intron HBV vaccine response (haplotype AG ↓ response) Chinese Chen et al., 2011 
rs1143627 IL1beta 2:112836810 5ʹ UTR HBV vaccine response  Chinese Chen et al., 2011 
rs2069763 IL2 4:122456327 
Exon, 
synonymous 
Measles vaccine response G ↑ response 
European-
American 
Dhiman et al., 2007 
rs2243248 IL4 5:132672952 Upstream HBV vaccine response 
(in haplotype T ↑ 
response) 
Various 
ethnicities (USA) 
Wang et al., 2004 
C ↓ response Chinese Chen et al., 2011 
rs2243250 IL4 5:132673462 Upstream 
HBV vaccine response 
(in haplotype T ↑ 
response) 
Various 
ethnicities (USA) 
Wang et al., 2004 
T(T) ↑ response 
Taiwanese Lin et al., 2012 
Asian Cui et al., 2013 
HBV infection outcome 
T ↑ susceptibility Caucasian Zheng et al., 2013 
T ↓ susceptibility Chinese males Lu et al., 2014 
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rs2070874 IL4 5:132674018 5ʹ UTR 
HBV vaccine response 
(in haplotype C ↑ 
response) 
Various 
ethnicities (USA) 
Wang et al., 2004 
T ↑ response Asian Cui et al., 2013 
HBV infection outcome T ↓ susceptibility Chinese Lu et al., 2014 
rs3212227 IL12B 5:159315942 3ʹ UTR 
HBV vaccine response AA ↑ response European 
American 
Yucesoy et al., 2009 
Measles vaccine response AA ↓ response Dhiman et al., 2007 
rs3213093 IL12B 5:159323971 Intron Measles vaccine response GG ↓ response 
European-
American 
Dhiman et al., 2007 
rs4711998* IL17A 6:52185555 Upstream HBV vaccine response GG ↑ response Iranian Borzooy et al., 2016 
rs2069727 IFNG 12:68154443 Downstream HBV vaccine response C ↑ response Gambian Hennig et al., 2008 
rs1805010* IL4R 16:27344882 Exon, missense 
HBV vaccine response 
AA ↑ response 
Taiwanese Lin et al., 2012 
Tetanus 
European-
American 
Yucesoy et al., 2009 
PCV7 
Measles vaccine response Dhiman et al., 2007 
rs1805015 IL4R 16:27362859 Exon, missense HBV vaccine response C ↑ response Chinese Chen et al., 2011 
rs2230433 ITGAL 16:30506720 Exon, missense HBV vaccine response C ↑ response Gambian Hennig et al., 2008 
rs8099917 IL28B 19:39252525 Upstream 
HBV viral load T(T) ↓ viral load 
Chinese Li et al., 2011 
IL28B expression levels; TT ↑ expression 
Influenza vaccine response TT ↓ response Canadian Egli et al., 2014 
rs3135363 HLA-DRA 6:32421871 Upstream HBV vaccine response C ↓ response 
Indonesian Png et al., 2011 
Chinese Pan et al., 2013 
rs7453920 HLA-DQB2 6:32762235 Intron HBV infection outcome A ↓ susceptibility 
Japanese Kamatani et al., 
2009 Thai 
Chinese 
Mbarek et al., 2011 
Hu et al., 2012 
Hu et al., 2013 
rs2395309 HLA-DPA1 6:33058469 Upstream HBV infection outcome G ↑ susceptibility 
Japanese         
Thai 
Kamatani et al., 
2009 
Chinese Guo et al., 2011 
rs2071349 
HLA-
DPA1/DPB1 
6:33075743 
Intron (DPA1), 
upstream (DPB1) 
- - - - 
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rs7770370 HLA-DPB1 6:33081144 Intron HBV vaccine response A ↑ response 
Taiwan Wu et al., 2015 
Korean Roh et al., 2016 
rs3749985* HLA-DPB1 6:33086656 3ʹ UTR - - - - 
rs931 HLA-DPB1 6:33086773 3ʹ UTR - - - - 
rs9277533* HLA-DPB1 6:33086944 3ʹ UTR 
HBV infection outcome GG ↑ susceptibility European- and 
African-American 
Thomas et al., 2012 
DPB1 expression levels GG ↑ expression 
rs9277534 HLA-DPB1 6:33087030 3ʹ UTR 
HBV infection outcome GG ↑ susceptibility 
European- and 
African American 
Thomas et al., 2012 
DPB1 expression levels GG ↑ expression 
Rubella virus vaccine 
response 
GG ↓ response Lambert et al., 2014 
rs9277535 HLA-DPB1 6:33087084 3ʹ UTR 
HBV infection outcome A ↓ susceptibility 
Thai 
Kamatani et al., 
2009 
Japanese Mbarek et al., 2011 
Chinese 
Hu et al., 2012 
Hu et al., 2013 
Guo et al., 2011 
HBV vaccine response A ↑ response 
Indonesian Png et al., 2011 
Korean Roh et al., 2016 
rs9277536* HLA-DPB1 6:33087113 3ʹ UTR 
HBV infection outcome GG ↑ susceptibility European- and 
African-American 
Thomas et al., 2012 
DPB1 expression levels GG ↑ expression 
rs3130186 HLA-DPB1 6:33088430 3ʹ UTR - - - - 
rs2064479 HLA-DPB1 6:33104463 Downstream 
Rubella virus vaccine 
response 
C ↑ response 
European-
American 
Lambert et al., 2014 
*SNPs not genotyped 
Abbreviations: HLA, Human Leukocyte Antigen; IFNG, Interferon-gamma; IL, Interleukin; HBV, Hepatitis B Virus; PCV7, Pneumococcal Conjugate Vaccine (heptavalent); 
USA, United States of America; UTR, untranslated region 
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3.2.3.2 MassArray Analysis 
The selected SNPs were genotyped by iPLEX® / MassArray® System by Inqaba Biotec 
(Pretoria, SA). SNP rs numbers were submitted to Inqaba Biotec for evaluation by the Assay 
Design Suite software which was used to design the PCR and extension primers. Of the 31 
SNPs submitted, it was possible to multiplex 24 of the SNPs in a single well.  
A region of DNA that contained each SNP was amplified by PCR using the components listed 
in Table 3.5, according to the cycling conditions in Table 3.6. The unincorporated 
deoxynucleotide triphosphates (dNTPs) were dephosphorylated by shrimp alkaline 
phosphatase (SAP) at 37°C for 40 minutes, followed by a 5 minute incubation period at 85°C 
to inactivate the enzyme. The samples were then submitted to the single base extension reaction 
using the extension primers and mass-modified dideoxynucleotides (ddNTPs) (see Tables 3.7 
and 3.8 for reaction components and cycling conditions). The single base extension reaction 
involved using an extension primer that bound directly adjacent to the SNP site. ddNTPs were 
utilized for this extension so that the primer was extended by only one nucleotide that is 
complementary to the nucleotide at the SNP site. The ddNTPs were also mass-modified so that 
DNA molecules produced differ by mass based on the allele (Gabriel et al., 2009; Agena 
Bioscience, iPLEX Reagents User Guide).  
 
Table 3.5. Reaction components for PCR of target regions 
Component Amount per PCR reaction (µl) 
Nanopure Water      0.8 
10× PCR Buffer       0.5  
25 mM MgCl2      0.4 
25 mM dNTP mix      0.1 
0.5 µM Primer Pool      1.0 
Polymerase, 5 U/µl      0.2 
DNA template (25 ng/µl)      2.0 
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Table 3.6. Thermal cycler conditions for amplification of target regions 
Step Temperature Incubation Time Number of Cycles 
1 94°C 2 minutes 1 
2 94°C 30 seconds  
46 56°C 30 seconds 
72°C 60 seconds 
3 72°C 5 minutes 1 
4 4°C ∞ 1 
 
Table 3.7. Reaction components for single base extension reaction 
Component Amount per PCR reaction (µl) 
NanoPure Water      0.6182 
10× iPLEX Buffer Plus      0.2 
iPLEX dNTP Termination mix, 45×      0.2 
Probe Pool (11 µM each)      0.9409 
iPLEX Polymerase, 220×      0.0409 
DNA template (PCR+SAP)      7.0 
 
Table 3.8. Thermal cycler conditions for single base extension reaction 
Step Temperature Incubation Time Number of Cycles 
1 94°C 30 seconds 1 
2 95°C 5 seconds   
52°C 3 seconds 
5 
60 
80°C 3 seconds  
3 72°C 3 minutes 1 
4 15°C HOLD 1 
 
The products from the single base extension reaction were diluted with approximately 20 µl 
NanoPure water after which the resin was added to the wells in order to desalt the extension 
products. The samples were transferred to the chip using a Nanodispenser where they 
crystalized with the MALDI matrix on the chip, and analysed by the MassARRAY Analyzer. 
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These products were then applied to a microchip and underwent Matrix-assisted laser 
desorption/ionization-time-of-flight (MALDI-TOF) mass spectrometry whereby a laser is used 
to generate ionized products. The ions accelerate into a tube and towards the detector. The time 
of flight of these ionized molecules differ depending on the mass of the molecule, which was 
measured by the mass spectrometer. The MassARRAY Analyzer can distinguish between 
molecules that differ by 16 Da, and therefore mass of PCR products determined which alleles 
were present. The MassARRAY Typer software automatically generated reports that identify 
the SNP alleles (homozygous and heterozygous) in each sample and SNP genotypes were 
finally exported into an Excel worksheet. 
 
3.2.3.3 Statistical analysis of SNP data 
gPLINK v1.07 (Purcell et al., 2007) was used to analyse the SNP results. To remove individuals 
or SNPs with a high amount of missing data, both the individual and SNP missingness rates 
were set thresholds of p<0.1. To remove SNPs with a low MAF, a MAF threshold of p<0.05 
was applied, and to remove SNPs that fail Hardy-Weinberg equilibrium (HWE) checks, a HWE 
threshold of p<0.001 was used. 
 
Allele, genotype and haplotype frequencies in the South African cohort 
Allele and genotype frequencies for each SNP were counted in the whole South African cohort 
and within each ethnicity in our cohort. Allele frequencies for each SNP were compared among 
ethnicities using chi-square tests in SPSS v24.0.  
Haplotypes were generated where >1 SNP per gene or chromosome were tested, including ten 
SNPs in the HLA class II region, three SNPs in IL1B, three SNPs in IL4, two SNPs in IL12B 
and two SNPs on chromosome 16 (genes IL4R and ITGAL). For the cytokine/signalling 
molecule genes (IL1B, IL4, IL12B and IL4R and ITGAL), two-, three- four- and five- SNP 
haplotypes were generated using the sliding window approach in gPLINK (Purcell et al., 2007). 
Linkage patterns (Dʹ) between SNPs were analysed using Haploview (Barrett et al., 2005). See 
Appendix D for r2 values. The LD blocks were generated using the Confidence Intervals 
algorithm (Gabriel et al., 2002).  
For the HLA region, we used the Arlequin v3.5 software (Excoffier and Lischer, 2010) to phase 
the genotypic data into haplotypes which included the 10 SNPs within the HLA region. We 
performed haplotype phasing using the Arlequin pseudo-Bayesian approach (ELB algorithm) 
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with 2000 iterations (Excoffier and Lischer, 2010) in the total cohort (n=149). This algorithm 
estimated haplotype frequencies in the total cohort, and also produced the estimated gametic 
phase of each individual. Because our cohort was of mixed ethnicity, we also repeated this 
phasing process in separate ethnic groups within our cohort to see if predicted haplotypes 
changed. 
 
Comparisons of allele frequencies to other populations 
Allele frequencies in our South African cohort from the 24 SNPs were compared to data from 
the 1000 Genomes Project (The 1000 Genomes Project Consortium, 2015), which is 
summarised in Ensembl (release 87) (Yates et al., 2016), using Fisher’s exact tests in SPSS 
v24.0.  The following reference populations were used: Luhya in Webuye, Kenya (LWK) and 
Yoruba in Ibadan, Nigeria (YRI) populations for the South African black population; Utah 
residents with Northern and Western European ancestry (CEU) for the South African 
Caucasian population and the Indian Telugu in the United Kingdom (ITU) for the South 
African Asian population. These reference populations were selected merely as representative 
of populations who share ancestry with the South African ethnic groups used in this study. 
 
Association of alleles, genotypes and haplotypes with response to HBV vaccination 
We compared SNP allele, genotype and haplotype frequencies in normal-responders to HBV 
vaccine versus low-responders to HBV vaccine. Both univariate and multivariate analyses were 
performed as described below.  
For univariate analyses, SNP allele frequencies were compared in responders versus low-
responders using Fisher’s exact test in gPLINK v1.07 (Purcell et al., 2007). SNP genotype 
frequencies were also compared in responders versus low-responders using chi-squared tests 
and three different genotypic models in gPLINK: genotypic, dominant and recessive. The 
genotypic model assessed the association between HBV vaccine response and the three 
possible genotypes (aa vs Aa vs AA, where ‘a’ is the minor allele and ‘A’ is the major allele). 
The dominant model assessed the association between HBV vaccine response and having at 
least one minor allele versus not having any minor allele (aa, Aa vs AA), and the recessive 
model assessed the association between HBV vaccine response and having two minor alleles 
versus having at least one major allele (aa vs AA, Aa). We also compared haplotype 
frequencies in the cases and controls using gPLINK. For the HLA region, haplotypes involving 
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SNPs with Dʹ value >0.8 (as determined by Haploview), were tested for association with 
vaccine response using gPLINK, and haplotypes of the HLA region generated by Arlequin 
were tested for association with HBV vaccine response using Fisher’s exact test in SPSS v24.0. 
Those SNPs that were significant in the univariate analysis were carried forward to multivariate 
analyses taking significant demographic variables (weight and smoker status at time of 
vaccination) into account as covariates. Multivariate analysis was conducted using logistic 
regression in gPLINK taking significant demographic variables (weight and smoker status at 
time of vaccination) into account as covariates. 
The empirical p-values were considered in the univariate and multivariate analyses. The 
empirical p-values (PEMP1) were generated using a Monte Carlo-based method and ten thousand 
simulations in gPLINK. The empirical p-values corrected for multiple testing (PEMP2) were 
calculated using the proportion of permutations in which any of the test statistics exceeded that 
particular observed statistic. P-values <0.05 were considered significant. 
The effects (odds ratio (OR)) presented in the results is with respect to the minor allele for 
individual SNP association analysis. An OR of greater than one indicates that the minor allele 
increases the risk of low-response to the HBV vaccine relative to the major allele and vice 
versa. For haplotype association analysis, the OR is with respect to the alleles indicated. 
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3.3 HLA-DPA1 and –DPB1 Genotyping Results 
The HLA-DPA1 and –DPB1 alleles were typed using DNA from 149 participants.  
 
3.3.1 HLA-DPA1 
The HLA-DPA1 typing was successful for all samples (n=149). HLA-DPA1 Luminex results 
were grouped as shown in Table 3.9 for analysis purposes. We observed five alleles at 4-digit 
resolution, while the HLA-DPA1*02:02:01 and the ambiguous *02:02/02:04/02:05 alleles 
were grouped together as a low resolution ‘*02:other’ category (meaning *02 excluding 
*02:01 alleles).  The frequencies of these alleles in the total South African cohort are shown in 
Table 3.9 and the frequencies of the HLA-DPA1 alleles in the different ethnicities are shown 
in Table 3.10. Allele HLA-DPA1*01:03 was the most frequent allele in all ethnicities (58% of 
total cohort and 31-77% in different ethnicities), and HLA-DPA1*02:01 alleles were also 
common (20% of total cohort and 17-24% in different ethnicities).  
 
Table 3.9. HLA-DPA1 allele groupings and frequencies in the cohort, n=149 
Luminex Result Allele Count in Total Cohort (2n) % in Total Cohort 
01:03:03 
01:03:01G 
01:03 172 57.7 
01:04 01:04 1 0.3 
02:01 
02:01:01G 
02:01:02 
02:01 59 19.8 
02:02:01 
02:02/02:04/02:05 
02:other 
(not 02:01) 
43 14.4 
03:01 03:01 21 7 
04:01 04:01 2 0.7 
Total  298 100 
 
Several HLA-DPA1 allele frequencies differed significantly by ethnicity (Table 3.10). HLA-
DPA1*01:03 and -DPA1*02:other allele frequencies differed significantly between the South 
African ethnic groups (p<0.0001). Due to low frequencies of HLA-DPA1*03:01 allele, the 
ethnicities were compared in a pairwise fashion using Fisher’s exact test: frequencies differed 
significantly between African and Caucasian (p<0.0001), between African and Asian 
(p=0.007) and between Caucasian and Asian (p=0.0003) populations. These results remained 
significant after Bonferroni adjustment (Table 3.10). 
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 Table 3.10. HLA-DPA1 allele frequencies according to ethnicity 
Allele 
African 
(count (%)) 
Caucasian 
(count (%)) 
Asian  
(count (%)) 
Coloured 
(count (%)) 
Chi-squared 
test 
p-value 
Fisher’s 
exact test 
p-value 
Bonferroni 
corrected 
p-value 
n 49 75 22 3    
2n 98 150 44 6    
01:03 30 (30.6) 115 (76.7) 26 (59.1) 1 (16.7) <0.0001 NA <0.0001 
01:04 1 (1.0) 0 0 0 NA 
*0.395 
**1.000 
1.000 
1.000 
02:01 23 (23.5) 26 (17.3) 9 (20.5) 1 (16.7) 0.493 NA 1.000 
02:other 
(not 02:01) 
25 (25.5) 6 (4) 8 (18.2) 4 (66.7) <0.0001 NA <0.0001 
03:01 18 (18.4) 2 (1.3) 1 (2.3) 0 (0) NA 
*<0.0001 
**0.007 
***0.0003 
<0.0001 
0.042 
0.002 
04:01 1 (1) 1 (0.7) 0 0 NA 
*1.000 
**1.000 
***1.000 
1.000 
1.000 
1.000 
P-values assessed by chi-squared test (excluding Coloured) or Fisher’s exact test  
*African vs Caucasian 
**African vs Asian 
***Caucasian vs Asian 
Abbreviation: NA, not applicable 
 
A comparison of the HLA-DPA1 allele frequencies observed in this study to the allele 
frequencies from reference populations is shown in Table 3.11. Allele frequencies from several 
reference populations were grouped into ‘superpopulations’ (sub-Saharan black, Caucasian and 
Indian) to provide a broad view of genetic affinities of South African ethnic groups.  Specific 
reference populations (for example, only Kenya) could alternatively have been used here to 
confirm which global populations are most similar to South African population groups. The 
reference population frequencies were obtained from the AFND as described previously in 
section 3.2.2.2. There were no significant differences in the allele frequencies in this cohort 
compared to the reference populations, as assessed by Fisher’s exact test and therefore, 
Bonferroni corrections for multiple comparisons were not performed for these p-values.  
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Table 3.11. HLA-DPA1 allele frequencies in this study compared to reference populations 
DPA1 
Alleles 
SA 
blacka 
Sub-
Saharan, 
blackb 
p-
value 
SA 
whitea 
European, 
Caucasoidc 
p-
value 
SA 
Asian/ 
Indiana 
Indiand 
p-
value 
01:03 0.306 0.290 0.877 0.767 0.842 0.284 0.591 0.593 1.000 
01:04 0.010 0.001 1.000 0.000 0.004 1.000 0.000 0.025 0.246 
02:01 0.235 0.338 0.121 0.173 0.127 0.553 0.205 0.212 1.000 
02:other 0.255 0.177 0.233 0.040 0.070 0.537 0.182 0.161 0.851 
03:01 0.184 0.174 1.000 0.013 0.002 1.000 0.023 0.000 0.497 
04:01 0.010 0.022 1.000 0.007 0.001 1.000 0.000 0.008 1.000 
Total 1.000 1.002  1.000 1.046  1.001 0.999  
Reference allele frequencies labelled in blue 
aAllele frequencies observed in this study 
bAverage allele frequencies across sub-Saharan black African populations (Cameroon, Gabon, Gambia, Kenya, 
Liberia, Nigeria, Uganda) in AFND 
cAverage allele frequencies across Caucasian populations from France, Norway, Sweden, UK (AFND) 
dAllele frequencies from a population in Bombay, India (AFND)  
Abbreviations: SA, South African 
 
There were no significant associations between HLA-DPA1 alleles and response to the HBV 
vaccine as determined by Fisher’s exact test (p>0.05), as seen in Table 3.12. As there were no 
significant associations, Bonferroni corrections for multiple comparisons were not performed 
for these p-values. 
 
Table 3.12. Frequency of HLA-DPA1 alleles in responders versus low-responders 
HLA-DPA1 Allele 
Count in Responders 
(2n=282) 
Count in Low-responders 
(2n=16) 
p-value 
01:03 165 7 0.30 
01:04 1 0 1.00 
02:01 53 6 0.10 
02:other 40 3 0.71 
03:01 21 0 0.61 
04:01 2 0 1.00 
Total 282 16  
 
 
3.3.2 HLA-DPB1 
HLA-DPB1 allele assignment failed for 1 sample (genotyped sample size was therefore n=148). 
Additionally, there were two cases where an unambiguous HLA-DPB1 allele could not be 
identified from the ambiguous string of alleles (HLA-
DPB1*131:01/241:01/343:01/361:01/407:01/447:01), even as a G group. This result was 
confirmed by repeating the typing. 
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We observed 25 different HLA-DPB1 alleles, the HLA-DPB1 allele frequencies in the different 
ethnicities are shown in Table 3.13. Allele HLA-DPB1*04:01:01G was the most common 
allele in the Caucasian (41.3%) and Asian (45.5%) populations. However, HLA-DPB1*01:01 
was the most frequent allele in the African (27.1%) and Coloured (50%) populations. This was 
followed closely by HLA-DPB1*105:01 in the African population (26%). 
There were statistically significant differences in HLA-DPB1 allele frequencies across the 
different ethnicities. HLA-DPB1*01:01, *04:01:01G and *105:01 allele frequencies in the 
South African black population were significantly different to the other populations 
(p<0.0001), and these remained significant after Bonferroni adjustment for multiple 
comparisons (p<0.0001). The allele frequencies of HLA-DPB1*04:02:1G and *13:01:01G 
significantly differed between the black African and Caucasian (p<0.0001 and p=0.035 
respectively) and between Caucasian and Asian (p=0.009 and p=0.037 respectively) 
populations. HLA-DPB1*05:01:01G and *18:01 allele frequencies only differed significantly 
between black and Caucasian populations (p=0.045 and p=0.003 respectively). While HLA-
DPB1*09:01 allele frequencies significantly differed between black and Asian (p=0.009), 
Caucasian and Asian (p=0.002). However, only the difference in HLA-DPB1*04:02:01G allele 
frequencies between the black African and Caucasian populations remained significant after 
Bonferroni adjustment for multiple comparisons (p=0.001) (Table 3.13). 
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Table 3.13. HLA-DPB1 frequencies according to SA ethnicities 
DPB1 
Allele 
African 
(n (%)) 
Caucasian 
(n (%)) 
Asian 
(n (%)) 
Coloured 
(n (%)) 
Total 
cohort 
(n (%)) 
Chi-squared 
test 
p-value 
Fisher’s 
exact test 
p-value 
Bonferroni 
corrected 
p-value 
n 48 75 22 3 148    
2n 96 150 44 6 296    
01:01 26 (27.1) 7 (4.7) 1 (2.3) 3 (50) 37 (12.5) <0.0001 NA <0.0001 
02:01:02G 10 (10.4) 24 (16.0) 7 (15.9) 0 (0) 41 (13.9) 0.369 NA 1.000 
02:02 0 (0) 0 (0) 1 (2.3) 0 (0) 1 (0.3) NA 
**0.314 
***0.227 
1.000 
1.000 
03:01:01G 6 (6.3) 9 (6.0) 2 (4.5) 0 (0) 17 (5.7) 0.933 NA 1.000 
04:01:01G 4 (4.2) 62 (41.3) 20 (45.5) 1 (16.7) 87 (29.4) <0.0001 NA <0.0001 
04:02:01G 0 (0) 20 (13.3) 0 (0) 0 (0) 20 (6.8) NA 
*<0.0001 
***0.009 
0.001 
0.225 
05:01:01G 0 (0) 7 (4.7) 2 (4.5) 0 (0) 9 (3.0) NA 
*0.045 
**0.097 
***1.000 
1.000 
1.000 
1.000 
06:01 0 (0) 2 (1.3) 0 (0) 0 (0) 2 (0.7) NA 
*0.522 
***1.000 
1.000 
1.000 
09:01 0 (0) 0 (0) 4 (9.1) 1 (16.7) 5 (1.7) NA 
**0.009 
***0.002 
0.225 
0.050 
10:01 0 (0) 5 (3.3) 0 (0) 0 (0) 5 (1.7) NA 
*0.160 
***0.590 
1.000 
1.000 
11:01:01 4 (4.2) 4 (2.7) 0 (0) 0 (0) 8 (2.7) NA 
*0.715 
**0.308 
***0.576 
1.000 
1.000 
1.000 
13:01:01G 5 (5.2) 1 (0.7) 3 (6.8) 0 (0) 9 (3.0) NA 
*0.035 
**0.706 
***0.037 
0.875 
1.000 
0.925 
14:01 1 (1.0) 1 (0.7) 0 (0) 0 (0) 2 (0.7) NA 
*1.000 
**1.000 
***1.000 
1.000 
1.000 
1.000 
15:01 1 (1.0) 0 (0) 0 (0) 0 (0) 1 (0.3) 
NA *0.390 
**1.000 
1.000 
1.000 
16:01 0 (0) 1 (0.7) 0 (0) 0 (0) 1 (0.3) 
NA *1.000 
***1.000 
1.000 
1.000 
17:01:01G 1 (1.0) 3 (2.0) 1 (2.3) 0 (0) 5 (1.7) 
NA *1.000 
**0.531 
***1.000 
1.000 
1.000 
1.000 
18:01 6 (6.3) 0 (0) 0 (0) 0 (0) 6 (2.0) 
NA *0.003 
**0.177 
0.075 
1.000 
19:01:01G 1 (1.0) 0 (0) 0 (0) 0 (0) 1 (0.3) 
NA *0.390 
**1.000 
1.000 
1.000 
20:01:01 0 (0) 1 (0.7) 0 (0) 0 (0) 1 (0.3) 
NA *1.000 
***1.000 
1.000 
1.000 
26:01:02 0 (0) 1 (0.7) 2 (4.5) 0 (0) 3 (1.0) 
NA *1.000 
**0.097 
*0.129 
1.000 
1.000 
1.000 
34:01 1 (1.0) 0 (0) 0 (0) 0 (0) 1 (0.3) 
NA *0.390 
**1.000 
1.000 
1.000 
58:01 1 (1.0) 0 (0) 0 (0) 0 (0) 1 (0.3) 
NA *0.390 
**1.000 
1.000 
1.000 
105:01 25 (26.0) 2 (1.3) 1 (1.3) 1 (16.7) 29 (9.8) <0.0001 NA <0.0001 
106:01 2 (2.1) 0 (0) 0 (0) 0 (0) 2 (0.7) 
NA *0.151 
**1.000 
1.000 
1.000 
131:01 2 (2.1) 0 (0) 0 (0) 0 (0) 2 (0.7) 
NA *0.151 
**1.000 
1.000 
1.000 
P-values assessed by chi-squared test (excluding Coloured) or Fisher’s exact test 
*African vs Caucasian 
**African vs Asian 
***Caucasian vs Asian 
Abbreviations: SA, South African; NA, not applicable
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The HLA-DPB1 allele frequencies observed in this study were compared to those in reference 
populations, shown in Table 3.14. There were significant differences between the HLA-
DPB1*04:02:01G and the *17:01:01G allele frequencies in the South African black population 
of this study compared to the sub-Saharan black reference populations, but only the difference 
between the HLA-DPB1*04:02:01G allele frequencies remained significant after Bonferroni 
correction for multiple comparisons (p<0.0001). The difference observed with regards to the 
*04:02 allele frequencies (0.0% in our cohort versus 18.6% in other cohorts) was due to the 
non-reporting of the HLA-DPB1*105 allele in the reference black populations. There is a single 
base difference in exon 3 between alleles *04:02 and *105 which is not detected in standard 
sequence-based typing of HLA-DPB1 which uses only exon 2 data, and was however, detected 
in our study using Luminex SSO genotyping. The HLA-DPB1*04:02:01G allele frequencies 
also significantly differed between the South African Asian population and the reference Indian 
population, however this did not remain significant after Bonferroni correction for multiple 
comparisons (p=0.396).
 
 
70 
 
Table 3.14. Comparison between HLA-DPB1 allele frequencies in this study cohort and reference 
populations 
DPB1 
Alleles 
SA 
blacka 
Sub-
Saharan, 
blackb 
p- 
value 
SA 
whitea 
European, 
Caucasoidc 
p-
value 
SA 
Asian/ 
Indiana 
Indiand 
p-
value 
01:01 0.271 0.311 0.640 0.047 0.049 1.000 0.023 0.041 0.683 
02:01:02G 0.104 0.112 1.000 0.160 0.126 0.689 0.159 0.195 0.582 
02:02 0.000 0.002 1.000 0.000 0.006 1.000 0.023 0.000 0.497 
03:01:01G 0.063 0.051 1.000 0.060 0.110 0.311 0.045 0.045 1.000 
04:01:01G 0.042 0.046 1.000 0.413 0.429 0.886 0.455 0.359 0.197 
04:02:01G 0.000 0.186 <0.0001 0.133 0.121 1.000 0.000 0.066 0.014 
05:01:01G 0.000 0.000 - 0.047 0.026 0.721 0.045 0.009 0.212 
06:01 0.000 0.003 1.000 0.013 0.018 1.000 0.000 0.000 - 
09:01 0.000 0.001 1.000 0.000 0.011 1.000 0.091 0.032 0.134 
10:01 0.000 0.011 1.000 0.033 0.015 0.683 0.000 0.011 1.000 
11:01:01 0.042 0.012 0.369 0.027 0.021 1.000 0.000 0.002 1.000 
13:01:01G 0.052 0.040 1.000 0.007 0.016 1.000 0.068 0.075 1.000 
14:01 0.010 0.005 1.000 0.007 0.015 1.000 0.000 0.029 0.246 
15:01 0.010 0.012 1.000 0.000 0.009 1.000 0.000 0.011 1.000 
16:01 0.000 0.007 1.000 0.007 0.005 1.000 0.000 0.000 - 
17:01:01G 0.010 0.091 0.018 0.020 0.009 1.000 0.023 0.024 1.000 
18:01 0.063 0.049 1.000 0.000 0.001 1.000 0.000 0.005 1.000 
19:01:01G 0.010 0.016 1.000 0.000 0.006 1.000 0.000 0.000 - 
20:01:01 0.000 0.003 1.000 0.007 0.005 1.000 0.000 0.000 - 
26:01:02 0.000 0.006 1.000 0.007 0 1.000 0.045 0.053 1.000 
34:01 0.010 0.010 1.000 0.000 0 - 0.000 0.000 - 
58:01 0.010 0.000 1.000 0.000 0 - 0.000 0.000 - 
105:01 0.26 NR - 0.013 NR - 0.013 NR - 
106:01 0.021 NR - 0.000 NR - 0.000 NR - 
131:01 
(ambiguous) 
0.021 NR - 0.000 NR - 0.000 NR - 
Total 0.999 0.974  1.001 0.998  0.990 0.957  
Reference allele frequencies labelled in blue 
aAllele frequencies observed in this study 
bAverage allele frequencies across sub-Saharan black African populations (Cameroon, Gabon, Gambia, Kenya, 
Liberia, Nigeria, Uganda, Zimbabwe) in AFND 
cAverage allele frequencies across Caucasian populations from France, Norway, Sweden, UK (AFND) 
dAllele frequencies from a population in Bombay, India (AFND) 
Abbreviations: SA, South African; NR, not reported 
 
 
We found that allele HLA-DPB1*04:01:01G was significantly more frequent in the normal 
responders compared to the low-responders (p=0.004), whereas HLA-DPB1*01:01 and *09:01 
were significantly more frequent in the low-responders compared to the normal responders 
(p=0.036 and 0.025 respectively, Table 3.15). After Bonferroni correction for multiple 
comparisons, the significance of these associations was lost.
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Table 3.15. HLA-DPB1 allele frequencies in responders and low-responders  
Allele 
Count in 
Responders 
(%) 
Count in Low-
responders (%) 
p-value 
Bonferroni 
corrected 
p-value 
n 140 8   
2n 280 16   
01:01 
(01:01:01G and 01:01:02G) 
32 (11.4) 5 (31.3) 0.036 0.9 
02:01:02G 38 (13.6) 3 (18.8) 0.472 1.0 
02:02 1 (0.4) 0 (0) 1.000 1.0 
03:01:01G 17 (6.1) 0 (0) 0.610 1.0 
04:01:01G 87 (31.1) 0 (0) 0.004 0.1 
04:02:01G 17 (6.1) 3 (18.8) 0.084 1.0 
05:01:01G 9 (3.2) 0 (0) 1.000 1.0 
06:01 2 (0.7) 0 (0) 1.000 1.0 
09:01 3 (1.1) 2 (12.5) 0.025 0.625 
10:01 5 (1.8) 0 (0) 1.000 1.0 
11:01:01 7 (2.5) 1 (6.3) 0.362 1.0 
13:01:01G 9 (3.2) 0 (0) 1.000 1.0 
14:01 2 (0.7) 0 (0) 1.000 1.0 
15:01 1 (0.4) 0 (0) 1.000 1.0 
16:01 1 (0.4) 0 (0) 1.000 1.0 
17:01:01G 5 (1.8) 0 (0) 1.000 1.0 
18:01 5 (1.8) 1 (6.3) 0.286 1.0 
19:01:01G 1 (0.4) 0 (0) 1.000 1.0 
20:01:01 1 (0.4) 0 (0) 1.000 1.0 
26:01:02 3 (1.1) 0 (0) 1.000 1.0 
34:01 1 (0.4) 0 (0) 1.000 1.0 
58:01 1 (0.4) 0 (0) 1.000 1.0 
105:01 29 (10.4) 0 (0) 0.382 1.0 
106:01 1 (0.4) 1 (6.3) 0.105 1.0 
131:01 2 (0.7) 0 (0) 1.000 1.0 
Total 280 (100.5) 16 (100.3)   
 
The frequencies of the three alleles that were significantly associated with HBV vaccine 
response in this cohort (HLA-DPB1*01:01, *04:01:01G and *09:01) in the different ethnicities 
are shown graphically in Figure 3.1.  
 
 
72 
 
HLA-DPB1*01:01 which associated with susceptibility to chronic HBV in the literature 
(Thomas et al., 2012), and here associated with poor vaccine response, was significantly more 
frequent in black African individuals compared to Asian and Caucasian individuals 
(p<0.0001), as seen in Figure 3.1 (also refer to Table 3.13).. These results remained significant 
after Bonferroni correction for multiple comparisons. HLA-DPB1*04:01, associated with 
clearance of HBV infection (Kamatani et al., 2009; Thomas et al., 2012), as well as with 
detectable anti-HBs levels post booster vaccination  (Wu et al., 2013) in the literature and here 
associated with good vaccine response, was significantly more frequent in Asian and Caucasian 
individuals compared to African individuals (p<0.0001), even after Bonferroni adjustment for 
multiple comparisons (p<0.0001), refer also to Table 3.13. HLA-DPB1*09:01, previously 
associated with undetectable anti-HBs following booster vaccination (Wu et al., 2013) and here 
associated with poor vaccine response, was found only in Asian and Coloured individuals in 
our cohort. HLA-DPB1*09:01 was significantly more frequent in Asian individuals compared 
to African and Caucasian individuals (p=0.009 and 0.002, respectively) (Table 3.13); although 
only the difference between Asian and Caucasian individuals remained significant after 
adjustment for multiple comparisons (p=0.012).  
 
 
Figure 3.1. Frequencies of HLA-DPB1*01:01, *04:01 and *09:01 according to ethnicity 
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3.4 Results of SNP Genotyping 
3.4.1 MassArray Analysis 
All 24 SNPs that passed the design stage were successfully genotyped in the 149 participants. 
Examples of the electropherograms produced by MassArray Analysis from which the 
genotypes are determined are shown in Figure 3.2. 
Figure 3.2. Example electropherograms produced by MassArray Analysis. (A) All SNP 
calls in a multiplex, SNP rs2230433 indicated in red. (B) Homozygous C call for rs2230433. 
(C) Homozygous G call for rs2230433. (D) Heterozygous GC call for rs2230433.  
 
A 
B C 
D 
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All SNPs passed the MAF QC threshold of 0.05 (see Table 3.16) and were in HWE (p>0.001) 
(Appendix E), thus all 24 SNPs were included in the analyses.  
 
3.4.2 Allele frequencies within South African ethnicities 
The MAFs of the SNPs in the total cohort and within the different ethnicities are shown in 
Table 3.16.  Due to frequency differences in different populations, there were seven cases 
where the allele deemed to be the minor allele in the whole cohort was actually the major allele 
in a particular ethnicity.  
Most of the SNP allele frequencies (18/24) differed between the ethnicities, as determined by 
chi-square test, and 14 of these remained significant after Bonferroni correction for multiple 
comparisons (Table 3.16). The allele frequencies of the IL4R and ITGAL SNPs significantly 
differed between all three ethnicities. The allele frequencies of the IL2 and IL4 SNPs as well 
as three of the HLA-DPB1 SNPs (rs7770370, rs931, rs9277534) significantly differed between 
the African and Caucasian and between the African and Asian populations. The IL10 SNP, 
rs1143627 of IL1B, the HLA-DRA SNP and rs2395309 of HLA-DPA1 differed significantly 
between the Caucasian and African populations and between the Caucasian and Asian 
populations. The allele frequencies of rs1143633 of IL1B, the HLA-DQB2 SNP, rs2064479 of 
HLA-DPB1, and the IFNG and IL28B SNPs differed significantly between the African and 
Caucasian populations. 
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Table 3.16. MAF of 24 SNPs in the cohort 
SNP ID Gene Chromosome 
Position 
(bp) 
Minor 
allelea 
Major 
allelea 
MAF  
p-value 
Bonferroni 
corrected 
p-value 
Total Cohort, 
n=149 
African,  
n=49 
Caucasian,  
n=75 
Asian,  
n=22 
rs1800896 IL10 1 206773552 C T 0.40 0.32 0.49 0.23 0.0005 0.011 
rs1143634 IL1B 2 112832813 A G 0.18 0.12 0.22 0.16 0.161 1.000 
rs1143633 IL1B 2 112832890 T C 0.27 0.15 0.35 0.23 0.004 0.096 
rs1143627 IL1B 2 112836810 A G 0.48 0.28 0.64* 0.41 <0.0001 <0.0001 
rs2069763 IL2 4 122456327 A C 0.23 0.04 0.30 0.43 <0.0001 <0.0001 
rs2243248 IL4 5 132672952 G T 0.20 0.40 0.11 0.05 <0.0001 <0.0001 
rs2243250 IL4 5 132673462 T C 0.36 0.67* 0.17 0.27 <0.0001 <0.0001 
rs2070874 IL4 5 132674018 T C 0.32 0.55* 0.17 0.27 <0.0001 <0.0001 
rs3212227 IL12B 5 159315942 G T 0.26 0.26 0.23 0.34 0.199 1.000 
rs3213093 IL12B 5 159323971 T C 0.26 0.28 0.23 0.34 0.225 1.000 
rs3135363 HLA-DRA 6 32421871 C T 0.22 0.12 0.32 0.09 <0.0001 0.001 
rs7453920 HLA-DQB2 6 32762235 A G 0.29 0.17 0.38 0.25 0.003 0.072 
rs2395309 HLA-DPA1 6 33058469 G A 0.35 0.50 0.22 0.39 0.0002 0.005 
rs2071349 HLA-DPA1 6 33075743 G C 0.13 0.11 0.13 0.16 0.578 1.000 
rs7770370 HLA-DPB1 6 33081144 G A 0.46 0.69* 0.33 0.34 <0.0001 <0.0001 
rs931 HLA-DPB1 6 33086773 A G 0.36 0.51* 0.25 0.32 0.0003 0.009 
rs9277534 HLA-DPB1 6 33087030 G A 0.37 0.54* 0.27 0.32 0.0001 0.004 
rs9277535 HLA-DPB1 6 33087084 G A 0.22 0.22 0.21 0.25 0.781 1.000 
rs3130186 HLA-DPB1 6 33088430 T C 0.22 0.22 0.21 0.25 0.781 1.000 
rs2064479 HLA-DPB1 6 33104463 T C 0.33 0.46 0.24 0.30 0.003 0.072 
rs2069727 IFNG 12 68154443 C T 0.32 0.22 0.39 0.32 0.033 0.792 
rs1805015 IL4R 16 27362859 C T 0.24 0.39 0.19 0.07 <0.0001 <0.0001 
rs2230433 ITGAL 16 30506720 C G 0.42 0.49 0.32 0.68* <0.0001 <0.0001 
rs8099917 IL28B 19 39252525 G T 0.13 0.04 0.20 0.09 0.001 0.024 
aMinor and major alleles determined for the entire cohort 
*as seen from these frequencies, the so-called minor allele is actually the major allele in this ethnicity 
Abbreviations: MAF, minor allele frequency 
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3.4.3 Comparison of allele frequencies to other populations 
Allele frequencies of the 24 SNPs in our South African ethnicities were compared to data from 
Ensembl (release 87) (Yates et al., 2016). The South African black population was compared 
to the average allele frequencies of the LWK and YRI populations, the South African 
Caucasian population was compared to the CEU population and the South African Asian 
population was compared to the ITU population, as seen in Table 3.17. As determined by 
Fisher’s exact test, the allele frequencies of rs2243248 and rs2243250, both of the IL4 gene, 
differed significantly between our South African black population and the reference 
populations (p=0.001 and p=0.023 respectively). The HLA-DPB1 intron variant, rs7770370, 
differed significantly between the South African Caucasian population and the CEU population 
(p=0.014). Three SNPs - rs2069763 in IL2, rs3135363 upstream of HLA-DRA and rs7770370 
in HLA-DPB1 - significantly differed in allele frequencies between the South African Asian 
population and the ITU population (p= 0.038, p=0.043 and p=0.015, respectively). However, 
only the difference in allele frequency of rs2243248 between the South African black and 
reference populations remained significant after Bonferroni correction for multiple 
comparisons.
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   Table 3.17. Comparison of allele frequencies in SA populations to reference populations 
  Allele Frequency   Allele Frequency   Allele Frequency  
SNP ID Allele 
SA blacka 
(n=49) 
LWK/YRI p-value 
 SA whitea 
(n=75) 
CEU p-value 
 SA Asian/Indiana 
(n=22) 
ITU p-value 
rs1800896 C 0.32 0.31 1.000  0.49 0.52 0.777  0.23 0.24 1.000 
rs1143634 A 0.12 0.11 1.000  0.22 0.23 1.000  0.16 0.13 0.689 
rs1143633 T 0.15 0.17 0.847  0.35 0.37 0.883  0.23 0.24 1.000 
rs1143627 A 0.28 0.32 0.644  0.64 0.65 1.000  0.41 0.38 0.772 
rs2069763 A 0.04 0.10 0.164  0.30 0.40 0.182  0.43 0.28 0.038 
rs2243248 G 0.40 0.17 0.001  0.11 0.09 0.814  0.05 0.13 0.081 
rs2243250 T 0.67 0.82 0.023  0.17 0.13 0.553  0.27 0.18 0.175 
rs2070874 T 0.55 0.53 0.887  0.17 0.13 0.553  0.27 0.18 0.175 
rs3212227 G 0.26 0.38 0.095  0.23 0.19 0.603  0.34 0.42 0.308 
rs3213093 T 0.28 0.38 0.176  0.23 0.19 0.603  0.34 0.42 0.308 
rs3135363 C 0.12 0.19 0.241  0.32 0.19 0.051  0.09 0.20 0.043 
rs7453920 A 0.17 0.28 0.090  0.38 0.46 0.316  0.25 0.24 1.000 
rs2395309 G 0.50 0.59 0.256  0.22 0.18 0.596  0.39 0.36 0.770 
rs2071349 G 0.11 0.12 1.000  0.13 0.12 1.000  0.16 0.28 0.060 
rs7770370 G 0.69 0.63 0.456  0.33 0.17 0.014  0.34 0.18 0.015 
rs931 A 0.51 0.57 0.478  0.25 0.27 0.872  0.32 0.37 0.552 
rs9277534 G 0.54 0.62 0.316  0.27 0.28 1.000  0.32 0.38 0.459 
rs9277535 G 0.22 0.17 0.476  0.21 0.24 0.735  0.25 0.30 0.527 
rs3130186 T 0.22 0.17 0.476  0.21 0.24 0.735  0.25 0.30 0.527 
rs2064479 T 0.46 0.53 0.396  0.24 0.21 0.735  0.30 0.33 0.761 
rs2069727 C 0.22 0.14 0.197  0.39 0.43 0.666  0.32 0.41 0.240 
rs1805015 C 0.39 0.48 0.254  0.19 0.17 0.854  0.07 0.07 1.000 
rs2230433 C 0.49 0.43 0.478  0.32 0.29 0.759  0.68 0.77 0.205 
rs8099917 G 0.04 0.06 0.748  0.20 0.15 0.457  0.09 0.18 0.097 
Reference alleles labelled in blue 
aAllele frequencies observed in this study 
Abbreviations: LWK, Luhya in Webuye, Kenya; SA, South African; YRI, Yoruba in Ibadan, Nigeria; CEU, Utah residents with Northern and Western European ancestry; ITU, 
Indian Teluga in the UK 
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3.4.4 Genotype frequencies 
The genotype frequencies of the 24 SNPs in the total cohort and within the South African 
ethnicities can be seen in Appendix F. 
 
3.4.5 Haplotype frequencies 
3.4.5.1 Haplotype frequencies in cytokine genes 
Haplotype analysis was performed using the sliding window approach for the chromosomes 
for which two or more SNPs were genotyped, that is, chromosome 2 (IL1B), chromosome 5 
(IL4 and IL12B) and chromosome 16 (IL4R and ITGAL). The frequencies of these haplotypes 
in the different South African ethnicities are shown in Table 3.18. 
 
Table 3.18. Chromosome 2, 5 and 16 haplotype frequencies 
Haplotype 
Frequency (%) 
Total 
cohort 
SA 
black 
SA 
Caucasian 
SA 
Asian 
Chromosome 2 
  rs1143634 rs1143633 rs1143627     
  G T A 23.40 6.58 34.30 22.70 
  A C A 13.10 1.66 20.10 13.60 
  G C A 11.80 19.30 9.61 4.61 
  G T G 2.64 8.22 1.07 0.00 
  A C G 4.56 10.10 1.88 2.34 
  G C G 44.00 53.60 33.10 56.80 
Chromosome 5 
rs2243248 rs2243250 rs2070874 rs3212227 rs3213093     
G T T G T 1.00 2.00 0.00 1.27 
T T T G T 5.80 11.00 0.00 10.60 
T T C G T 1.20 3.80 0.00 0.00 
G C C G T 3.60 3.70 3.60 3.28 
T C C G T 13.80 5.00 19.70 19.00 
G T T T C 3.40 9.60 0.00 0.00 
T T T T C 19.60 25.40 16.70 15.40 
G C T T C 1.90 6.20 0.00 0.00 
G T C T C 3.30 7.00 0.00 0.00 
G C C T C 6.20 10.40 7.70 0.00 
T C C T C 38.60 7.40 52.30 50.50 
T T C T T 0.00 1.00 0.00 0.00 
G T T T T 0.00 1.00 0.00 0.00 
T T T T C 0.00 6.60 0.00 0.00 
Chromosome 16 
   rs1805015 rs2230433     
   C C 9.00 16.50 6.02 4.18 
   T C 33.60 32.50 26.00 64.00 
   C G 15.20 22.30 12.60 2.64 
   T G 42.20 28.70 55.40 29.20 
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Linkage maps for the SNPs in the cytokine genes, based on the whole cohort, were generated 
using Haploview, shown in Figure 3.3. In the IL1B gene, rs1143634 was in complete LD with 
rs1143633, and rs1143633 was partially in LD with rs114627. In the IL4 gene, rs2243250 was 
in near complete LD with rs2070874, while rs3212227 was in complete LD with rs3213093 in 
IL12B. There was no LD between the rs1805015 and rs2230433 SNPs on chromosome 16. 
 
Figure 3.3. LD maps generated by Haploview for SNPs in chromosomes 2, 5, and 16. Numbers 
within the blocks represent Dʹ values. A) Chromosome 2, all SNPs located within IL1B gene region. B) 
Chromosome 5, SNPs located within IL4 and IL12B gene regions. C) Chromosome 16, SNPs located 
within the IL4R and ITGAL genes. 
 
3.4.5.2 Haplotypes frequencies of HLA class II region 
Haplotypes of the HLA region, including ten SNPs (one in HLA-DR, one in –DQ and eight in 
–DPA1 or –DPB1 genes), and the HLA-DPA1 and -DPB1 alleles were generated using 
Arlequin v3.5. The ten most frequent haplotypes of the HLA class II region SNPs and the HLA-
DP alleles, in the total cohort are shown in Table 3.19. The complete set of these haplotypes 
and their frequencies are shown in Appendix G.  
The ten most frequent haplotypes account for 45.5% of the total cohort. Five of these ten most 
frequent haplotypes differ significantly between the different South African ethnicities and four 
remained significant following Bonferroni correction for multiple comparisons (Table 3.19). 
A) Chromosome 2 B) Chromosome 5 C) Chromosome 16 
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Table 3.19. Chromosome 6 SNP and HLA-DP allele haplotype frequencies 
Haplotype Frequency (%)   
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Total 
cohort 
SA 
black 
SA 
Caucasian 
SA 
Indian 
p-value 
Bonferroni 
corrected 
p-value 
T G A C A G A A C C 01:03 04:01 10.7 0.0 10.7 36.1 <0.0001 <0.0001 
T A A C A G A A C C 01:03 04:01 7.7 0.0 15.3 0.0 <0.0001 <0.0001 
T G G C G A G A C T 02:other 01:01 6.0 15.2 0.0 0.0 <0.0001 <0.0001 
T G A C A A G G T T 01:03 03:01 4.0 6.1 3.3 2.8 0.458 1.000 
T G G C G A G A C T 02:01 01:01 3.7 5.1 2.0 2.8 0.485 1.000 
C G A C A G A A C C 01:03 04:01 3.0 0.0 6.0 0.0 0.002 0.020 
T G A G A G A A C C 01:03 02:01 2.7 3.0 6.7 5.6 0.424 1.000 
C A A C A G A A C C 01:03 04:01 2.7 0.0 1.3 0.0 0.367 1.000 
C A A C G G A A C C 01:03 04:01 2.7 0.0 4.7 5.6 0.054 0.540 
T A A G A G A A C C 01:03 02:01 2.3 4.0 0.0 0.0 0.017 0.170 
 
 
 
81 
 
The linkage map for the HLA region SNPs, based on the whole cohort, as generated by 
Haploview, is shown in Figure 3.4. The HLA-DPA1 SNPs rs2395309 and rs2071349 were in 
complete LD. In the HLA-DPB1 3ʹ untranslated region (UTR), rs931 was in complete LD with 
rs9277534, and rs9277534, rs9277535 and rs3130186 were in complete LD with one another. 
There were also several SNPs in partial LD with one another (Figure 3.4). 
 
Figure 3.4. LD map of chromosome 6 SNPs generated by Haploview. Numbers within the blocks 
represent Dʹ values.  
 
3.4.6 Association of alleles, genotypes and haplotypes with antibody response to HBV 
vaccination  
Only significant results are shown in this section (the complete results set is shown in Appendix 
H). SNPs that were significant at the univariate level were then analysed in multivariate 
analysis taking weight and ‘smoker during vaccination period’ status into account using logistic 
regression. Results from both univariate and multivariate analyses are shown in a Table 3.20. 
Significant SNP associations using the four models (allelic, genotypic, dominant and recessive) 
are shown in Table 3.20. 
 
Chromosome 6 
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Table 3.20. SNP associations with HBV vaccine response  
Model Gene SNP ID 
UNIVARIATE MULTIVARIATE Risk 
of LR PEMP1 PEMP2 OR PEMP1 PEMP2 OR 
Allelic 
IL1B rs1143634 0.038 0.560 2.93 0.135 0.560 2.62 ↑ 
HLA-DPB1 rs931 0.048 0.360 3.23 0.013 0.071 2.16 ↑ 
Genotypic 
IL1B rs1143634 0.048 0.599 - 0.052 0.407 -  
IL4 rs2070874 0.044 0.512 - 0.111 0.350 -  
HLA-DPB1 rs7770370 0.010 0.199 - 0.027 0.180 -  
IFNG rs2069727 0.029 0.421 - 0.209 0.059 -  
Dominant IL4 rs2070874 0.028 0.329 - 0.004 0.029 12.08 ↑ 
 IFNG rs2069727 0.019 0.320 - 0.030 0.124 0.12 ↓ 
Recessive HLA-DPB1 rs7770370 0.012 0.117 - 0.011 0.050 8.52 ↑ 
Abbreviations: PEMP1, pointwise empirical p-value; PEMP2, p-value corrected for multiple comparisons; OR, odds 
ratio; LR; low-response 
 
3.4.6.1 Associations between HLA SNPs and vaccine response 
SNP rs931 (located in the 3ʹ UTR of HLA-DPB1) was significantly associated with HBV 
vaccine response in our South African cohort during univariate allelic analysis. The A variant 
(minor allele) was associated with an increased risk of low-response to the HBV vaccine 
relative to the major allele (OR>1.0).  
Genotypes of only one SNP in the HLA region were significantly associated with HBV 
response in cohort. SNP rs7770370, located in an HLA-DPB1 intron, was significantly 
associated with HBV vaccine response in genotypic and recessive models of inheritance. These 
results indicate that the rs7770370 GG genotype was associated with an increased risk of low 
anti-HBs response. The GG genotype of rs7770370 was found at rather low frequencies <10% 
in the different ethnicities in our study cohort. 
The HLA-DPB1 SNPs rs931 and rs7770370 were still significant after multivariate analysis 
and rs7770370 remained significant even after correction for multiple comparisons in the 
recessive model of inheritance. This indicates a strong association of these two variants with 
HBV vaccine response.  
From the HLA class II region haplotypes (Table 3.19), it appears that the rs931 A allele and 
the rs7770370 G allele are inherited with HLA-DPB1*01:01, all of which were associated with 
poor anti-HBs response in this South African cohort; whereas the rs931 G allele and rs7770370 
A allele are inherited with HLA-DPB1*04:01, which were all associated with good anti-HBs 
response in this study.  
 
 
 
83 
 
3.4.6.2 Associations between HLA SNP haplotypes and vaccine response 
Haplotypes including SNPs of the HLA region with an LD Dʹ value greater than 0.8 (as 
determined by Haploview) were tested for association with vaccine response. Six haplotypes 
were significantly associated after univariate analysis, and all of these haplotypes remained 
significant after multivariate analysis (Table 3.21). However, after adjustment for multiple 
comparisons, the significance of these haplotypes was lost (see Appendix H for the complete 
set of results).  
 
Table 3.21. HLA region haplotypes significantly associated with vaccine response 
Haplotype 
Haplotype 
Frequency 
Univariate Multivariate 
Risk 
of 
LR 
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PEMP1 PEMP2 OR PEMP1 PEMP2 OR 
A C      0.523 0.042 0.251 0.30 0.045 0.308 0.30 ↓ 
 C G     0.523 0.032 0.260 0.31 0.029 0.255 0.25 ↓ 
 C  A    0.506 0.031 0.296 0.32 0.028 0.268 0.26 ↓ 
  A G    0.356 0.013 0.257 2.79 0.006 0.191 3.47 ↑ 
  G A A C  0.628 0.021 0.296 0.38 0.011 0.219 0.30 ↓ 
  G A A C C 0.606 0.012 0.187 0.30 0.005 0.121 0.21 ↓ 
Abbreviations: PEMP1, pointwise empirical p-value; PEMP2, p-value corrected for multiple comparisons; OR, odds 
ratio; LR, low-response 
 
Four of the six significant haplotypes included SNPs rs931 and rs9277534, located within the 
3ʹ UTR of HLA-DPB1. The haplotype involving the A allele of rs931 and the G allele of 
rs9277534 is the only haplotype associated with an increased risk of low anti-HBs response. 
rs931, which was also significant at an allelic level of analysis, has not previously been 
associated with HBV vaccine response. As mentioned previously, rs931 alleles seem to be 
linked to the HLA-DPB1*01:01 and *04:01 alleles, this also seems to be the case with 
rs2395309, rs9277534 and rs2064479. 
The frequencies of the haplotypes composed of the ten HLA region SNPs and the HLA-DPA1 
and HLA-DPB1 alleles were compared between the low-responders and responders. Only two 
haplotypes were significantly associated with HBV vaccine response, and these are shown in 
Table 3.22. 
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Table 3.22. HLA class II region haplotypes associated with HBV vaccine response 
Haplotype  Frequency (n, %) 
p-value 
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T G G C A A G G T T 02:01 09:01  3 (1.1) 2 (12.5) 0.025 
T A A C G G A A C C 01:03 04:02  1 (0.4) 2 (12.5) 0.008 
 
Both of the haplotypes are observed at significantly higher frequencies in low-responders, 
however their significance is lost after Bonferroni correction for multiple comparisons 
(p=1.000 and p=0.760, respectively). These haplotypes are only similar at SNPs rs3135363 and 
rs2071349; and only HLA-DPB1*09:01, present in the first haplotype, was previously 
associated with HBV vaccine response in this study. However, due to the large number of 
possible haplotypes and the small sample sizes in each, significance testing may not be very 
reliable. 
 
3.4.6.3 Associations between cytokine SNPs and vaccine response 
IL1B: SNP rs1143634 (a synonymous variant in the IL1B gene) was significantly associated 
with HBV vaccine response in our South African cohort during univariate allelic analysis. The 
A variant (minor allele) was associated with an increased risk of low-response to the HBV 
vaccine relative to the major allele (OR>1.0). 
IL4: rs2070874, located in the 5ʹ UTR of IL4, was significantly associated with HBV vaccine 
response in the genotypic and dominant models of inheritance. These results suggested that in 
our cohort having at least one T allele at rs2070874 was associated with low anti-HBs response. 
In our cohort, the T allele was much more frequent in black Africans (55%) than in other 
ethnicities (<30%; Table 3.16). The associations observed with the IL4 SNP rs2070874 
remained significant after multivariate analysis in the dominant model of inheritance. 
Moreover, IL4 SNP rs2070874 stayed significant after adjustment for multiple comparisons, 
indicating a very significant result. 
IFNG: the rs2069727 SNP which is located downstream of the IFNG gene was significantly 
associated with HBV vaccine response in the genotypic and dominant models of inheritance. 
Having at least one C allele at rs2069727 in our cohort was associated with an increased anti-
HBs response. The associations observed with the IFNG rs2069727 remained significant after 
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multivariate analysis in the dominant model of inheritance. These results re-enforce the 
association described for the univariate analysis. 
 
3.4.6.4 Associations between haplotypes in cytokine genes and vaccine response 
Haplotype frequencies for IL1B on chromosome 2, IL4 and IL12B on chromosome 5, and IL4R 
and ITGAL on chromosome 16 were compared between low-responders and normal-
responders. Only significant results are shown here (see Appendix H for the full results set). 
Results from both univariate and multivariate analyses are shown in a single table, Table 3.23.  
 
Table 3.23. Significant haplotype associations with vaccine response 
Haplotype 
Haplotype 
Frequency 
Univariate Multivariate Risk 
of LR PEMP1 PEMP2 OR PEMP1 PEMP2 OR 
Chromosome 2 
IL1B 
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A C   0.181 0.039 0.457 3.48 0.151 0.857 2.62 ↑ 
A C G  0.046 0.009 0.071 10.5 0.006 0.047 19.4 ↑ 
Chromosome 5  
IL4 IL12B         
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T T T  0.231 0.029 0.564 2.79 0.010 0.187 4.35 ↑ 
T T T C 0.227 0.029 0.526 2.84 0.008 0.174 4.38 ↑ 
 T T  0.251 0.050 0.736 2.45 0.017 0.259 3.74 ↑ 
 T T C 0.244 0.043 0.692 2.49 0.013 0.252 3.74 ↑ 
Abbreviations: PEMP1, pointwise empirical p-value; PEMP2, p-value corrected for multiple comparisons; OR, odds 
ratio; LR, low-response 
 
Two haplotypes involving the SNPs of IL1B surpassed the univariate threshold of PEMP1<0.05, 
but only the three-SNP haplotype, rs1143634-rs1143633-rs1143627 ACG, was significant 
after multivariate analysis (Table 3.21). Furthermore, this three-SNP haplotype was significant 
after adjusting for multiple comparisons (PEMP2<0.05). Both these haplotypes were associated 
with increased risk of low antibody response to the HBV vaccine (OR>1.0). This haplotype 
contained rs1143634 A, which was also significantly associated with low vaccine response in 
allelic and genotypic models. 
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Four haplotypes in chromosome 5 encompassing genes IL4 and IL12B (all various 
combinations of rs2243250-rs2070874-rs3212227-rs3213094 TTTC), were significantly 
associated with increased risk of low anti-HBs response, and the associations remained 
significant following multivariate analysis. All haplotypes included the IL4 SNP (rs2070874 
T) that was also associated with poor HBV vaccine response in genotype analysis.  
In summary, the HLA and cytokine SNPs that remained significantly associated with HBV 
vaccine response in our cohort in multivariate analysis were rs931 (HLA-DPB1), rs7770370 
(HLA-DPB1), rs2070874 (IL4) and rs2069727 (IFNG); and haplotypes that remained 
significantly associated with HBV vaccine response in our cohort in multivariate analysis 
involved the HLA class II region, IL1B and IL4/IL12B genes (HLA class II region haplotypes 
rs2395309-rs2071349 AC, rs207349-rs931 CG, rs2071349-rs9277534 CA, rs931-rs9277534-
rs9277535-rs3130186 GAAC and rs931-rs9277534-rs9277535-rs3130186-rs2064479 
GAACC, and cytokine gene IL1B haplotype rs1143634-rs1143633-rs1143627 ACG and 
IL4/IL12B haplotypes rs2243250-rs2070874-rs3212227 TTT, rs2243250-rs2070874-
rs3212227-rs3213093 TTTC, rs2070874-rs3212227 TT and rs2070874-rs3212227-rs3213093 
TTC). Those that remained significant in multivariate analysis and after correction for multiple 
testing included rs2070874 (IL4) and rs7770370 (HLA-DPB1), and the IL1B haplotype 
rs1143634-rs1143633-rs1143627 ACG. 
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3.5 Discussion 
We investigated HLA class II variation and cytokine SNPs in a South African cohort, and 
compared genetic variation to response to HBV vaccination. 
 
3.5.1 HLA class II variation in the South African cohort  
We reported HLA-DPA1 and -DPB1 allele frequencies and HLA class II region SNP allele and 
genotype frequencies in the whole cohort, as well as per ethnic group in the cohort. 
There is limited HLA-DP region data available for South African cohorts. No data on HLA-
DPA1 alleles in South African cohorts was found, and very few papers in the literature have 
reported on HLA-DPB1 data in South Africans (Lombard et al., 2006; Tikly et al., 2004; 
Tshabalala et al., 2015). Additionally, HLA-DPB1*105:01 frequencies have not been reported 
previously, likely due to the inability to differentiate between *105:01 and *04:02 using 
standard sequence-based typing techniques. The HLA class II region SNP data have also not 
been previously reported in South African populations. 
We found that most of the HLA-DPA1/DPB1 allele frequencies and SNP frequencies differed 
significantly among different ethnic groups in our cohort. This was similar to reports for other 
HLA loci in South African populations (Paximadis et al., 2012). In addition, significant 
differences among the allele frequencies of the three ethnicities were found for 7/10 SNPs.  
In contrast, HLA and SNP frequencies were similar to those observed in reference (shared 
ancestry) populations for all South African ethnicities examined. The few cases where 
differences were observed between the ethnic groups of this cohort and the reference 
populations may be due to the small sample size of each group. In addition, the reference 
populations used may not be ideal reference populations due to the broad ancestral grouping 
used. For example, there were no data in AFND for South African black populations so several 
sub-Saharan black populations were used as the reference instead; yet African populations 
remain largely subdivided (Campbell and Tishkoff, 2008).  
 
3.5.2 Cytokine genetic variation in the South African cohort  
We reported allele and genotype frequencies of fourteen SNPs in cytokine genes in a South 
African cohort, and compared these frequencies between different South African ethnicities. 
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The investigated SNPs have been reported on previously in South African cohorts (Govan et 
al., 2003; Meenagh et al., 2002; Moller et al., 2010; Naicker et al., 2009; Wadley et al., 2013), 
and differences among ethnicities have been previously reported (Govan et al., 2003; Meenagh 
et al., 2002). We observed SNP allele frequency differences between the South African ethnic 
groups in majority (11/14) of the cytokine SNPs. 
There were only a few significant differences when comparing the South African ethnic groups 
to reference populations. Reasons for these differences were discussed above.  
 
3.5.3 Genetic variation and HBV vaccine response 
In addition to the clinical factors influencing anti-HBs titres, genetic factors also play a role. 
The heritability of anti-HBs titres after vaccination has been estimated to be more than 70% 
(Newport et al., 2004).  
 
3.5.3.1 HLA-DPA1 variation 
HLA-DPA1 alleles 
We observed five HLA-DPA1 alleles (at 4-digit resolution). This relatively low number of 
alleles was expected as, globally, HLA-DPA1 has the lowest number of alleles compared to the 
other class II HLA genes (Sidney et al., 2010; Tshabalala et al., 2015). Four HLA-DPA1 alleles 
account for more than 90% of all HLA-DPA1 genes and -DPA1*01:03 representing 
approximately 60% of them (Sidney et al., 2010). These frequencies are seen in this study as 
well 
Some previous studies have associated HLA-DPA1*01:03 and 02:02 with HBV infection 
outcome and vaccine response (Kamatani et al., 2009; Mineta et al., 1996). However, another 
report found no association between HLA-DPA1 alleles and HBV infection outcome (Thomas 
et al., 2012). In concordance with Thomas et al., (2012), our study did not find any significant 
associations between HLA-DPA1 alleles and anti-HBs titres. Additionally, the small sample 
size may not have allowed the detection of small associations. 
 
HLA-DPA1 region SNPs 
The two HLA-DPA1 SNPs investigated, rs2395309 located upstream and rs2071349 located in 
an intron, were not associated with HBV vaccine response in the allelic or genotypic analyses. 
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However, they are in complete LD with one another (Figure 3.4) and the rs2395309-rs2071349 
haplotype AC was associated with decreased risk of low anti-HBs response. 
The rs2395309 C allele was previously associated with increased susceptibility of chronic HBV 
infection (Guo et al., 2011; Kamatani et al., 2009), so our finding that the A allele (in the 
haplotype) contributes positively to the response suggests that the same genetic variation 
contributes to both poor response to HBV infection and poor response to HBV vaccination. 
While we did not study HLA-DPA1 rs3077 in this study, this SNP has been associated with 
HBV vaccine response (Pan et al., 2013) as well as with HBV infection outcome in Asian 
populations (Guo et al., 2011; Hu et al., 2012; Kamatani et al., 2009; Mbarek et al., 2011; 
Nishida et al., 2012).  The HLA-DPA1 SNPs rs2395309 and rs3077 are in high LD in Europeans 
and Asians (O’Brien et al., 2011), as well as in Africans (as determined from the LWK 
population which is representative of the South African black population). The haplotype 
containing rs2395309 that associated with poor vaccine response in the current study should 
also be examined for linkage to rs3077. 
The SNP rs2071349 has not been associated with HBV vaccine response previously. 
Although not formally analysed, it appears that rs2395309 A allele is linked to HLA-
DPA1*01:03, while the rs2395309 G allele is linked to HLA-DPA1*02 alleles. HLA-
DPA1*01:03 has previously been associated with HBV infection clearance and with good 
HBV vaccine response (Kamatani et al., 2009; Mineta et al., 1996), and the rs2395309 A allele 
(in haplotype) was associated with good HBV vaccine response in this study, which supports 
the observation of the linkage that possibly exists between them. 
 
3.5.3.2 HLA-DPB1 variation 
HLA-DPB1 alleles 
In this study, HLA-DPB1*01:01 and 09:01 alleles were significantly associated with low anti-
HBs titre after vaccination, and HLA-DPB1*04:01:01G allele was significantly associated with 
good anti-HBs response after vaccination.  
HLA-DPB1*0101 has previously been reported in association with persistent HBV infection 
(Kamatani et al., 2009; Thomas et al., 2012), but it has not been previously associated with 
HBV vaccine response. This could be due to the fact that many of the vaccine response 
association studies were performed in Asian populations which have low HLA-DPB1*01:01 
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allele frequencies, and none were performed in African populations which have high HLA-
DPB1*01:01 frequencies (Thomas et al., 2012; Table 3.14). 
HLA-DPB1*09:01 has previously been reported in association with HBV vaccine non- or low-
response (Desombere et al., 1998; Wu et al., 2013). The previous association of HLA-
DPB1*09:01 with HBV vaccine response was identified in an Asian population; and although 
the association was observed in our total cohort, the 09:01 allele is significantly more common 
in our South African Asian population compared to the South African black or Caucasian 
populations. 
In this study, we found the HLA-DPB1*04:01:01G allele to be significantly associated with 
good anti-HBs response. Both *04:01 and *04:02 have previously been reported as associated 
with HBV infection clearance (Kamatani et al., 2009; Thomas et al., 2012). HLA-DPB1*04:01 
has also previously been associated with good HBV vaccine response (Desombere et al., 1998; 
Martinetti et al., 1995; Wu et al., 2015, 2013). 
While ethnicity was not associated with HBV vaccine response in our analyses of demographic 
data, we did note that certain risk alleles were increased/decreased in particular South African 
ethnicities. The HLA-DPB1*01:01 (risk) allele was significantly more frequent in the South 
African black population, while the -DPB1*04:01 (protective) allele was significantly less 
frequent in the South African black population compared to the other populations. If the same 
risk alleles act in both HBV infection and HBV vaccine response then this might indicate a 
genetic reason as to why chronic HBV infection is increased in the South African black 
population compared to other population groups (Kew, 2008, 1996). 
 
HLA-DPB1 region SNPs 
We examined six HLA-DPB1 region SNPs (rs7770370, rs931, rs9277534, rs9277535, 
rs3130186, rs2064479) and two (rs7770370 and rs931) were associated with antibody response 
to HBV vaccination. In addition, six haplotypes were associated with antibody response to 
HBV vaccination in multivariate analysis.  
The rs7770370 intronic variant was the one of two HLA-DPB1 SNP to be associated with HBV 
vaccine response in the allelic and genotypic analyses in this study, but the only one to remain 
significant after adjustment for multiple comparisons. The rs7770370 GG genotype was 
associated with an increased risk of low anti-HBs response. Similar results have been reported 
previously in Asian populations (Roh et al., 2016; Wu et al., 2015). 
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The other SNP associated with HBV vaccine response in the allelic model was rs931, located 
in the 3ʹ UTR. It was also in complete or partial LD with other SNPs of located in the 3ʹ UTR 
and downstream of the HLA-DPB1 gene. rs931 has not been associated with HBV vaccine 
response previously, so the protective effect of the G allele cannot be confirmed. The rs931 A 
allele was more frequent in the black African population compared to the others in this South 
African cohort. These frequencies were similar to those of reference populations (Table 3.17). 
In our study, the rs9277534, rs9277535 and rs313086 HLA-DPB1 3ʹ UTR variants were in 
complete LD with one another (Figure 3.4). The AAC haplotype of these SNPs was associated 
with a decreased risk of low-response. In a population of European- and African-Americans, 
the SNP rs9277534 showed the most significant association with HBV infection outcome, even 
stronger than the SNPs identified in Asian studies (Thomas et al., 2012). The rs9277534 GG 
genotype was previously associated with chronic HBV infection (Thomas et al., 2012) and with 
a decrease in Rubella virus antibodies (Lambert et al., 2014). Thus, the effect of rs9277534 is 
consistent in HBV infection outcome (Thomas et al., 2012), Rubella virus vaccine response 
(Lambert et al., 2014) and with HBV vaccine response (in this study). While rs9277535 has 
previously been associated with HBV vaccine response in an Indonesian and Korean 
populations (Png et al., 2011; Roh et al., 2016), this association was not observed in a Chinese 
population (Pan et al., 2013). However, rs9277535 has been repeatedly associated with HBV 
infection outcome in Asian populations in both GWAS (Hu et al., 2013; Kamatani et al., 2009; 
Mbarek et al., 2011) and candidate-gene studies (Guo et al., 2011; Hu et al., 2012; Wang, 
2011). The rs9277535 A allele has a protective effect in both HBV vaccine response and 
infection outcome. The SNP rs3130186 has not been associated with HBV previously, likely 
due to its LD with adjacent SNPs; it is in complete LD with rs9277535 in the LWK population 
and in this South African population (determined by Haploview; Figure 3.4). 
The variant rs2064479, located downstream of HLA-DPB1, was associated with HBV vaccine 
response in our study. The C allele was the protective allele in this study, which has also been 
found to be the case in Rubella virus vaccine response (Lambert et al., 2014). 
These SNPs have previously been found to be in LD with HLA-DP alleles. For example, HLA-
DPB1*01:01 and *05:01 was in perfect LD with the G allele rs9277534, but *04:01 was in LD 
with the A allele in Asian and European- and African-American populations (Thomas et al., 
2012); while the rs7770370 A allele was correlated with the HLA-DPB1*02:01, *02:02, 
*03:01, *04:01 and *14:01, and negatively correlated with HLA-DPB1*05:01 allele in an 
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Asian population (Wu et al., 2015); and HLA-DPB1*05:01 is also in LD with rs9277535 G in 
an Asian population (Kamatani et al., 2009). Consequently, it is difficult to ascertain the precise 
causative variant, or combination thereof, although Thomas et al. (2012) did find that the 
rs9277534 variant had a stronger effect than any particular HLA allele. 
Of the SNPs included in the haplotype analysis, the allele frequencies of rs2395309, rs931, 
rs9277534 and rs2064479 significantly differ between the South African ethnicities, with 
increased frequency of the minor allele in the South African black population (Table 3.16). In 
fact, the minor alleles of rs931 and rs9277534 of the total cohort are the major alleles in the 
South African black population. These allele frequencies are similar to those observed in the 
reference populations (Table 3.17). Of these four SNPs, the alleles of rs2395309, rs931, and 
rs9277534 that are associated with an increased risk of low-response (that is, G, A and G alleles 
respectively) are found at higher frequencies in the South African black population. Together 
with the HLA-DPB1 allele findings, this supports the genetic reason behind an increased rate 
of chronic HBV infection and HBV vaccine non-response (average of 14%, as discussed in 
section 1.6) in the South African black population (Hino et al., 2001; Kew, 2008, 1996; 
Mphahlele et al., 2002; Schoub et al., 2002; Simani et al., 2009; Tsebe et al., 2001; Young et 
al., 2013). These findings also suggest the importance of the HLA-DP region in the HBV 
immune response. 
 
3.5.3.3 Other SNPs of the HLA region 
Neither the SNP upstream of HLA-DRA (rs3135363) nor the HLA-DQB2 intronic SNP 
(rs7453920) were significantly associated with HBV vaccine response. Although these SNPs 
represent a very small portion of the variation of the HLA-DR or -DQ genes that may play a 
role in the response to the HBV vaccine, the HLA-DP region is the focus of association in this 
study.  
In summary, rs931 which associated with HBV vaccine response on its own and in a haplotype, 
and rs2071347 and rs3130186 which associated with HBV vaccine response in haplotype, were 
novel associations. Additionally, SNPs that were previously associated with HBV infection 
outcome and/or other vaccine response, and were associated (in haplotype) with HBV vaccine 
response in the current study, included rs2395309, rs9277534 and rs2064479. The risk alleles 
of these SNPs were consistent in this, and previous studies. HLA-DPB1*01:01 was previously 
associated with HBV chronic infection, and in this study, with poor HBV vaccine response. 
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The findings relating to SNPs rs7770370 and rs9277535, and to HLA-DPB1*04:01 and *09:01, 
alleles were consistent with previous findings of HBV vaccine response (and HBV infection 
outcome).  
 
3.5.3.4 Cytokine gene variation 
It has been noted that variation within the HLA region only accounts for part of the HBV 
vaccine response variability, suggesting that other factors contribute to this response (Mineta 
et al., 1996). Indeed, non-HLA genes may account for as much as 60% of the genetic factors 
influencing HBV vaccine response (Höhler et al., 2002b). Additionally, non-HLA genetic 
variation may be linked with the HLA alleles (Yucesoy et al., 2009). Furthermore, the HBV 
vaccine response ranges from no anti-HBs production to low anti-HBs levels and to very high 
titres which suggests that multiple gene interactions may underlie the mechanism of vaccine-
induced immune response (Desombere et al., 1998). Thus, variation in cytokine genes was also 
investigated in this study. The following genes contained SNPs that were significantly 
associated with HBV vaccine response: IL1B, IL4, IL12B and IFNG. 
IL1B: IL1β is produced by monocytes, macrophages and dendritic cells (Garlanda et al., 2013). 
It plays a role in inflammation and host defence and is involved in Th17 cell differentiation 
(Garlanda et al., 2013). 
In this study, the A allele of rs1143634 (a synonymous SNP in the IL1B gene) was associated 
with an increased risk of low-response in our South African cohort at the univariate level. In 
contrast, the A allele has previously been associated with a good response to the HBV vaccine 
in European-Americans adults (Yucesoy et al., 2002), although this association was not seen 
in infants (Yucesoy et al., 2009). 
Although a synonymous SNP does not change the amino acid encoded by the codon, it can 
interrupt a splicing donor site, which could result in an inappropriate stop codon or exon 
skipping and thereby generating an incomplete mRNA (Thi Tran et al., 2005). The shorter 
mRNA would result in a truncated protein that may be non-functional or may be degraded 
rapidly (Bellone et al., 2006). It has been reported that the rs1143634 AA genotype is associated 
with increased IL1β levels (Pociot et al., 1992). As the A allele was associated with low 
response in our study, increased IL1β levels may lead to decreased anti-HBs response.  
Additionally, the IL1B haplotype ACG (involving SNPS rs1143634, rs1143633 and 
rs1143627) was associated with an increased risk of low-response, and remained significant 
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after multivariate analysis and after adjusting for multiple comparisons (PEMP2<0.05). 
Previously, the AG haplotype defined by SNPs rs1143633 and rs1143627 was found to 
correlate with non-response to HBV vaccine in a Chinese population (Chen et al., 2011). 
Therefore, the risk allele of rs1143633 also differs from previous studies but, the risk-
associated G allele of rs1143627 is consistent between the two studies. 
IL4: rs2070874 located in the 5ʹ UTR of IL4 was significantly associated with HBV vaccine 
response in the genotypic and dominant models of inheritance. These results suggested that in 
our cohort having at least one T allele at rs2070874 was associated with low anti-HBs response. 
Contradictory associations have been reported in the literature regarding the role of the 
rs2070874 allele in HBV vaccine response: the T allele has been associated with increased 
vaccine response in Asian populations but not in Caucasian populations (Cui et al., 2013), and 
the C allele (in a haplotype) has been associated with increased response in various ethnicities 
in the USA (Wang et al., 2004). Our study supported the findings by Wang et al. (2004). 
While the IL12B gene variants were not associated with HBV vaccine response in allelic and 
genotypic analyses, haplotypes involving the IL4 and IL12B gene variants were significantly 
associated. The TTTC haplotype defined by rs2243250, rs2070874, rs3212227 and rs3213093 
was associated with an increased risk of low-response. This haplotype included the IL4 SNP 
(rs2070874 T) that was also associated with poor HBV vaccine response in genotype analysis. 
Previously, the TTC haplotype of rs2243248, rs2243250 and rs2070874 was associated with 
increased response in an African- and European-American population (Wang et al., 2004). 
While rs2243248 was not associated with HBV vaccine response in this study, the effect of the 
T allele of rs2243250 was contradictory and yet the rs2070874 risk allele was consistent. 
Moreover, the T allele of rs2243250 was associated with chronic HBV infection in Caucasians 
(Zheng et al., 2013), but HBV clearance in a Chinese male population (Lu et al., 2014). The 
contradictory findings regarding rs2243250 may be due to ethnicity of the cohorts. Lu et al. 
(2014) noted that susceptibility to HBV infection was linked to the rs2243250 C allele, but that 
a meta-analysis found the risk allele to be a T at this position in Caucasian populations (Zheng 
et al., 2013). Differences in allele frequencies between populations may explain the observation 
that the same allele may have different effects in different ethnic groups (Lu et al., 2014). 
Indeed, the rs2243250 T allele is the minor allele in our South African Caucasian and Asian 
populations, but the major allele in the South African black (Table 3.16). Thus, a minor, risk 
allele in one population may be the major, non-risk allele in another (Lu et al., 2014). However, 
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the same differences in the allele frequencies between the South African ethnic groups were 
seen for both rs224350 and rs2070874, which showed consistent effects in the studies. 
Alternatively, these results may suggest the rs2070874 variant is more predictive of the 
immune response than the other IL4 SNPs investigated. 
With regards to the IL12B SNPs, rs3212227 TT genotype has been associated with increased 
antibody response against the HBV vaccine but decreased antibody response against the 
measles virus vaccine in European-American populations (Dhiman et al., 2007; Yucesoy et al., 
2009). In this study, the IL12B rs3212227 T allele was only associated with low anti-HBs 
response in haplotype with IL4 SNPs. Possibly, the effect of rs3212227 is influenced by the 
effect of the other SNPs in the haplotype. The IL12B rs3213093 CC genotype has previously 
been associated with decreased antibody response to the measles vaccine in a European-
American population (Dhiman et al., 2007), and here the C allele (in the IL4 linked haplotype) 
was associated with low-response to the HBV vaccine. 
IFNG: the rs2069727 SNP which is located downstream of the IFNG gene, was significantly 
associated with HBV vaccine response in the genotypic and dominant models of inheritance. 
Having at least one C allele at rs2069727 in our cohort was significantly associated with an 
increased anti-HBs response. In line with the results of our study, the C allele of rs2069727 has 
previously been associated with a good anti-HBs response in Gambians, although this was not 
significant in a replication study (Hennig et al., 2008) 
Having at least one T allele at rs2070874, located in the 5ʹ UTR of the IL4 gene, was 
significantly associated with the low-responder phenotype this study. IL4 gene variants have 
previously been associated with both HBV vaccine response and HBV infection outcome, 
although the results are often seemingly contradictory. This risk-associated T allele has been 
observed an American population of various ethnicities (Wang et al., 2004) and negatively 
influences long-term anti-HBs duration (Wang et al., 2012). Furthermore, a small meta-
analysis investigating IL4 polymorphisms with response to HBV vaccination and HBV 
infection outcome found that the T allele of rs2070874 was associated with high response to 
the vaccine in Asian populations but this association was not seen in Caucasian populations 
(Cui et al., 2013).  
While the IL12B gene variants were not associated with HBV vaccine response in allelic and 
genotypic analyses, haplotypes involving the IL4 and IL12B gene variants were significantly 
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associated. The TTTC haplotype defined by rs2243250, rs2070874, rs3212227 and rs3213093 
was associated with an increased risk of low-response.  
Previously, the TTC haplotype of rs2243248, rs2243250 and rs2070874 in an African- and 
European-American population was associated with increased response. While rs2243248 was 
not associated with HBV vaccine response in this study, the effect of the T allele of rs2243250 
was contradictory in the two studies and yet the rs2070874 risk allele was consistent. Moreover, 
the T allele of rs2243250 was associated with chronic HBV infection in Caucasians (Zheng et 
al., 2013), but HBV clearance in a Chinese male population (Lu et al., 2014). The ethnicity of 
the cohorts may play a role in the difference seen in the effect of rs2243250. Lu et al. (2014) 
noted that susceptibility to HBV infection was linked to the rs2243250 C allele, but that a meta-
analysis found the risk allele to be a T at this position in Caucasian populations (Zheng et al., 
2013). This difference in roles of a particular allele in different populations may be due to the 
differences in allele frequencies between populations, based on the genetic disparities between 
ethnicities (Lu et al., 2014). Indeed, the rs2243250 T allele is the minor allele in our South 
African Caucasian and Asian populations, but the major allele in the South African black 
(Table 3.16). Thus, a minor, risk allele in one population may be the major, non-risk allele in 
another (Lu et al., 2014). However, the same differences in the allele frequencies between the 
South African ethnic groups were seen for both rs224350 and rs2070874. Alternatively, these 
results may suggest the rs2070874 variant is more predictive of the immune response than the 
other IL4 SNPs investigated. 
With regards to the IL12B SNPs, rs3212227 TT genotype has been associated with increased 
antibody response against the HBV vaccine but decreased antibody response against the 
measles virus vaccine in European-American populations (Dhiman et al., 2007; Yucesoy et al., 
2009). In this study, the T allele was associated with low anti-HBs response in a haplotype. 
The allele frequencies of rs3212227 do not differ significantly between the South African 
ethnic groups or between the South African ethnicities and the reference populations so ethnic 
differences are unlikely to explain the contradictions. Possibly, the effect of rs3212227 is 
influenced by the effect of the other SNPs in the haplotype. The rs3213093 CC genotype has 
previously been associated with decreased antibody response to the Measles vaccine in a 
European-American population (Dhiman et al., 2007), and here the C allele (in the haplotype) 
is associated with low-response to the HBV vaccine. 
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The rs2069767 variant, downstream of the IFNG gene, was one of the most significant 
associations detected with HBV vaccine response in a Gambian population, although this was 
not significant in a replication study (Hennig et al., 2008). The protective effect of the C allele 
was consistent in both studies.  
In summary, cytokine SNPs associated with HBV vaccine response (on their own or in 
haplotype) that were consistent with previous studies on HBV vaccine response include 
rs1143627, rs2070874, rs2069727. The SNP rs32130186 has not previously been associated 
with HBV vaccine response, but had a consistent effect to response to measles vaccination. 
Several SNPs, including rs1143634, rs1143633, rs2243250 and rs3212227, had contradictory 
effects to those reported in the literature (and often these contradictory effects were noted in 
the literature as well). 
From these results, and noted previously (Hu et al., 2013; Lu et al., 2014, 2010), there are often 
contradictory results where an association may be identified in one study but not in another or 
the same polymorphism is associated with different roles in different studies. These differences 
may arise due to various factors: genetic heterogeneity is apparent in different ethnic 
populations and HBV infection and vaccine response may be described as complex traits; 
therefore, the population being studied may affect the study outcomes due to genetic 
differences that exist (such as allele frequencies) and the numerous factors that will contribute 
to the phenotype. Additionally, population structure may play a role – where LD patterns differ 
and as such, an identified variant may not be the causal variant but is linked to the causal variant 
in some populations but not in others. Furthermore, the study populations’ attributes often 
differ between the studies, such as age, weight, gender proportions, time since 
onset/vaccination and case/control definitions. 
Nonetheless, these results support the significance of genetic variation in interacting cytokine 
genes in vaccine-induced immune responses. It is possible that the effect of an individual SNP 
may be limited, but contributes to the non-responder phenotype along with other variations. 
 
3.5.4 Sample size and statistical power 
An effective sample size is required to achieve an adequate statistical power that can reliably 
detect the causal variants of a phenotype (Hong and Parks, 2012). A sample size that is too 
small to detect a true association increases the rate of false negative results and thus, reduces 
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the reliability of the study (Hong and Parks, 2012). Power is also affected by MAF, case:control 
ratio, the frequency of phenotype of interest, LD, effect size and number of SNPs studied (Hong 
and Parks, 2012). The required sample size decreases with increasing MAF, increasing LD, 
increasing strength of effect size and decreasing number of SNPs studied (Hong and Parks, 
2012). 
The required case sample sizes for the different genetic models, under the assumptions of 5% 
phenotype prevalence, 5% MAF, complete LD, equal cases and controls and a 5% significance 
level, are shown in Table 3.24. For even a dominant genetic model where there is a very strong 
genetic association with the phenotype (that is, heterozygotes have an OR of 2 and 
homozygotes have an OR of 3), the case sample size should be at least 90 to achieve 80% 
power (Table 3.24). Thus, in this study, a sample size of at least 90 non-responders or low-
responders should have been used to detect effects of dominant genotypes of OR>2 at 80% 
power, and should be much greater (in the region of 1000s) to detect effects of recessive 
genotypes of OR>2 at 80% power (Table 3.24). For SNPs with weak genetic association with 
the phenotype (for example, OR~1.3), the power to detect these would require even greater 
sample sizes (Table 3.24). The sample size of this study (n=8 cases) is clearly insufficient to 
achieve sufficient power to detect any effect size with confidence. Therefore, significant results 
in this section should be viewed with caution. 
Table 3.24. Number of cases necessary to achieve 80% power for the different genetic models in 
a case-control study (adapted from Hong and Park, 2012) 
Genetic Model 
ORheterozygotes/ORhomozygotes 
1.3/1.6 1.5/2 2/3 2.5/4 
Allelic 1 974 789 248 134 
Dominant 606 258 90 53 
Co-dominant 2 418 964 301 161 
Recessive 20 294 8 390 2 776 1 536 
Assumptions: 5% phenotype prevalence, 5% MAF, complete LD (Dʹ=1), 1:1 case:control ratio and 5% 
significance level for single marker analyses 
Abbreviations: OR, odds ratios 
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4.1 Introduction 
The complexity of the HLA effects in immune response extends beyond the genetic variation 
to include HLA expression levels. HLA-DPB1*01:01, *02:01, *04:01, *04:02 and *05:01 are 
common alleles in most populations (Sidney et al., 2010) and represent alleles associated with 
both HBV recovery and persistence (Kamatani et al., 2009; Thomas et al., 2012) and with both 
low and high anti-HBs response (Desombere et al., 1998; Martinetti et al., 1995; Mineta et al., 
1996; Wu et al., 2014, 2013). Yet, these alleles share largely overlapping peptide binding 
repertoires (Sidney et al., 2010). This data supports the findings that the mechanism of HBV 
vaccine response is not (or not entirely) due to a defect in antigen binding capabilities 
(Desombere et al., 2005, 1995; Godkin et al., 2005). Thus, Thomas et al., (2012) postulated 
that the effect of HLA-DP on HBV infection outcome may be due to differences in the 
expression levels rather than to differences in peptide presentation.  
HLA expression levels have been shown to affect disease progression of a variety of diseases. 
HLA-C expression levels have been implicated in HIV disease progression (Apps et al., 2013; 
Thomas et al., 2009) and Crohn’s disease (Apps et al., 2013). Increased HLA-C expression 
levels associated with slower progression to Acquired Immunodeficiency Syndrome (AIDS), 
attributed, in part, to an enhanced CTL-mediated response; whereas higher HLA-C levels 
increase the risk of Crohn’s disease (Apps et al., 2013). Both variants upstream of the HLA-C 
gene and in its 3ʹ UTR have been associated with the differential expression levels (Kulkarni 
et al., 2011; Thomas et al., 2009). Additionally, seroconversion to the influenza vaccine has 
been associated with higher HLA-DR expression (Egli et al., 2014). HLA-DPB1 expression 
levels have been associated with HBV infection outcome, with lower expression levels 
associating with HBV clearance (Thomas et al., 2012). The major determinant of the HLA-DP 
expression levels was the rs9277534 variant, located in the HLA-DPB1 3ʹ UTR (Thomas et al., 
2012). Individuals with GG genotype (which was linked to the HLA-DPB1*01:01 allele) had 
higher levels of HLA-DP expression than individuals with AA/AG genotypes. These findings 
are in contrast to another study which found that the rs9277535 G allele associated with both 
lower levels of HLA-DP expression and with HBV persistence (O’Brien et al., 2011). 
Based on the findings of Thomas et al. (2012), our study hypothesis was that individuals with 
HLA-DPB1*04:01 versus 01:01 homozygous genotypes would have low and high HLA-DPB1 
expression levels respectively, which might influence their Th1/Th2 cytokine production. Poor 
responders were also hypothesised to also have high HLA-DPB1 expression levels, similar to 
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the HLA-DPB1*01:01 homozygotes. We also wanted to test how HLA-DPB1 expression levels 
changed after HBsAg stimulation. 
Therefore, we aimed to investigate whether HLA-DPB1 expression levels were associated with 
HBV vaccine response. As both HLA-DPB1 SNPs and alleles have been associated with 
variability in vaccine response we aimed to investigate whether HLA-DPB1 expression levels 
differed between groups defined by both HLA-DPB1 alleles and HLA-DPB1 SNP genotypes; 
and whether HLA-DPB1 expression levels directly affected anti-HBs titre. 
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4.2 Materials and Methods 
4.2.1 Selection of samples for expression analysis 
Twenty-seven participants were selected for analysis of HLA-DPB1 expression analysis based 
on their HBV vaccine response status and on their HLA-DPB1 alleles. We selected all poor 
responders in our cohort (n=8), as well as all participants in our cohort who were 04:01 
homozygous (n=8), or 01:01 homozygous (n=4) for further analysis of HLA-DPB1 expression 
levels, as shown in Table 4.1. We had space on our plates for extra samples and therefore also 
included 04:01 heterozygotes (n=7) in these analyses. 
 
4.2.2 Stimulation of selected samples with HBsAg 
We stimulated cells with whole HBsAg subtype adw (Novus Biologicals, UK). This subtype 
is used in several common vaccines such as Engerix-B (Hernández-Bernal et al., 2011) as well 
as in the vaccine used for the booster vaccinations in this study (Heberbio HBV, The Biovac 
Institute, SA). Moreover, the ‘a’ determinant is common to all types of HBV and anti-HBs 
mainly target this determinant (Kramvis et al., 2005; Michel and Tiollais, 2010); thus we were 
confident of the stimulating capabilities of this HBsAg subtype on PBMCs from HBV 
vaccinated individuals. We used PHA (Sigma, Germany) as a positive stimulation control 
because it is a commonly used mitogen of T lymphocytes, and commonly used in stimulation 
assays (Jafarzadeh and Shokri, 2012, 2003; Jarrosson et al., 2004; Kardar et al., 2002; Velu et 
al., 2008; Wataya et al., 2001). 
 
4.2.3 Thawing of PBMCs  
PBMCs were thawed in a 37°C water bath and then transferred drop-wise to warmed R20 
media (RPMI-1640 with 20% foetal calf serum (FCS)). The cells were pelleted by 
centrifugation at 250 g for 10 minutes at 23°C. The supernatant was discarded and the cells 
resuspended in the remaining media. This wash was repeated once, after which the volume was 
increased to 2 ml using R20 media. Ten microliters of the cell suspension were removed for a 
cell count using Trypan Blue and the TC20 Automated Cell counter. (If necessary, additional 
cells were thawed to ensure sufficient cells were recovered for a consistent count across all 
stimulations). The cells were then incubated overnight at 37°C in a humidified CO2 (5%) 
incubator. The cell count was repeated the following day. 
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Table 4.1. Samples selected for HLA-DPB1 expression assays 
Sample ID Category 
Ab titre 1 
(IU/L; after 3 doses, from 
records) 
Ab titre 2 
(IU/L; cross sectional, 
this study) 
Ab titre 3 
(IU/L; after boost, this 
study) 
HLA-DPB1 
Genotype 
HEP035 Poor responder 107 (2 mo after 3rd dose) 106 NA 01:01/18:01 
HEP057 Poor responder 45 (1 mo after 3rd dose) 0 146 (1 mo after boost) 09:01/09:01 
HEP059 Poor responder 122 (3 mo after 3rd dose) 1 83 (1 mo after boost) 02:01/02:01 
HEP071 Poor responder 17 (1 mo after 3rd dose)  1 >1000 (1 mo after boost) 01:01/04:02 
HEP086 Poor responder 198 (5 mo after 3rd dose) 13 96 (1 mo after boost)  04:02/11:01 
HEP102 Poor responder 196 (1 mo after 3rd dose) 4 468 (1 mo after boost) 01:01/106:01 
HEP111 Poor responder 74 (5 mo after 3rd dose) 12 >1000 (2 mo after boost) 01:01/01:01 
HEP134 Poor responder 198 (2 mo after 3rd dose) 6 151 (1 mo after boost) 02:01/04:02 
HEP011 0401 homozygote, High responder ? >1000 NA 04:01/04:01 
HEP017 0401 homozygote, High responder ? >1000 NA 04:01/04:01 
HEP037 0401 homozygote, High responder >1000 43 NA 04:01/04:01 
HEP065 0401 homozygote, High responder >1000 407 NA 04:01/04:01 
HEP068 0401 homozygote, High responder >1000 90 NA 04:01/04:01 
HEP085 0401 homozygote, High responder ? >1000 NA 04:01/04:01 
HEP091 0401 homozygote, High responder ? >1000 NA 04:01/04:01 
HEP157 0401 homozygote, High responder ? >1000 NA 04:01/04:01 
HEP001 0101 homozygote 742 (2 mo after 3rd dose) 3 >1000 (1 mo after boost) 01:01/01:01 
HEP003 0101 homozygote ? 7 675 (1 mo after boost) 01:01/01:01 
HEP049 0101 homozygote ? 64 NA 01:01/01:01 
HEP108 0101 homozygote 236 (5 mo after 3rd dose) 23 NA 01:01/01:01 
HEP005 0401 heterozygote (High responder) ? >1000 NA 04:01/02:01 
HEP015 0401 heterozygote (High responder) >1000 (2 mo after 3rd dose) >1000 NA 04:01/05:01 
HEP019 0401 heterozygote (High responder) ? >1000 NA 04:01/09:01 
HEP060 0401 heterozygote (High responder) ? >1000 NA 04:01/02:01 
HEP090 0401 heterozygote (High responder) >1000 >1000 NA 04:01/01:01 
HEP092 0401 heterozygote (High responder) ? >1000 NA 04:01/03:01 
HEP096 0401 heterozygote (High responder) ? >1000 NA 04:01/09:01 
? – no records 
Abbreviations: Mo, months; NA, not applicable as participant did not receive a boost 
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4.2.4 In vitro stimulation of PBMCs 
PBMC stimulation in cohort samples was conducted as follows. Two million cell/ml were 
stimulated with 10 µg/ml PHA (as a control), or 5 µg/ml purified HBsAg adw protein in a final 
volume of 0.5 ml and were incubated for 5 days at 37°C in a humidified CO2 (5%) incubator. 
Thereafter, the cell suspensions were centrifuged at 250 g for 10 minutes at 23°C. The cell 
pellets were combined with (350 µl) RLT/β-mercaptoethanol solution and stored at -70°C for 
future RNA extraction. 
 
4.2.5 HLA-DPB1 mRNA expression level analysis 
HLA-DPB1 mRNA was measured under two conditions in selected samples: firstly, at the time 
of sample collection without any specific antigen stimulation, and secondly after cell 
stimulation with HBsAg. Samples used for the first measurement were PBMC stored in RLT/β-
mercaptoethanol solution on the day of blood collection. Samples used for the antigen specific 
measurements were the remaining cells after 5 days of stimulation with HBsAg, stored in 
RLT/β-mercaptoethanol solution. 
 
4.2.5.1 Extraction of RNA 
Total RNA was extracted from the lysate of PBMCs stored in RLT/β-mercaptoethanol solution 
using the QIAamp RNA Blood Mini Kit (Qiagen), a column based method. The lysate was 
thawed at room temperature and transferred to a QIAshredder spin column which was then 
centrifuged at maximum speed (16 100 g) for 2 minutes. One volume of 70% ethanol was 
added to the homogenised lysate in the collection tube and mixed by pipetting. This lysate was 
then transferred to a QIAamp spin column and centrifuged for 15 seconds at 10 200 g. If the 
sample volume exceeded the maximum loading volume of 700 µl, the sample was loaded in 
successive aliquots and the centrifugation step repeated.  After transferring the spin column to 
a new collection tube, 700 µl Buffer RW1 was applied to it and the column centrifuged for 15 
seconds at 10 200 g. Five hundred microliters of Buffer RPE was added to the spin column in 
a new collection tube and centrifuged again at 10 200 g for 15 seconds. After discarding the 
flow-through, an additional 500 µl Buffer RPE was added to the spin column which was then 
centrifuged at 16 200 g for 3 minutes. The spin column was then placed in a new collection 
tube and centrifuged at 16 100 g for 1 minute in order to minimize the possibility of Buffer 
RPE carryover. Finally, the spin column was transferred to a 1.5 ml microcentrifuge tube, 30 
 
 
105 
 
µl RNase-free water (warmed to 95°C) was applied to the column membrane and centrifuged 
at 10 200 g for 1 minute to elute the RNA. 
Five microliters were removed for RNA quality and quantity analysis by NanoDrop 1000 and 
Agilent 2100 Bioanalyzer using the Agilent RNA 6000 Nano kit. The extracted RNA samples 
were stored at -70°C until use. 
 
4.2.5.2 RNA quantity and quality assessment 
The Agilent technique is an automated procedure for assessing RNA quality by calculating an 
RNA integrity number (RIN). RIN values are based on several features that contribute 
information about RNA integrity, not only on the traditional measure of 18S to 28S rRNA ratio 
(Schroeder et al., 2006). RIN values range from 10 (intact RNA) to 1 (totally degraded RNA). 
The technique utilizes microcapillary electrophoresis whereby molecules are separated 
according to size in gel filled capillaries, and detection is by laser-induced fluorescence of an 
intercalating dye. Each chip can analyse 12 samples and requires only 1 µl of sample 
(Schroeder et al., 2006). 
The gel was prepared by filtering the gel matrix through the provided spin filter and then adding 
1 µl of the dye concentrate to a 65 µl aliquot of the filtered gel matrix. The gel-dye mix was 
vortexed thoroughly and then centrifuged for 10 minutes at 13 000 g. The tube was protected 
from light and stored at room temperature until use. The ladder and samples to be analysed 
were heat-denatured for 2 minutes at 70°C and then cooled immediately on ice. 
The chip was then prepared according to the manufacturer’s instructions, adding the gel, ladder, 
marker and samples to specified wells. The chip was vortexed prior to inserting it into the 
Bioanalyzer for analysis. The RIN for good quality RNA to be used in downstream applications 
is debatable. Intact RNA is generally considered for samples with RIN >8, but samples with 
RIN >6 are considered good enough for downstream quantitative PCR (qPCR) (de Cremoux 
et al., 2011; Fleige and Pfaffl, 2006). Furthermore, it has been suggested that the amplification 
of small PCR products (<250 bp) is less dependent on good RNA quality than larger amplicon 
sizes (Fleige and Pfaffl, 2006). 
Additionally, the A260/A280 and A260/A230 quality ratios were determined for each sample 
by NanoDrop. 
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4.2.5.3 cDNA synthesis 
The High Capacity RNA-to-cDNA Kit (Applied Biosystems) was used to synthesize cDNA. 
The reaction mix included 1× RT Buffer (containing dNTPs, random octamers and oligo dT-
16), 1× RT Enzyme mix (MultiScribe™ MuLV reverse transcriptase and an RNase inhibitor) 
and 234 ng RNA template in a final volume of 20 µl. cDNA was synthesized at 37°C for 60 
min, followed by 95°C for 5 minutes and then 4°C for infinity. The samples were stored at -
20°C until use. The cDNA was then evaluated by UV absorbance using the NanoDrop 1000. 
 
4.2.5.4 qPCR 
Relative gene expression level of HLA-DPB1 was determined by qPCR and the Comparative 
quantification cycle (Cq) method, also known as the delta delta Cq (ddCq) method (Livak and 
Schmittgen, 2001). The mRNA levels of HLA-DPB1 were normalized against two reference 
genes, Importin-8 (IPO8) and TATA-binding protein (TBP). The reference genes were selected 
based on previous reports of their stability in PBMCs and stimulated PBMCs (Bibova et al., 
2012; Ledderose et al., 2011; Piehler et al., 2010; Radke et al., 2014; Wang et al., 2014). 
Predesigned TaqMan® Gene Expression Assays (Applied Biosystems) were used. The assay 
IDs for HLA-DPB1, IPO8 and TBP were Hs03045104_m1, Hs00183533_m1 and 
Hs00427621_m1 respectively. These assays rely on three sequence-specific binding events 
involving two primers and a probe which are designed to ensure high target specificity and to 
guarantee amplification at least ten Cq values earlier than the gene with the closest sequence 
homology (Applied Biosystems, 2010).  
To determine whether the efficiencies of the three genes were similar, as well as to determine 
the minimum quantity of cDNA required, a standard curve was constructed for each gene, from 
the average results of three replicate wells, using 150 ng, 15 ng, 1.5 ng, 0.15 ng and 0.015 ng 
cDNA. 
To analyse cohort samples, a qPCR reaction mix of 20 µl was used, consisting of 1× TaqMan® 
Gene Expression Master Mix (Applied Biosystems), 1× TaqMan Gene Expression Assay 
(Applied Biosystems), and 17.6 ng of cDNA. The TaqMan® Gene Expression Master Mix 
contains AmpliTaq Gold® DNA Polymerase, Uracil-DNA glycosylase, dNTPs (with dUTP) 
and ROX™ Passive Reference in an optimised buffer. The TaqMan® Gene Expression Assays 
consist of a PCR primer pair and a hydrolysis probe with FAM™ dye label on the 5ʹ end and 
minor groove binder (MGB) and nonfluorescent quencher (NFQ) on the 3ʹ end. Amplification 
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was achieved using the Applied Biosystems 7500 Real-Time PCR System under the cycling 
conditions listed in Table 4.2. Each gene was quantified on its own (single plex), each sample 
was measured in triplicate wells and a no-template control was included in each run. 
Since the ddCq method requires the efficiencies of the genes to be similar, a validation 
experiment was performed using the data generated by the standard curves. A semi-regression 
line was produced by plotting the delta Cq (dCq) value versus log input amount. If the absolute 
value of the slope is <0.1, the efficiencies of the genes are considered sufficiently similar for 
the ddCq method to be used (Applied Biosystems, 2004; Livak and Schmittgen, 2001). 
 
Table 4.2: Cycling conditions for qPCR 
Step Temperature Incubation Time Number of Cycles 
1* 50°C 2 minutes 1 
2 95°C 10 minutes 1 
3 95°C 15 seconds  
45 60°C 1 minute 
*Required for Uracil-DNA glycosylase (UNG) activity. 
 
The dCq was calculated by subtracting the geometric mean Cq of the reference genes from the 
Cq of the target gene. The samples were grouped based on HLA-DPB1 alleles (Low-
responders, 04:01 homozygotes, 04:01 heterozygotes, 01:01 homozygotes), as well as on 
genotypes of the SNP rs9277534 and the SNPs significantly associated with HBV vaccine 
response in the study. The ddCq value for each group was determined by subtracting the mean 
dCq of an assigned calibrator group from the mean dCq of that group. 
The quality of the qPCR data was controlled by considering the standard deviation (SD) of the 
replicates as well as the Cq values. We removed any outliers of samples with replicates SD 
>0.3, and removed any samples with an average Cq >35 from the analysis. Inter-plate variation 
was controlled for by running the same calibrator sample in each plate and adjusting the Cq 
values accordingly. 
Using SPSS v24.0, ANOVA (or the non-parametric Kruskal-Wallis test) were performed to 
compare expression levels between ≥3 groups:  
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1. HLA-DPB1 genotypes, in particular, low-responders versus HLA-DPB1*04:01 
homozygotes versus *01:01 homozygotes versus *04:01 heterozygotes 
2. Genotypes of the SNP previously associated with HLA-DPB1 expression levels 
(rs9277534) (Thomas et al., 2012), and SNPs in the HLA class II region that were 
significantly associate with HBV vaccine response (rs931, rs7770370) 
The Mann-Whitney U test was performed to analyse differences in expression levels between 
two groups, that is, when genotypes were combined, for example, rs7770370 GG vs AG+AA. 
The expression levels were compared to anti-HBs titre using a Spearman’s rank-order 
correlation in SPSS v24.0. 
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4.3 Results 
4.3.1 RNA quality  
The RNA extracted from the PBMCs stored on the day of blood collection was of good quality: 
the samples (n=27) had an average RIN of 8.7 (range 4.5 - 9.6) and a high average concentration 
of 157 ng/µl (range 26-414 ng/µl). An example of Agilent digital gel image and 
electropherograms is shown in Figure 4.1. The average A260/A280 quality ratio determined 
by NanoDrop was also very good at 1.96 (range 1.3-2.1). The average A260/A230 ratio was 
1.39 (range 0.3-2.3), suggesting that other contaminants, such as ethanol, were present in the 
samples. We used all 27 RNA samples from the collection time-point for cDNA synthesis and 
qPCR. 
Next, we tested the RNA extracted from HBsAg-stimulated PBMC samples after five-day 
stimulation. Due to limited stimulation reagents, only 24 samples were stimulated with HBsAg. 
Agilent quality indicators for the 24 RNA samples extracted from cells remaining from the 
five-day stimulation with HBsAg included an average concentration of 70 ng/µl. The Agilent 
assay could only determine a RIN for seven of the 24 samples tested, and showed, an average 
RIN of 5.2 (for seven samples) which is relatively poor quality. The average A260/A280 ratio 
following RNA extraction was 1.89 (range 1.8-1.9). However, the A260/A230 ratio at this 
stage was less than ideal (lower than 2), with an average of 1.67, suggesting the presence of 
contaminants. Overall, the RNA extracted from these post-stimulation samples was of poor 
quality/degraded, as determined by the Agilent assay. RNA quality in two samples stimulated 
with PHA was also of poor quality as measured by RIN, suggesting that the long stimulation 
period or the culture conditions played a role in RNA degradation. Unfortunately, we therefore 
did not continue with qPCR for samples post-antigen stimulation. Consequently, pre- and post-
stimulation expression levels could not be compared and HBsAg-specific HLA-DPB1 
expression levels could not be compared between low-responders and responders. 
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Figure 4.1. An example of Agilent assay gel images and electropherograms for total RNA 
extracted from six samples. RIN values are shown in brackets below sample number. Samples 1-6 are 
in order of increasingly good quality (RIN values ranging from ‘not any’ – 9.6) 
A) Digital gel images for Ladder and 6 samples.  
B) The corresponding digital electropherograms. The y-axis represents fluorescence units [FU], and the 
x-axis represents runtime [s]. 
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4.3.2. qPCR validation 
The efficiency of the qPCR reactions for each gene was determined from the standard curves 
(Figure 4.2). HLA-DPB1 had a percentage efficiency of 83%, whereas IPO8 and TBP had 
efficiencies of 81% and 82%, respectively. 
The standard curves also showed that 15 ng input cDNA resulted in Cq values of approximately 
25 and 30 for the target and reference genes, respectively. As the sample with the lowest RNA 
concentration would result in a cDNA input of 17.6 ng, it was decided that this would be a 
satisfactory input amount as it would result in Cq values <30 for all genes. 
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Figure 4.2. Standard curves of Cq versus log cDNA input for HLA-DPB1 (A), IPO8 (B) 
and TBP (C). The equation of the line and the R2 and E values for each graph are shown 
alongside the line of best fit. 
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The semi-log regression line of the dCq versus log input amount (Figure 4.3) was drawn to 
check if the efficiencies of the PCR reactions were similar enough to use the Livak method. 
The slope of this line was 0.0693. As this value was <0.1, the efficiencies of the genes were 
similar and therefore, the Comparative Cq method could be used (Applied Biosystems, 2004; 
Livak and Schmittgen, 2001). The E value of 1.82 was therefore used for the ddCq calculations 
below.   
 
 
Figure 4.3. Regression line of dCq (Cqtarget – Cqgeometric mean of references) versus log input 
amount. The key and the formula of the line are shown to the right of the graph. 
 
4.3.3 qPCR assays in cohort samples  
4.3.3.1 cDNA quality 
Using cDNA generated from 27 samples pre-stimulation, HLA-DPB1 Cq values (averaged 
from three replicate wells) ranged from 23.79 to 27.05 and had a mean value of 25.04. Mean 
Cq values for IPO8 and TBP for the same 27 samples were 28.67 (range 27.45 - 29.80) and 
29.15 (range 27.60 - 30.3). The average SD for the three replicate samples was 0.07 for all 
genes and the SD was never more than 0.2. The SD range for HLA-DPB1 was 0.01 to 0.18, for 
IPO8: 0.02 to 0.19, and for TBP: 0 to 0.19. These values suggested that the replicates were 
reliable and the results were of good quality; thus, no replicates were excluded based on the 
above results. 
 
4.3.3.2 HLA-DPB1 relative expression (pre-stimulation), compared to genetic data   
We compared relative HLA-DPB1 expression levels in the 27 samples used for qPCR to: 
1. HLA-DPB1 genotypes, in particular, low-responders versus HLA-DPB1*04:01 
homozygotes versus *01:01 homozygotes versus *04:01 heterozygotes 
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2. Genotypes of the SNP previously associated with HLA-DPB1 expression levels 
(rs9277534) (Thomas et al., 2012), and SNPs in the HLA class II region that were 
significantly associate with HBV vaccine response (rs931, rs7770370) 
With regards to HLA-DPB1 genotype: the 27 samples (pre-stimulation) used in qPCR were 
grouped into low-responders (n=8), HLA-DPB1*04:01 homozygotes (n=8), HLA-DPB1*01:01 
homozygotes (n=4) and HLA-DPB1*04:01 heterozygotes (n=7) (Table 4.1). Initial statistics 
of the qPCR dCq data identified a significant outlier (as assessed by inspection of box-plot of 
dCq values). Closer inspection of this sample showed that it had a RIN of 4.5 and this was 
considered a valid reason to exclude the sample from the analysis. Thus, n=26, with only three 
individuals in the HLA-DPB1*01:01 homozygote group. Following removal of this sample, 
the data were determined to be normally distributed (Shapiro-Wilk test, p>0.05 for all groups), 
there were no further outliers in each group (assessed by inspection of a box-plot) and there 
was homogeneity of variance (Levene’s test, p>0.05), thus an ANOVA was performed to 
compare HLA-DPB1 expression among low-responders (n=8), HLA-DPB1*04:01 
homozygotes (n=8), HLA-DPB1*01:01 homozygotes (n=3) and HLA-DPB1*04:01 
heterozygotes (n=7). Data is presented as mean dCq ± standard deviation, but for graphical 
representation, fold change is used (Figure 4.4). 
 
 
Figure 4.4. Comparison of HLA-DPB1 gene expression levels between 04:01 homozygotes, 
low-responders, 04:01 heterozygotes and 01:01 homozygotes. Fold change (1.82-ddCq) 
relative to 04:01 homozygotes is shown on the y-axis. P=0.277. 
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The HLA-DPB1 gene expression levels increased slightly from the 04:01 homozygotes (-
3.73±0.44) to low-responders (-3.86±0.33) to 04:01 heterozygotes (-4.00±0.20) to 01:01 
homozygotes (-4.12±0.19) in that order (see Figure 4.4). These results confirmed the literature 
description that the HLA-DPB1*04:01 allele is associated with lower expression and the 01:01 
with higher HLA-DPB1 expression (Thomas et al., 2012). However, the differences between 
these groups were not significant (p>0.05); indeed, the fold changes (1.82-ddCq) relative to the 
04:01 homozygote group were <2. The expression level of the poor responders was 
intermediate between 04:01 homozygotes and 01:01 homozygotes but was also not 
significantly different to these groups. Due to the very small sample sizes, significance testing 
may not have been very reliable.   
Next, the HLA-DPB1 expression levels were compared to an HLA class II SNP which has 
previously been associated with HLA-DPB1 expression levels and HBV infection outcome 
(rs9277534, HLA-DPB1 3ʹ UTR) (Thomas et al., 2012), and to HLA class II SNPs which were 
significantly associated with antibody response to HBV vaccine, including rs7770370 in HLA-
DPB1 intron and rs931 in HLA-DPB1 3ʹ UTR (Figure 4.5). 
Since rs9277534 3’UTR GG genotype was associated with HBV infection persistence, and 
with higher HLA-DPB1 expression in the literature (Thomas et al., 2012), we aimed to confirm 
whether this SNP would be associated with HLA-DPB1 expression levels in this cohort. Once 
again, as can be seen in Figure 4.5 (A), although rs9277534 GG had the highest expression (-
4.10±0.16), followed by GA (-3.94±0.28) and then AA (-3.73±0.40), the differences were not 
significant (p=0.09). Additionally, there was no significant difference between the GG (-
4.10±0.16) and the AX (-3.83±0.36) genotypes (p=0.062), as determined by a Mann-Whitney 
U test. These results were expected due to the fact that rs9277534 A allele is in LD with HLA-
DPB1*04:01 and the G allele with HLA-DPB1*01:01 in African- and European-Americans 
(Thomas et al., 2012). 
The HLA-DPB1 intron variant rs7770370 was associated with response to the HBV in this 
cohort (in the genotypic and recessive models). Additionally, having an rs7770370 A allele has 
been associated with good HBV vaccine response (Roh et al., 2016; Wu et al., 2015). Thus, it 
was expected that the A allele would be associated with lower HLA-DPB1 mRNA expression 
levels and therefore the association of this SNP with HLA-DPB1 mRNA expression levels was 
tested. Having an A allele did result in lower expression levels than the GG genotype (Figure 
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4.5 (B)). However, the differences in fold expression among genotypes was not significant 
(Kruskal Wallis H test, p=0.287). 
Figure 4.5. HLA-DPB1 expression levels according to: 
A) rs9277534 genotypes, p=0.090 
B) rs7770370 genotypes, p=0.287 
C) rs931 genotypes, p=0.090 
Fold change (1.82-ddCq) is shown on the y-axis. 
 
rs931 is located in the 3ʹ UTR of HLA-DPB1 and was associated with HBV vaccine response 
at allelic level with the A allele associating with an increased risk of low-response. Therefore, 
the A allele was expected to be associated with higher HLA-DPB1 expression levels. This was 
indeed the case (Figure 4.5 (C)), however the differences were not significant (p=0.09), as 
assessed by ANOVA. 
 
4.3.3.3 HLA-DPB1 relative expression (pre-stimulation), compared to anti-HBs 
In order to assess whether HLA-DPB1 expression directly affected the anti-HBs titre, a 
Spearman’s rank-order correlation was performed, comparing dCq values for the 26 samples 
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to the corresponding anti-HBs titre at time of blood collection. There was no significant 
correlation between HLA-DPB1 expression (pre-stimulation) and anti-HBs titre (p=0.843).
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4.4 Discussion 
We found a similar trend to that noted by Thomas et al. (2012) – higher HLA-DPB1 expression 
levels in low-responders and HLA-DPB1*01:01 homozygotes compared to HLA-DPB1*04:01 
homozygotes, and higher expression levels in individuals with the rs9277534 GG genotype. 
However, these associations did not reach significance at the 5% level. The mRNA expression 
level study by Thomas et al. (2012) was performed in healthy European-American subjects, 
comparing ten AX samples to five GG samples; whereas this study was performed in mixed-
ethnicity group involving twenty AX samples and six GG samples. The ethnicity may have 
influenced the results as level of gene expression has been noted to differ between individuals, 
and particularly, between population groups; although this is often due to differences in allele 
frequencies between the populations (Spielman et al., 2007). Additionally, HBsAg-specific 
expression may be more important to investigate in vaccine response.  
We also found that when comparing expression levels between the genotypes of HLA-DPB1 
SNPs rs7770370 and rs931, the alleles associated with low anti-HBs response were also linked 
to higher HLA-DPB1 expression levels, although not statistically significant.  
We hypothesize that genetic variation of the HLA-DP region may affect HLA-DPB1 
expression, which in turn, may influence the Th1/Th2 cytokine production, thereby affecting 
anti-HBs production. Several studies have associated MHC expression levels with the cytokine 
profile in other phenotypes (Baumgart et al., 1998; Cavalli et al., 2016), or cytokine with MHC 
expression level (de Waal Malefyt et al., 1991). This theory could provide a link between the 
two characteristics commonly associated with HBV vaccine response, namely, HLA allele and 
cytokine profile. 
In summary, these results show a trend of lower HLA-DPB1 expression associating with better 
anti-HBs response (by proxy of other allele association with HBV vaccine response), as has 
been seen with HBV infection outcome (Thomas et al., 2012), although these associations were 
not significant. It is possible that a clearer (and significant) difference would be seen following 
HBsAg-specific stimulation and/or between high-responders and true non-responders to the 
HBV vaccine. 
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CHAPTER 5 
 
Summary and Conclusions
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Characterising the mechanism underlying HBV vaccine response is important in order to 
identify targets for more effective HBV vaccines that will provide protection to all vaccinees. 
In the broader picture, understanding the mechanisms behind HBV vaccine non-response may 
shed light on the pathways of normal immune response to vaccines, and thereby enable us to 
improve the current vaccines and to design novel vaccines against diseases for which no 
vaccine is yet available. 
This research aimed to, firstly, establish a South African cohort in which response to HBV 
vaccination, and immunogenetic mechanisms for this response, could be explored. Secondly, 
we aimed to explore HLA-DP and other HLA class II and cytokine SNP variation in South 
African individuals, and to investigate the association between these genetic variants and anti-
HBs titres. Thirdly, we aimed to explore the relationship between HLA-DPB1 expression levels 
and HBV vaccine response in South Africans.  
Despite not finding any true non-responders in our cohort, we found several significant 
associations when comparing low anti-HBs responders to normal responders. HLA-
DPB1*01:01 and 09:01 alleles were associated with low anti-HBs response, while *04:01 was 
associated with good HBV vaccine response. We identified four SNPs that significantly 
associated with HBV vaccine response in our cohort in multivariate analysis: rs931 (HLA-
DPB1) which has not previously been associated with HBV vaccine response, rs7770370 
(HLA-DPB1), rs2070874 (IL4) and rs2069727 (IFNG). We also identified several significant 
haplotypes involving SNPs in the HLA-DP region and in the cytokine genes IL1B and 
IL4/IL12B. Those that remained significant in multivariate analysis and after correction for 
multiple testing included rs2070874 (IL4) and rs7770370 (HLA-DPB1), and the IL1B 
haplotype rs1143634-rs1143633-rs1143627 ACG. Thus, it can be concluded that HLA class II, 
particularly HLA-DP genetic variation and cytokine genetic variation associates with antibody 
response to the HBV vaccination in South African individuals. 
The HLA-DPB1 expression levels were not significantly associated with HBV vaccine 
response, but a trend of lower HLA-DPB1 expression associating with better anti-HBs response 
was observed. Thus, HLA-DPB1 expression levels may influence immune responses to HBV 
vaccination however these findings need to be confirmed. 
It seems that a complex interplay of genes and pathways is involved in HBV vaccine response, 
and the combination of these factors will determine the overall effect and the immune response. 
Nevertheless, such association studies enable us to better understand the complexity and the 
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diversity of genetic factors that influence the efficacy of the HBV vaccine. These results may 
assist in the identification of specific genetic targets to be used in the development of more 
effective and novel vaccines. 
There are several similarities between the genetic associations observed in HBV infection 
outcome and in HBV vaccine response, including HLA alleles and HLA and cytokine SNPs. 
These findings suggest that similar mechanisms cause persistent HBV infection and HBV 
vaccine non-response. Thus, these two phenotypes can act as models for each other and assist 
in understanding the mechanism underlying both these phenotypes. Typically, one would 
assume that immune response to a viral infection (that is, cellular-mediated) should differ to 
that of a protein antigen, as is found in the HBV vaccine (that is, humoral-mediated). This 
highlights the overlap between pathways of immune response. 
Inconsistencies between this study’s results and previous studies’ results were noted for some 
of the associations, for which there could be several explanations. Firstly, associations may be 
specific to particular populations or ethnic groups. We observed significant differences 
between the different South African ethnic groups, and these ethnic groups were similar to 
similar ancestral reference groups. Differences in associations between populations may be due 
to the population-specific genetic structure, including variations in allele frequencies, different 
LD structures and the consequent fact that different SNPs may be in LD with the causal SNP 
in different ethnic groups. Secondly, differences in other study cohort characteristics, such as 
age, or study definitions, for example, studies may compare non-responders (<10 IU/L) or low-
responders (typically 10-100 IU/L) to responders (>10 IU/L) or to high-responders (>1000 
IU/L), may exist between studies which could affect the associations observed. Thirdly, study 
sample sizes may differ, and small associations may not be detected in small sample sizes. 
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5.1 Limitations 
There were several limitations of this study. Importantly, the sample size is small (n=149) and 
the proportion classified as low-responders is very small (n=8). Such small sample sizes may 
not have sufficient power to detect small differences or effects of a particular factor, which 
could lead to important associations being missed. In addition, with such a small sample size, 
the study was underpowered which consequently reduced the reliability of the results. Another 
limitation that may have masked important associations is the classification we used due to the 
lack of true non-responders in our cohort. This resulted in us comparing low-responders 
(though responders nonetheless) to normal-responders, and thus associations with HBV 
vaccine response that may be detected when comparing more distinct groups such as non-
responders to responders, or even high-responders, may have been missed. Additionally, the 
cohort was of mixed ethnicities and differences in allele frequencies and LD patterns between 
ethnic groups may have masked associations that are population-specific. Furthermore, the 
presence of population stratification is indicated by the observed differences in allele 
frequencies between the South African populations. The cohort largely consisted of discrete 
populations which are remotely related, yet, unfortunately, the sample size was too small to 
analyse ethnicities separately in order to identify population-specific associations. Methods are 
available to correct for population stratification, however, these generally involve the typing of 
numerous SNPs which are unrelated to the SNPs under investigation (Mingyao et al., 2010). 
These methods are more suited to GWAS or large gene association studies, and were not 
possible to utilise in this study. Including ethnicity as a covariate in the analyses could have at 
least accounted for some of the population stratification. 
With regards to the HLA-DPB1 allele associations: the HLA-DP genotyping technique reported 
many alleles in G groups. If the association with HBV vaccine response is not based on antigen 
binding capabilities, this may have masked some associations. This could have also affected 
the differences in HLA-DPB1 expression levels since the hypothesis was based on HLA-
DPB1*04:01 alleles, whereas we used *04:01:01G group alleles in the comparison. We also 
did not use antigen-specific stimulated samples for the expression work. It is possible that 
stimulation would have resulted in increased expression of the HLA-DPB1 gene, at which point 
differences between the low-responders and responders may have been significant. 
Additionally, we only measured expression level in a portion of the cohort. A larger sample 
size may have allowed for the detection of small differences.  
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Furthermore, several limitations arose from the cross-sectional study design, including 
differences in vaccine type used, vaccination site and schedule and time since vaccination. 
These differences were exacerbated by the lack of vaccination history and antibody titre records 
which consequently made it difficult to account for them in analysis. Additionally, the 
participant historical data were obtained by way of self-reported questionnaires which is 
subject to recall bias. There was also a fair amount of missing data due to inability to recall 
certain facts. Both of these may have distorted the data. A prospective or retrospective study 
design, with full vaccination history and antibody titre would have provided a more complete 
and homogenous sample from which more clear outcomes could have been concluded. 
Another limitation of the study is that the demographics of the cohort is not a true representation 
of the general South African population. According to Statistics South Africa’s mid-year 
population estimates report (2016), the South African population is majority black African 
(80.7%), followed by Coloured and Caucasian (8.8% and 8.1%, respectively) and lastly by 
Indian/Asian (2.5%). Whereas, in our cohort, Caucasian was the majority ethnicity (50.3%) 
followed by black African (32.9%), Asian (14.8%) and Coloured (2.0%). Additionally, 
approximately 51% of the South African population is estimated to be female (Statistics South 
Africa, 2016), but our cohort was 79.2% female. Lastly, 30.1% of the South population is 
estimated to be younger than 15 years and 8.0% is 60 years or older (Statistics South Africa, 
2016), whereas the age of our cohort ranged from 21 to 74 years. Thus, results obtained from 
this study may not apply to the general South African population. 
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5.2 Strengths 
This research has gone some way to addressing the paucity of HLA-DP and cytokine SNP data 
in SA. To the best of our knowledge, this is the first study to investigate the genetics of HBV 
vaccine response in SA. 
HLA-DP is less often studied compared to the other classical HLA loci, so this data contributes 
to a somewhat lacking area. 
The low-responders were confirmed with booster vaccination and re-testing of antibody titres 
thereafter, and we did not only rely on anti-HBs, HBsAg testing was performed to confirm that 
these individuals were not currently infected with HBV. Results of these tests were shared to 
the participants. 
The cohort was established by myself, with the help of many people who are acknowledged in 
the Acknowledgements section. This included recruitment, sample processing and storage, 
assay optimization (including for PBMC isolation, DNA extraction, HLA-DP allele 
genotyping, RNA extraction, cDNA synthesis and qPCR), data analysis and feedback to 
participants regarding their results. 
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5.3 Future Work 
Future work in this area of research could include establishing a larger cohort in order for the 
study to have adequate power. The inclusion of true non-responders could also assist in 
identifying important factors in the HBV vaccine-induced immune response. Expanding the 
number genes investigated would be beneficial in attempting to understand the genetics 
underlying HBV vaccine response. In particular, including the HLA-DQ and -DR alleles in the 
analysis could provide essential information on the role of haplotypes of the HLA class II genes 
in HBV vaccine response. Furthermore, it is possible that multiple variants could contribute 
small effects which influence the antibody response to the HBV vaccine in a cumulative 
manner. The only way to test this would be to perform GWAS. As noted in the introduction, 
GWAS related to Hepatitis B vaccination outcomes have been performed in Asian populations 
(Png et al., 2011; Pan et al., 2014; Wu et al., 2015), and identified SNPs in the HLA class II 
region as important. GWAS of HBV vaccine response have not yet been performed in a South 
African population.  The recent introduction of an African-specific genotyping array (Mulder 
et al., 2016) would make such a study more relevant. Another important aspect would be to use 
HBsAg-stimulated samples in the expression level experiments, and to perform these 
experiments in a larger sample. It would also be of interest to quantify cytokine levels in non- 
and/or low-responders versus responders in order to assess the T cell-mediated responses 
involved in HBV vaccine response. Additionally, determining the association between 
cytokine SNP genotypes and their corresponding cytokine levels would provide information 
on the functional importance of cytokine gene variation. Cytokine quantification could assist 
in determining whether HLA-DP antigen density contributes to the fate of the Th cell, and the 
subsequent cytokines produced.  
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APPENDIX B 
Participant Questionnaire 
 
Participant questionnaire.  
Please fill in, and circle the correct answer where required.  Please hand this completed 
questionnaire to the nurse upon blood draw and enrolment into the study.  
 
Date of questionnaire completion by participant: _______________(YYYY/MMM/DD) 
 
Participant details: 
Name: ________________________________ 
Date of birth:  _____/____/____ (YYYY/MMM/DD) 
Gender ______ 
Ethnicity: ____________ 
Weight (kg): ______ 
Study number: ______________________ (to be filled in by investigator) 
 
Infection history  
Have you ever been infected with hepatitis?   yes / no / don’t know 
If yes, when?  _________________ / current / don’t know  
If yes, what type of hepatitis?  A / B / C / D / E / don’t know  
If yes, do you know if you are still a chronic carrier?   yes / no / don’t know  
Are you currently taking medication for hepatitis infection? ___________________ 
 
Vaccination history  
Have you been previously vaccinated for Hep B?  yes / no / don’t know 
Dates previously vaccinated? _____________________ 
Place previously vaccinated? ____________________ 
Number of doses received?  1 / 2 / 3 / more than 3 /   don’t remember 
Can you provide any proof of vaccination e.g. immunisation card if necessary?  yes / no  
Do you know if you are a responder / non-responder to HBV vaccination?   Yes / no  
If known non-responder: please explain how you came to know this? e.g.  Who diagnosed this 
__________________________________________________________________ 
If known non-responder: please explain how this was managed?  e.g. further booster.  
__________________________________________________________________ 
__________________________________________________________________ 
Do you know if you are a responder / non-responder to other vaccines?  yes / no / don’t know. If yes, 
to which other vaccines are you a non-responder?  
__________________________________________________________________ 
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Participant name: ____________________ 
Study number: __________________ (to be filled in by investigator) 
 
Factors affecting immune responses  
Do you smoke currently? Yes / no.  If yes, number of cigarettes per day: __________ 
Did you smoke at during the period of vaccination:  yes / no 
If yes, number of cigarettes per day at that time: __________ 
Any previous or current malignancy?    Yes / no 
If yes: further details (type and date) ______________________________ 
If yes: being treated?  yes / no / type of treatment: _____________________________ 
____________________________________________________________________ 
Do you have any primary immunodeficiency? yes / no / don’t know 
If yes, type? ___________________________________________ 
If yes: are you currently taking medication for this disease? Yes / no / details: 
___________________________________________ 
 
Do you suffer any auto-immune diseases? yes / no / don’t know  
If yes, what type?  Eczema / asthma / inflammatory bowel disease / arthritis / celiac disease / other: 
________________________________ 
If yes: are you currently taking medication for this disease? Yes / no / details: 
___________________________________________ 
 
Current infections / illness?  _________________________________________ 
Do you have any liver disease?  _________________________________ 
Current medication _________________________________________ 
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APPENDIX C 
SNPs (of the 31 Selected SNPs) Captured by TagSNPs 
 
Chromosome  TagSNP Captured SNPs 
6  rs2395309 rs3077, rs2301220 
6  rs3130186 rs9277535, rs3117229 
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APPENDIX D 
LD Maps Generated by Haploview, r2 values 
 
 
Chromosome 2 Chromosome 5 Chromosome 16 
Chromosome 6 
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APPENDIX E 
SNP Hardy-Weinberg Equilibrium P-Values 
 
SNP ID 
Total cohort African Caucasian Asian Coloured 
HWE 
(Unaff) 
HWE 
(All) 
HWE 
(Unaff) 
HWE 
(All) 
HWE 
(Unaff) 
HWE 
(All) 
HWE 
(Unaff) 
HWE 
(All) 
HWE 
(Unaff) 
HWE 
(All) 
rs1800896 1.00 1.00 0.75 0.75 1.00 1.00 1.00 1.00 1.00 1.00 
rs1143634 0.37 0.41 1.00 1.00 0.50 0.75 1.00 1.00 1.00 1.00 
rs1143633 0.13 0.06 1.00 1.00 0.31 0.20 0.54 0.27 1.00 1.00 
rs1143627 0.04 0.02 1.00 1.00 0.80 0.81 0.07 0.07 1.00 1.00 
rs2069763 0.47 0.64 0.06 0.10 0.78 0.60 0.66 0.66 1.00 1.00 
rs2243248 0.17 0.12 1.00 0.77 0.56 0.22 1.00 1.00 1.00 1.00 
rs2243250 0.01 0.02 0.52 0.74 0.66 1.00 0.58 0.62 1.00 1.00 
rs2070874 0.003 0.01 0.16 0.17 0.66 1.00 0.58 0.62 1.00 1.00 
rs3212227 0.38 0.39 0.71 0.71 0.20 0.20 0.66 1.00 1.00 1.00 
rs3213093 0.28 0.29 0.47 0.49 0.20 0.20 0.66 1.00 1.00 1.00 
rs3135363 0.81 1.00 0.54 0.53 0.28 0.43 1.00 1.00 1.00 1.00 
rs7453920 0.15 0.23 1.00 1.00 0.05 0.09 1.00 1.00 1.00 1.00 
rs2395309 0.13 0.10 0.57 0.58 0.73 0.74 1.00 0.65 1.00 1.00 
rs2071349 1.00 0.71 0.48 0.46 1.00 0.60 1.00 1.00 1.00 1.00 
rs7770370 0.87 0.74 0.75 1.00 0.05 0.19 0.66 1.00 0.33 0.20 
rs931 0.09 0.07 0.16 0.16 0.75 1.00 1.00 0.62 1.00 1.00 
rs9277534 0.15 0.16 0.26 0.27 1.00 1.00 1.00 0.62 1.00 1.00 
rs9277535 0.62 0.64 0.42 0.42 1.00 1.00 1.00 0.57 1.00 1.00 
rs3130186 0.62 0.64 0.42 0.42 1.00 1.00 1.00 0.57 1.00 1.00 
rs2064479 0.70 0.46 0.57 0.58 1.00 1.00 1.00 1.00 1.00 1.00 
rs2069727 0.57 0.26 0.23 0.21 0.63 1.00 0.62 0.62 1.00 1.00 
rs1805015 0.82 0.51 1.00 1.00 0.68 1.00 1.00 1.00 1.00 1.00 
rs2230433 0.17 0.32 0.56 0.57 0.42 0.60 0.33 0.62 1.00 1.00 
rs8099917 0.28 0.28 1.00 1.00 0.73 0.49 1.00 1.00 1.00 1.00 
Unaff – Responders 
All – Responders and low-responders 
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APPENDIX F 
SNP Genotype Frequencies 
 
SNP Genotype 
Frequency (%) 
Total cohort SA black SA Caucasian SA Asian 
rs1800896 
CC 16.1 8.2 24.0 4.5 
CT 47.7 46.9 50.7 36.4 
TT 36.2 44.9 25.3 59.1 
rs1143634 
AA 2.0 0.0 4.0 0.0 
AG 32.2 24.5 36.0 31.8 
GG 65.8 75.5 60.0 68.2 
rs1143633 
TT 10.1 2.0 16.0 9.1 
TC 32.9 26.5 38.7 27.3 
CC 57.0 71.4 45.3 63.6 
rs1143627 
AA 28.2 8.2 13.3 27.3 
AG 40.3 38.8 45.3 27.3 
GG 31.5 53.1 41.3 45.5 
rs2069763 
AA 6.0 2.0 6.7 13.6 
AC 33.6 4.1 46.7 59.1 
CC 60.4 93.9 46.7 27.3 
rs2243248 
GG 6.0 14.3 2.7 0.0 
GT 27.5 51.0 17.3 9.1 
TT 66.4 34.7 80.0 90.9 
rs2243250 
TT 17.4 8.2 2.7 9.1 
TC 36.9 49.0 28.0 36.4 
CC 45.6 42.9 69.3 54.5 
rs2070874 
TT 14.8 24.5 2.7 9.1 
TC 34.2 40.8 28.0 36.4 
CC 51.0 34.7 69.3 54.5 
rs3212227 
GG 8.1 8.2 8.0 9.1 
GT 34.9 34.7 30.7 50.0 
TT 57.0 57.1 61.3 40.9 
rs3213093 
TT 8.7 10.2 8.0 9.1 
TC 34.9 34.7 30.7 50.0 
CC 56.4 55.1 61.3 40.9 
rs3135363 
CC 4.7 2.0 8.0 0.0 
CT 34.2 20.4 48.0 18.2 
TT 61.1 77.6 44.0 81.8 
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rs7453920 
AA 6.0 2.0 9.3 4.5 
AG 45.6 30.6 57.3 40.9 
GG 48.3 67.3 33.3 54.5 
rs2395309 
GG 15.4 26.5 5.3 18.2 
GA 38.9 46.9 33.3 40.9 
AA 45.6 26.5 61.3 40.9 
rs2071349 
GG 2.0 2.0 2.7 0.0 
GC 21.5 18.4 21.3 31.8 
CC 76.5 79.6 76.0 68.2 
rs7770370 
GG 21.5 8.2 6.7 9.1 
GA 48.3 44.9 52.0 50.0 
AA 30.2 46.9 41.3 40.9 
rs931 
AA 16.1 28.6 6.7 13.6 
AG 38.9 40.8 37.3 36.4 
GG 45.0 30.6 56.0 50.0 
rs9277534 
GG 16.8 24.5 6.7 13.6 
GA 40.9 42.9 40.0 36.4 
AA 42.3 32.7 53.3 50.0 
rs9277535 
GG 4.0 2.0 4.0 9.1 
GA 36.2 40.8 34.7 31.8 
AA 59.7 57.1 61.3 59.1 
rs3130186 
TT 4.0 2.0 4.0 9.1 
TC 36.2 40.8 34.7 31.8 
CC 59.7 57.1 61.3 59.1 
rs2064479 
TT 12.1 22.4 5.3 9.1 
TC 41.6 46.9 37.3 40.9 
CC 46.3 30.6 57.3 50.0 
rs2069727 
CC 12.1 8.2 14.7 13.6 
CT 39.6 28.6 48.0 36.4 
TT 48.3 63.3 37.3 50.0 
rs1805015 
CC 6.7 14.3 2.7 0.0 
CT 34.9 49.0 32.0 13.6 
TT 58.4 36.7 65.3 86.4 
rs2230433 
CC 20.1 20.4 12.0 13.6 
CG 45.0 57.1 40.0 36.4 
GG 34.9 22.4 48.0 50.0 
rs8099917 
GG 2.7 0.0 5.3 0.0 
GT 20.8 8.2 29.3 18.2 
TT 76.5 91.8 65.3 81.8 
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APPENDIX G 
Chromosome 6 SNP and HLA-DP Haplotype Frequencies 
 
Haplotype Frequency (%) 
rs
3
1
3
5
3
6
3
 
rs
7
4
5
3
9
2
0
 
rs
2
3
9
5
3
0
9
 
rs
2
0
7
1
3
4
9
 
rs
7
7
7
0
3
7
0
 
rs
9
3
1
 
rs
9
2
7
7
5
3
4
 
rs
9
2
7
7
5
3
5
 
rs
3
1
3
0
1
8
6
 
rs
2
0
6
4
4
7
9
 
H
L
A
-D
P
A
1
 
H
L
A
-D
P
B
1
 
Total 
cohort 
SA 
black 
SA 
Caucasian 
SA 
Indian 
T G A C A G A A C C 01:03 04:01 10.7 0.0 10.7 36.1 
T A A C A G A A C C 01:03 04:01 7.7 0.0 15.3 0.0 
T G G C G A G A C T 02:other 01:01 6.0 15.2 0.0 0.0 
T G A C A A G G T T 01:03 03:01 4.0 6.1 3.3 2.8 
T G G C G A G A C T 02:01 01:01 3.7 5.1 2.0 2.8 
C G A C A G A A C C 01:03 04:01 3.0 0.0 6.0 0.0 
T G A G A G A A C C 01:03 02:01 2.7 3.0 6.7 5.6 
C A A C A G A A C C 01:03 04:01 2.7 0.0 1.3 0.0 
C A A C G G A A C C 01:03 04:01 2.7 0.0 4.7 5.6 
T A A G A G A A C C 01:03 02:01 2.3 4.0 0.0 0.0 
T G A C A G A A C C 01:03 04:02 2.3 0.0 4.7 0.0 
T G A C G G A A C C 03:01 105:01 2.3 7.1 0.0 0.0 
T G A G G G A A C C 01:03 02:01 2.3 0.0 0.0 8.3 
C A A G A G A A C C 01:03 02:01 2.0 1.0 1.3 0.0 
T G G C A A G G T T 02:01 09:01 1.7 0.0 0.0 8.3 
T G G C G A G G T T 02:other 05:01 1.7 0.0 2.7 0.0 
T G A C A G A A C C 03:01 105:01 1.7 5.1 0.7 0.0 
C G A C A G A A C C 03:01 105:01 1.7 4.0 0.0 0.0 
C A A C G G A A C C 01:03 04:02 1.7 0.0 4.0 0.0 
T G G C A A G G T T 02:01 10:01 1.7 0.0 2.7 0.0 
T G A C G A G G T C 01:03 18:01 1.3 5.1 0.0 0.0 
C G A G A G A A C C 01:03 02:01 1.3 0.0 2.7 0.0 
T G A C A G A A C C 01:03 02:01 1.0 0.0 1.3 0.0 
T A A C G G A A C C 01:03 04:02 1.0 0.0 2.7 0.0 
C A G C G A G A C T 02:01 01:01 1.0 0.0 2.7 0.0 
T G G C G A G G T T 02:01 11:01 1.0 2.0 0.0 0.0 
T G G C G G G G T C 02:01 11:01 1.0 0.0 1.3 0.0 
T G G C A G A A C C 02:other 04:01 0.7 0.0 0.0 5.6 
T G G C A A G G T T 02:01 14:01 0.7 1.0 0.7 0.0 
T A A C G G A A C C 01:03 04:01 0.7 1.0 2.7 2.8 
C G G C G A G A C T 02:other 01:01 0.7 2.0 0.0 0.0 
T G G C G G A A C C 02:01 105:01 0.7 2.0 0.0 0.0 
T G G C G A G G T C 02:01 13:01 0.7 2.0 0.0 0.0 
C G G C G A G G T C 02:01 13:01 0.7 0.0 0.0 0.0 
T G G C G A G G T T 02:01 05:01 0.7 0.0 0.0 0.0 
T G G C G G A A C C 02:01 17:01 0.7 0.0 0.0 0.0 
T G G C G A G G T C 02:01 11:01 0.7 0.0 1.3 0.0 
T A A C G A G G T T 01:03 06:01 0.7 0.0 1.3 0.0 
T G G C G A G G T C 02:other 18:01 0.7 0.0 0.0 0.0 
T G A C A G A A C C 01:03 105:01 0.7 0.0 0.0 0.0 
T A G C G A G A C T 02:01 01:01 0.7 3.0 0.0 0.0 
T G G C G A G A C T 02:01 26:01 0.3 0.0 0.0 5.6 
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T A G C G A G A C T 02:other 01:01 0.3 1.0 0.0 0.0 
T G A C A G A A C T 03:01 105:01 0.3 0.0 0.0 2.8 
C A A C A G A A C C 01:03 105:01 0.3 1.0 0.0 0.0 
T G G C G G A A C T 02:other 34:01 0.3 1.0 0.0 0.0 
T G A G A A G G T T 01:03 16:01 0.3 0.0 0.7 0.0 
T G G C G A G A C T 02:other 17:01 0.3 1.0 0.0 0.0 
T G A C G G A A C C 01:03 105:01 0.3 1.0 0.0 0.0 
T G G C G G A A C C 02:01 13:01 0.3 1.0 0.0 0.0 
T G G C G G A A C T 02:01 19:01 0.3 1.0 0.0 0.0 
T G G C G G A A C C 02:01 04:01 0.3 0.0 0.0 0.0 
T G A G G G A A C C 01:03 04:02 0.3 0.0 0.0 0.0 
C G A C G A G A C T 01:03 26:01 0.3 0.0 0.0 0.0 
T G G C G G A A C C 02:other 105:01 0.3 0.0 0.0 0.0 
T A A C G A G G T T 01:04 15:01 0.3 0.0 0.0 0.0 
T G G C A G A A C T 02:01 02:01 0.3 0.0 0.0 0.0 
T G A G A A G G T T 01:03 02:01 0.3 0.0 0.7 0.0 
C A A C A A G G T T 01:03 03:01 0.3 0.0 0.7 0.0 
C A G C G A G A C T 02:01 26:01 0.3 0.0 0.0 0.0 
T G G C G A G G T C 02:other 13:01 0.3 0.0 0.0 0.0 
T G G C G G A A C C 04:01 17:01 0.3 0.0 0.0 0.0 
T A G C G A G G T T 02:other 05:01 0.3 0.0 0.0 0.0 
T G G C A A G G T T 02:01 03:01 0.3 0.0 1.3 0.0 
C G G C G A G G T T 02:other 05:01 0.3 0.0 0.7 0.0 
T A G C G A G G T T 02:other 13:01 0.3 0.0 0.0 0.0 
T G A C A G G A C C 01:03 04:01 0.3 0.0 0.0 0.0 
T G G C A G A A C C 02:01 02:01 0.3 0.0 0.7 0.0 
T G G C G G A A C T 02:other 106:01 0.3 0.0 0.0 0.0 
C A A G G G A A C C 01:03 02:01 0.3 1.0 0.0 0.0 
T G G C G G A A C C 02:other 106:01 0.3 1.0 0.0 0.0 
T G G C G G A A C C 02:other 04:01 0.3 0.0 0.0 0.0 
T A A C A G A A C C 01:03 04:02 0.3 0.0 0.0 0.0 
T A A C A G A A C C 01:03 03:01 0.3 0.0 0.0 0.0 
T G G C G A G G T T 02:other 02:02 0.3 0.0 0.0 0.0 
C A A C A G A A C C 01:03 03:01 0.3 0.0 0.0 0.0 
T G G C G A G G T T 02:01 17:01 0.3 0.0 0.0 0.0 
T A A G G G A A C C 01:03 02:01 0.3 1.0 0.0 0.0 
C G A C A A G G T T 01:03 03:01 0.3 0.0 0.7 0.0 
C A G C G A G A C T 02:01 131 0.3 0.0 0.0 0.0 
T G A C G A G A C C 01:03 13:01 0.3 0.0 0.0 0.0 
T A A C G A G G T T 01:03 131 0.3 0.0 0.0 0.0 
T G G C A G A A C C 02:other 105:01 0.3 3.0 0.0 0.0 
T G A C G G A A C C 01:03 04:02 0.3 0.0 0.0 0.0 
C A A C A G A A C C 01:03 04:02 0.3 0.0 0.0 0.0 
T G G C G G A A C C 02:01 02:01 0.3 0.0 0.0 0.0 
C G A C A G A A C C 01:03 04:02 0.3 0.0 0.0 0.0 
T G A C A A G G T T 01:03 20:01 0.3 0.0 0.7 0.0 
T G A G G G A A C T 03:01 58:01 0.3 1.0 0.0 0.0 
T G G C G G A A C C 04:01 105:01 0.3 1.0 0.0 0.0 
C A A C G G A A C C 03:01 105:01 0.3 0.0 0.0 0.0 
T A G C G A G A C T 02:other ? 0.3 1.0 0.0 0.0 
T G G C G G A A C C 02:01 ? 0.3 1.0 0.0 0.0 
C G A C G G A A C C 03:01 105:01 0.3 0.0 0.0 0.0 
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T G G C G G G G T C 02:01 13:01 0.3 1.0 0.0 0.0 
T G A C G A G G T T 01:04 15:01 0.0 1.0 0.0 0.0 
T A G C G A G A C T 02:01 131 0.0 1.0 0.0 0.0 
C G A C G A G G T C 01:03 18:01 0.0 1.0 0.0 0.0 
T G A C G A G G T C 01:03 13:01 0.0 1.0 0.0 0.0 
T A A C G A G A C T 01:03 131 0.0 1.0 0.0 0.0 
C A A C A G A A C C 03:01 105:01 0.0 1.0 0.0 0.0 
C G G C G G G G T C 02:01 11:01 0.0 1.0 0.0 0.0 
T G A C G G A A C C 01:03 04:01 0.0 2.0 0.0 0.0 
T G A C A G G G T C 01:03 04:01 0.0 1.0 0.0 0.0 
T G G C G A G A C T 02:01 11:01 0.0 2.0 0.0 0.0 
T G G C G G A A C T 02:01 106:01 0.0 1.0 0.0 0.0 
T A G C A A G G T T 02:01 09:01 0.0 0.0 0.0 2.8 
C A G C G A G G T C 02:01 13:01 0.0 0.0 0.0 2.8 
C A G C G A G G T C 02:other 13:01 0.0 0.0 0.0 2.8 
T A G C A A G G T T 02:other 13:01 0.0 0.0 0.0 2.8 
T G G C A G A A C C 02:01 17:01 0.0 0.0 0.0 2.8 
T A A C A G A A C C 03:01 105:01 0.0 0.0 0.7 0.0 
T G G C A A G G T T 02:other 10:01 0.0 0.0 0.7 0.0 
C G G C G G A A C C 02:01 04:01 0.0 0.0 0.7 0.0 
C G A C G G A A C C 01:03 04:02 0.0 0.0 2.0 0.0 
T G A G G A G A C T 01:03 26:01 0.0 0.0 0.7 0.0 
C G A C A G A A C C 01:03 02:01 0.0 0.0 0.7 0.0 
C G G C A G A A C T 02:01 02:01 0.0 0.0 0.7 0.0 
T G G C G A G G T C 04:01 13:01 0.0 0.0 0.7 0.0 
C G G C G G A A C C 02:01 17:01 0.0 0.0 1.3 0.0 
T G G C A A G G T T 02:01 05:01 0.0 0.0 1.3 0.0 
C G G C A G A A C C 02:01 02:01 0.0 0.0 0.7 0.0 
C A A C G G A A C C 01:03 17:01 0.0 0.0 0.7 0.0 
C G A G G G A A C C 01:03 02:01 0.0 0.0 0.7 0.0 
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APPENDIX H 
Complete Results Set (SNP Data) 
 
Univariate single SNP analysis 
SNP 
Minor 
Allele 
ALLELIC MODEL 
GENOTYPIC 
MODEL 
DOMINANT 
MODEL 
RECESSIVE 
MODEL 
PEMP1 PEMP2 OR PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 
rs1800896 C 0.450 1.000 1.54 0.602 1.000 0.673 1.000 0.626 1.000 
rs1143634 A 0.038 0.560 2.93 0.048 0.599 0.117 0.762 0.164 0.809 
rs1143633 T 0.602 1.000 0.63 0.447 1.000 0.471 1.000 0.580 1.000 
rs1143627 A 0.495 1.000 0.63 0.574 1.000 0.257 0.965 1.000 1.000 
rs2069763 A 0.755 1.000 1.14 0.680 1.000 0.720 1.000 1.000 1.000 
rs2243248 G 0.376 1.000 1.92 0.259 0.995 0.455 0.999 0.414 1.000 
rs2243250 T 0.167 0.830 2.41 0.120 0.874 0.069 0.614 0.632 1.000 
rs2070874 T 0.211 0.937 2.24 0.044 0.512 0.028 0.329 1.000 1.000 
rs3212227 G 0.371 1.000 0.40 0.852 1.000 0.480 1.000 1.000 1.000 
rs3213093 T 0.251 0.995 0.39 0.762 1.000 0.479 1.000 1.000 1.000 
rs3135363 C 1.000 1.000 0.82 0.192 0.972 0.484 1.000 0.312 0.974 
rs7453920 A 1.000 1.000 0.81 0.292 0.998 0.507 1.000 0.413 1.000 
rs2395309 G 0.116 0.802 2.53 0.178 0.933 0.279 0.997 0.110 0.620 
rs2071349 G 0.435 1.000 1.63 0.201 0.980 1.000 1.000 0.161 0.809 
rs7770370 G 0.065 0.694 2.76 0.010 0.199 1.000 1.000 0.012 0.117 
rs931 A 0.048 0.360 3.23 0.067 0.723 0.082 0.621 0.135 0.682 
rs9277534 G 0.086 0.624 2.99 0.065 0.739 0.159 0.801 0.142 0.724 
rs9277535 G 0.360 1.000 1.65 0.399 1.000 0.736 1.000 0.289 0.961 
rs3130186 T 0.360 1.000 1.65 0.399 1.000 0.736 1.000 0.289 0.961 
rs2064479 T 0.062 0.600 2.79 0.075 0.800 0.275 0.996 0.063 0.379 
rs2069727 C 0.116 0.821 0.29 0.029 0.421 0.019 0.320 1.000 1.000 
rs1805015 C 0.776 1.000 0.71 0.240 0.978 0.486 1.000 0.444 1.000 
rs2230433 C 0.822 1.000 0.80 0.165 0.967 0.711 1.000 0.376 0.996 
rs8099917 G 0.709 1.000 0.43 1.000 1.000 0.687 1.000 1.000 1.000 
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Haplotype analysis - chromosome 2 
Haplotype Frequency 
Univariate 
PEMP1 PEMP2 OR 
rs
1
1
4
3
6
3
4
 
(I
L
1
B
) 
rs
1
1
4
3
6
3
3
 
(I
L
1
B
) 
rs
1
1
4
3
6
2
7
 
(I
L
1
B
) 
    
G T  0.265 0.559 1.000 0.66 
G T A 0.234 0.364 0.998 0.49 
G T G 0.026 0.224 0.999 2.33 
A C  0.181 0.039 0.457 3.48 
A C A 0.131 0.526 1.000 1.52 
A C G 0.046 0.009 0.071 10.50 
G C  0.554 0.421 0.999 0.65 
G C A 0.118 0.455 1.000 0.46 
G C G 0.440 0.574 1.000 0.74 
 T A 0.233 0.378 0.998 0.50 
 C A 0.250 0.985 1.000 1.00 
 T G 0.032 0.286 1.000 1.98 
 C G 0.485 0.513 1.000 1.33 
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Haplotype analysis - chromosome 5 
Haplotype Frequency 
Univariate 
PEMP1 PEMP2 OR 
rs
2
2
4
3
2
4
8
 
(I
L
4
) 
rs
2
2
4
3
2
5
0
 
(I
L
4
) 
rs
2
0
7
0
8
7
4
 
(I
L
4
) 
rs
3
2
1
2
2
2
7
 
(I
L
1
2
B
) 
rs
3
2
1
3
0
9
3
 
(I
L
1
2
B
) 
    
G C    0.112 0.471 1.000 1.49 
G C C   0.096 0.281 1.000 1.82 
G C C G  0.035 0.853 1.000 0.00 
G C C G T 0.036 0.975 1.000 0.00 
G C C T  0.062 0.058 0.881 2.90 
G C C T C 0.062 0.057 0.876 2.92 
G C T   0.018 0.553 1.000 0.00 
G C T T  0.019 0.741 1.000 0.00 
G C T T C 0.019 0.614 1.000 0.00 
G T    0.086 0.097 0.981 2.52 
G T C   0.035 0.503 1.000 1.86 
G T C T  0.032 0.508 1.000 1.36 
G T C T C 0.033 0.494 1.000 1.45 
G T T   0.049 0.130 0.998 2.40 
G T T G  0.014 0.263 1.000 0.08 
G T T G T 0.010 0.226 1.000 0.02 
G T T T  0.034 0.070 0.907 3.55 
G T T T C 0.034 0.071 0.891 3.60 
T C    0.529 0.062 0.742 0.37 
T C C   0.527 0.064 0.742 0.38 
T C C G  0.139 0.221 0.993 0.16 
T C C G T 0.138 0.219 0.993 0.15 
T C C T  0.386 0.234 0.991 0.50 
T C C T C 0.386 0.240 0.992 0.50 
T T    0.273 0.253 0.995 1.69 
T T C   0.024 0.527 1.000 0.26 
T T C G  0.011 0.227 1.000 0.75 
T T C G T 0.012 0.425 1.000 0.71 
T T C T  0.014 0.433 1.000 0.16 
T T T   0.252 0.171 0.958 1.96 
T T T G  0.055 0.581 1.000 1.35 
T T T G T 0.058 0.610 1.000 1.36 
T T T T  0.197 0.181 0.958 2.14 
T T T T C 0.196 0.185 0.958 2.13 
 C C   0.623 0.141 0.936 0.53 
 C C G  0.173 0.109 0.962 0.15 
 C C G T 0.173 0.123 0.962 0.14 
 C C T  0.450 0.730 1.000 0.82 
 C C T C 0.450 0.745 1.000 0.82 
 C T   0.018 0.440 1.000 0.00 
 C T T  0.018 0.440 1.000 0.00 
 C T T C 0.018 0.440 1.000 0.00 
 T C   0.058 0.365 1.000 1.10 
 T C G  0.011 0.185 1.000 3.60 
 T C G T 0.011 0.250 1.000 3.69 
 T C T  0.047 0.590 1.000 0.72 
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 T C T C 0.044 0.537 1.000 0.74 
 T T   0.301 0.107 0.845 2.18 
 T T G  0.070 0.647 1.000 0.85 
 T T G T 0.070 0.646 1.000 0.84 
 T T T  0.231 0.029 0.564 2.79 
 T T T C 0.227 0.029 0.527 2.84 
  C G  0.187 0.233 0.992 0.32 
  C G T 0.187 0.237 0.992 0.31 
  C T  0.494 0.612 1.000 0.76 
  C T C 0.495 0.616 1.000 0.76 
  T G  0.068 0.593 1.000 0.70 
  T G T 0.069 0.625 1.000 0.71 
  T T  0.251 0.050 0.736 2.45 
  T T C 0.244 0.043 0.692 2.49 
   G T 0.255 0.196 0.990 0.42 
   T C 0.738 0.182 0.982 2.42 
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Haplotype analysis - chromosome 6 
Haplotype Frequency 
Univariate 
PEMP1 PEMP2 OR 
rs
2
3
9
5
3
0
9
 
(H
L
A
-D
P
A
1
) 
rs
2
0
7
1
3
4
9
 
(H
L
A
-D
P
A
1
) 
rs
9
3
1
 
(H
L
A
-D
P
B
1
) 
rs
9
2
7
7
5
3
4
 
(H
L
A
-D
P
B
1
) 
rs
9
2
7
7
5
3
5
 
(H
L
A
-D
P
B
1
) 
rs
3
1
3
0
1
8
6
 
(H
L
A
-D
P
B
1
) 
rs
2
0
6
4
4
7
9
 
(H
L
A
-D
P
B
1
) 
    
A C      0.523 0.042 0.251 0.30 
A G      0.128 0.430 0.981 1.60 
G C      0.349 0.123 0.449 2.26 
 C A     0.349 0.092 0.454 2.22 
 C G     0.523 0.032 0.260 0.31 
 G G     0.121 0.724 1.000 1.04 
 C  A    0.506 0.031 0.296 0.32 
 C  G    0.367 0.083 0.531 2.11 
 G  A    0.122 0.678 1.000 1.03 
  A G    0.356 0.013 0.257 2.79 
  A G A   0.151 0.056 0.414 2.40 
  A G A C  0.151 0.056 0.414 2.40 
  A G A C T 0.151 0.056 0.414 2.40 
  A G G   0.205 0.214 0.893 1.85 
  A G G T  0.205 0.214 0.893 1.85 
  A G G T C 0.048 0.127 0.608 3.58 
  A G G T T 0.157 0.763 1.000 1.22 
  G A    0.628 0.021 0.296 0.38 
  G A A   0.628 0.021 0.296 0.38 
  G A A C  0.628 0.021 0.296 0.38 
  G A A C C 0.606 0.012 0.187 0.30 
  G A A C T 0.021 0.213 0.857 3.87 
  G G    0.017 0.837 1.000 0.00 
  G G G   0.017 0.837 1.000 0.00 
  G G G T  0.017 0.837 1.000 0.00 
  G G G T C 0.017 0.837 1.000 0.00 
   A A   0.628 0.021 0.296 0.38 
   A A C  0.628 0.021 0.296 0.38 
   A A C C 0.606 0.011 0.187 0.30 
   A A C T 0.022 0.164 0.857 3.86 
   G A   0.151 0.056 0.414 2.40 
   G A C  0.151 0.056 0.414 2.40 
   G A C T 0.151 0.056 0.414 2.40 
   G G   0.221 0.384 0.957 1.70 
   G G T  0.221 0.384 0.957 1.70 
   G G T C 0.065 0.205 0.919 2.43 
   G G T T 0.156 0.726 1.000 1.23 
     A C 0.779 0.359 0.957 0.59 
     G T 0.221 0.384 0.957 1.70 
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Haplotype analysis - chromosome 16 
Haplotype Frequency 
Univariate 
PEMP1 PEMP2 OR 
rs
1
8
0
5
0
1
5
 
(I
L
4
R
) 
rs
2
2
3
0
4
3
3
 
(I
T
G
A
L
) 
    
C C 0.090 0.211 1.000 0.14 
C G 0.152 0.888 1.000 1.08 
T C 0.336 0.925 1.000 1.06 
T G 0.422 0.723 1.000 1.20 
 
